Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
Organoids represent an important bridge between 2D cultures and in vivo mouse/human models. The organoid technology exerts enormous potential in evaluation of efficacy and toxicity of drugs, regenerative medicine, and precision medicine.In this article, we will briefly introduce organoid technology.
-
Development of Intestinal Organoid
2022-07-28
3D organoid is one of the revolutionary developments in biomedical field during the past 10 years. The establishment of intestinal organoids is an important milestone in the development of organoid technology. -
RNA therapeutics have changed the landscape of drug development, which possess broader spectrum of drug targets, simplicity and efficiency in development and manufacturing.In this article, we will discuss the underlying mechanisms of RNA-based drugs on the market or in clinical stages.
-
Tsvetkov et al. published in Science and demonstrated a copper-induced programmed cell death — Cuproptosis. As a novel programmed cell death, excess copper triggers abnormal aggregation of lipoylated proteins in TCA cycle and clearance of Fe-S cluster proteins, ultimately leading to cell death.
-
A comprehensive explanation of ferroptosis
2022-09-15
Ferroptosis is a new type of RCD that depends on iron and characterized by the accumulation of lipid peroxides. In this article, we will pay our attention on ferroptosis and briefly discusses its mechanism. -
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
Organoids have great potential in research of organ development, disease modeling, drug screening and, precision and regenerative medicin. In this article, we will expalin the origin of the organoids. Adult stem cells (ASCs) or pluripotent stem cells (PSCs) , which is the better choice.
-
Autophagy, derived from the Greek meaning "eating of self", plays an indispensable role in maintaining homeostasis. p27 is an inhibitor of cyclin CDKs, but how p27 regulates autophagy remains unknown. This article will cover the mechanism of autophagy and p27-related cell cycle regulation.
-
AlphaFold2 can predict disease-related protein structures at low cost, and then find potential drugs for these diseases through drug repositioning, virtual screening, and other methods. ZINC is a public database summarizing information about billions of compounds. AlphaFold2 + ZINC20 speeds up the virtual screening process and improves the computing speed.
-
CMA (chaperone-mediated autophagy) plays an essential role in maintaining neuronal protein stability and preventing neurodegeneration. In this article, we will comprehensively clarify the role of CMA in the occurrence and development of neurodegenerative diseases.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
As powerful pain relievers, the opioids morphine and fentanyl have been "checked" by their side effects (listed as controlled substances). How to reduce its side effects? What is its mechanism? This research will explore its mechanism.
-
Efferocytosis is the process in which phagocytes remove programmed dead cells. It prevents secondary necrosis of dying cells from releasing harmful cell contents (such as oxides and proteases) that may cause inflammation. Here, we will introduce three stages of efferocytosis: Find, Eat, Digest.
-
Understanding the mechanism of aging not only has guiding significance for prolonging human life but also has important clinical significance for the prevention and treatment of diseases in the elderly population , thus, improving their life quality and well-being.
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Stem cell classification and its application
2023-05-18
Stem cells (SCs) have the unique ability to self-renew and differentiate into different cell types. SCs can differentiate into various types of tissue cells under specific conditions. Additionally, they can be further cultured to form different tissues and organs in the human body. Stem cells have numerous applications in various fields, including cell therapy, organ transplantation, neurodegenerative disease modeling, and drug screening. -
Mitophagy:Mechanisms and Detection
2023-05-25
About 60 years ago, Christian de Duve first used the term "autophagy" to describe his observation of the degradation of mitochondria and other intracellular structures in lysosomes of rat liver. Over the years, autophagy has remained a beloved topic of research by the National Natural Science Foundation of China (NSFC).Today, let's talk about mitochondrial autophagy. -
Structure of Lipid Droplets
2023-06-15
Huh? Lipid droplets? Organelles? In the past, biological data usually only show the traditional organelles, such as mitochondria, Golgi apparatus, endoplasmic reticulum, etc., lipid droplets are often not mentioned by people. Today, we will make a systematic explanation of lipid droplets, so that everyone has a clear understanding! -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
How to Perform Western Blot?
2023-07-13
Western blot is one of the most frequently performed experiments in molecular biology, biochemistry and immunology. This article describes in detail how to do WB. -
Organoid Culture: Questions & Answers
2023-07-26
In the last issue, we conducted a live lecture on the theme of organoid culture. Today, we have a special topic to solve your doubts in the last live class! -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
Are frozen cells always damaged? Is the survival rate of revived cells low? When is it appropriate to freeze cells? What should be considered when reviving them? Today, we're sharing a guide to avoid pitfalls in cell freezing and revival!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
SPR, which stands for Surface Plasmon Resonance, essentially works by detecting the interaction between ligands and analytes on a biosensor chip. This in turn allows us to probe the properties and structure of substances. With this technology, we can analyze molecules, proteins, DNA, and various organic and inorganic substances in samples in real-time with precision.
-
Common Questions and Solutions for WB
2024-05-09
Come to understand the common problems and solutions of WB, and better complete the experiment! -
Still struggling to find the preparation methods for various solutions? Save your time! Here comes a nanny-level tutorial!
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
Streptavidin-Biotin System
2024-08-03
Streptavidin strongly binding small molecule biotin is one of the most popular non-covalent coupling methods. Streptavidin can be coupled to various carriers such as magnetic beads and agarose matrix, and become a highly specific affinity medium to capture various biotin-labeled ligands. -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Cuproptosis, How much do you know?
2024-08-22
Cells die in a variety of ways, including apoptosis, pyroptosis, necrosis, and ferroptosis......And, of course, cuproptosis. So, how much do you know about cuproptosis? -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
Recently, Mol Cell reported the discovery of the first ferroptosis marker, Hyperoxidized PRDX3! Let’s take a look together~
-
Cuproptosis's Knowledge Points!
2024-09-25
With the establishment of the cuproptosis mechanism related research has attracted more and more attention from major journals. Expect to use the sharp sword of cuproptosis to stab the tumor cells. -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
How they used PKH 26 for cellular studies?
2024-10-21
We are thrilled to highlight our client study using PKH 26 (MedChemExpress) , a red fluorescent dye that has proven invaluable for in vitro cell labeling and tracing. This innovative research, published in the Journal of Nanobiotechnology. -
Delve into the intricate networks that govern mitochondrial quality control. By examining key mechanisms such as biogenesis, mitochondrial dynamics (fission and fusion), proteolysis, and mitophagy.
-
A New Form of Cell Death: PANoptosis!
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
In early January 2025, MIT Tech Review unveiled its annual list of top 10 breakthrough technologies poised to redefine the future. Among these, stem cell therapy stood out for its potential to treat diverse diseases—including neurodegenerative disorders, diabetes, cancer, and heart failure. This groundbreaking approach uses stem cells to replace damaged cells, offering hope for millions worldwide.
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
Autophagy is a fundamental process that degrades various components within the cell.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
Do you feel confused when you start culturing cells? This article will show you the basic methods and steps of cell culture!
-
As a pivotal branch in the post - genomic era, proteomics is committed to comprehensively elucidating the types, abundances, structures, functions, and interactions of all proteins within living organisms. This article will tell you the key steps of proteomics sample preparation based on mass spectrometry. This article will tell you the key steps of proteomics sample preparation based on mass spectrometry.
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
Western blotting is a crucial and fundamental technique in life science research. It plays a significant role in exploring protein expression and function. The following article will comprehensively and thoroughly elaborate on the specific procedures and detailed key points of this experiment.
-
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
In protein biology, Co-IP is a powerful tool to uncover protein "social networks." But poorly performed, it easily becomes an awkward lab "meet-and-greet." Today, we discuss making Co-IP experiments elegant and efficient—so you pull down target proteins with confidence and precision.
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
Chromatin Immunoprecipitation (ChIP) Demystified: A Complete Guide to Epigenetic Analysis
2025-08-05
In this issue, we introduce a powerful technique for detecting interactions between epigenetic regulatory factors and DNA—Chromatin Immunoprecipitation (ChIP)! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
The article introduces the mechanisms of ROS generation and the methods for their detection.
-
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
Generating Stable Cell Lines with Lentivirus
2025-09-16
A step-by-step protocol of establishing stable cell lines using lentivirus -
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
For all the protein research folks out there, techniques like IP and Co-IP are no stranger, right? And of course, there's a faster and more convenient go-to tool—Protein A/G magnetic beads! In this article, let's chat about how these beads work their magic in classic experiments like IP and Co-IP.
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Efficient Generation of Mouse Small Intestinal Organoids: A Complete Experimental Protocol Guide
2025-12-10
How to successfully create mouse small intestine organoids? A detailed, hands-on guide to the entire process, all in one article! -
A November 2025 Cell study discovers Mitoxyperilysis, a new mTOR-regulated, caspase-independent cell death pathway driven by innate immune and metabolic dysregulation via mitochondrial-plasma membrane contact and oxidative damage, and verifies its potential to induce tumor necrosis for cancer therapy with key regulators including BAX, BAK1 and BID.
-
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
Essential for High-Impact Papers: Present Your CCK-8 Experimental Results in a More Outstanding Way!
2026-03-18
CCK-8 is a widely used WST‑8‑based reagent for cell proliferation and cytotoxicity assays. It features high sensitivity, reliable results and easy operation, and is applicable to cell viability analysis, drug screening and growth inhibition testing. -
FISH is a molecular technique using fluorescent probes to detect specific nucleic acids in cells, with high sensitivity and diverse biomedical applications.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
This review introduces the major forms of programmed cell death, with a focus on the molecular mechanisms of ferroptosis and the methods used for its detection.
-
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review summarizes the mechanisms of DSS-induced colitis, commonly used modeling approaches, and key considerations related to DSS molecular weight.
-
This review provides a practical guide to the fundamental mechanisms, regulatory pathways, and detection methods of pyroptosis.
-
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
Review the metabolic regulation of ferroptosis through iron homeostasis, lipid peroxidation and antioxidant defence, and the emerging polyamine–iron buffering axis.
-
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
AZD5991, a macrocyclic molecule with high selectivity for Mcl-1, reduces Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines.
-
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
HJB97 is a BET PROTAC inhibitor with good anti-tumor activity, and effectively blocks the degradation of BRD2, BRD3, and BRD4 proteins induced by BETd-260.
-
CCB02 is an tubulin binder and has potential in the therapy of cancer cells with extra centrosomes. CCB02 also activates spindle assembly checkpoint.
-
H3B-5942 is a selective and irreversible estrogen receptor covalent antagonist, inactivates both ERαWT and ERα mutation.
-
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
Nevanimibe is a selective and potent ACAT1 inhibitor. An excellent drug candidate in the treatment of adrenocortical cancer.
-
PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM.
-
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
Novel Greatwall Kinase Inhibitor GKI-1
2019-04-13
GKI-1, a GWL inhibitor, robustly inhibited ROCK1 with an IC50 of ~11 μM, but only weakly affected PKA and had no observable inhibition towards CDK2. -
IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.
-
SSE15206 is a microtubule polymerization inhibitor, with a GI50 of 197 nM in HCT116 cells. Causes aberrant mitosis resulting in G2/M arrest.
-
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
Cevipabulin is a microtubule-active compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for in human tumor cell line.
-
BTR-1 potently inhibits cell growth. It induces S phase arrest, affects DNA replication. Dose-dependently induces cytotoxicity in leukemic cell lines.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
CB-6644 is a selective non-ATP-competitive inhibitor of the RUVBL1/2 complex. CB-6644 significantly reduces tumor growth without obvious toxicity.
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
NSC 228155 is a activator of EGFR and a potent inhibitor of KIX-KID interaction. NSC 228155 shows excellent anti-tumor activity.
-
BSJ-03-123, a Degrader with Proteome-wide Selectivity for CDK6 (PROTAC). Induces a G1 cell-cycle arrest without a measurable increase in apoptosis.
-
FT671 is a potent, non-covalent and selective USP7 inhibitor with an IC50 of 52 nM and binds to the USP7 catalytic domain with a Kd of 65 nM.
-
BSc5371 is a potent and irreversible FLT3 inhibitor. BSc5371 is cytotoxic to FLT3-dependent cell line. BSc5371 has potential to treat Acute Leukemia.
-
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
SJ572403 (SJ403) is an inhibitor of disordered protein p27 (Kip1). p27 (Kip1) is a regulator of the CDKs that control eukaryotic cell division.
-
ZM223 is a non-sulfamide NEDD8 activating enzyme (NAE) inhibitor, with IC50 value of 100 nM in cells. ZM223 has potential to treat colon cancer.
-
JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association. JR-AB2-011 has anti-glioblastoma multiforme (GBM) properties.
-
CHMFL-ABL-039 is a Type II native and drug-resistant mutant BCR-ABL inhibitor for chronic myeloid leukemia. The IC50s are 7.9 nM and 27.9 nM, respectively.
-
MM-589 is an inhibitor of WDR5 and MLL protein-protein interaction. Binds to WDR5 (IC50=0.90 nM) and inhibits the MLL H3K4 methyltransferase activity.
-
GNE-955 is a potent and orally active pan Pim kinase inhibitor with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.
-
STL127705 is a Ku 70/80 heterodimer protein inhibitor, inhibits Ku70/80-DNA interaction (IC50 of 3.5 μM) and Ku-dependent activation of DNA-PKCS kinase.
-
SRT 1460, a Sirtuin-1 Activator, Negatively Regulate Pancreatic Cancer Cell Growth and Viability
2019-05-18
SRT 1460, a selective SIRT1 activator with an EC1.5 value of 2.9 μM, is more potent than Resveratrol and the closest sirtuin homologues. -
MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) with a Kd of 37 nM for binding affinity to ALK. Efficacy for breast cancer and lung cancer.
-
A Potent and Specific Tankyrase Inhibitor RK-287107, Blocks Colorectal Cancer Cell Growth
2019-05-20
RK-287107 is a specific tankyrase inhibitor with IC50s of 14.3 and 10.6 nM for tankyrase-1 and tankyrase-2, respectively. -
JI051 is a stabilizer for the Hes1-PHB2 interaction, induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1.
-
ORIC-101 is a highly potent and selective glucocorticoid receptor antagonist, with an EC50 of 5.6 nM. ORIC-101 has anti-cancer activity.
-
BGT226 is a Dual PI3K/mTOR Inhibitor
2019-05-25
BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor. -
SNIPER(TACC3)-1 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway. SNIPER(TACC3)-1 induces cancer cell death.
-
MDL-800 is an allosteric and selective SIRT6 activator. MDL-800 increases SIRT6 deacetylation activity with an EC50 of 10.3 µM
-
TAS-114 is a dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine.
-
CFI-402257 is a highly selective and oral active TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK. CFI-402257 has potential to treat ovary cancer and TNBC.
-
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 less than 500 nM.
-
GGTI-2418 is a selective GGTase I inhibitor. GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.5 nM and 53 μM, respectively.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
-
PF-06821497 (compound 23a) is an orally active EZH2 inhibitor, with a Ki value <0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition.
-
OTS186935 is a methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 reveales significant inhibition of tumor growth in animal models.
-
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM. Potently blocks the TNF response and RIP1-dependent inflammatory cytokine MIP-1β production.
-
IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity. IZCZ-3 induces an apparent accumulation of cells in the G0/G1 phase.
-
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
Riviciclib is a Potent CDKs Inhibitor
2019-06-09
Riviciclib P276-00 free base) is a potent CDK inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively -
Olutasidenib is a highly potent, selective inhibitor of mutant IDH1 that could be used in the treatment of AML or myelodysplastic syndrome (MDS).
-
SJFδ, a 10-atom Linker PROTAC, Degrades p38δ
2019-06-11
SJFδ, a 10-atom Linker PROTAC, Degrades p38δ, degrades p38δwith strong capacity. SJFδ degrades p38δ with a DC50 of 46.17±9.85 nM and a Dmax of 99.41±3.31%. -
Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase and shows antitumour activity.
-
CBS9106, a Reversible Oral CRM1 Inhibitor, Causes Arrest of the Cell Cycle and Induces Apoptosis
2019-06-14
CBS9106 (SL-801) is a reversible oral CRM1 inhibitor antitumor activities. CBS9106 causes arrest of the cell cycle and induces apoptosis. -
Ralimetinib (LY2228820) is a selective and ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Anti-tumor activity.
-
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM). NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively
-
ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity.
-
SPP-86 is a selective inhibitor of RET tyrosine kinase, with an IC50 of 8 nM. SPP-86 inhibits RET-induced PI3K/Akt and MAPK signaling.
-
S130, Targeting ATG4B, Inhibits Autophagy and Activates Apoptosis in Colorectal Colon Cancer
2019-06-19
S130 is a high affinity, selective inhibitor of ATG4B (a major cysteine protease) with an IC50 of 3.24 µM. S130 suppresses autophagy flux. -
BI8622 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC50 of 3.1 μM. BI8622 suppresses colony formation of Ls174T cells.
-
RO-5963 is a dual p53-MDM2 and p53-MDMX inhibitor with IC50s of ~17 nM and ~24 nM, respectively. Potently shows apoptotic activity.
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
TH34, an HDAC6/8/10 inhibitor with IC50s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3.
-
Alisertib (MLN 8237) is an oral active and selective Aurora A kinase inhibitor with an IC50 of 1.2 nM. To treat hematologic malignancies and solid tumors.
-
MA242 is a Dual Inhibitor of MDM2 and NFAT1
2019-06-24
MA242 is a dual inhibitor of murine double minute 2 (MDM2) and nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy. -
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
NG25, a Dual Inhibitor of TAK1 and MAP4K2, Enhances Doxorubicin-mediated Apoptosis in Breast Cancer
2019-06-26
NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively. NG25 enhances Dox-mediated apoptosis in breast cancer. -
GW7604 is an antiestrogen. GW7604 is the metabolite of GW5638, which is a high affinity estrogen receptor (ER) antagonist
-
TAS4464 is a highly potent and selective inhibitor of NEDD8 activating enzyme (NAE), with an IC50 of 0.955 nM. TAS4464 shows antitumor activity.
-
DK419 is an orally active Wnt/β-catenin inhibitor, with an IC50 of 0.19 μM. DK419 reduces Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin expression.
-
AZ82 is a selective kinesin-like protein KIFC1 (HSET/KIFC1) inhibitor, with a Ki of 43 nM and an IC50 of 300 nM for KIFC1.
-
CH-223191 is a Specific Antagonist of Aryl Hydrocarbon Receptor (AhR) with Anti-Tumor Activity
2019-07-02
CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR). CH-223191 blocks the binding of TCDD to AhR with an IC50 of 0.03 µM. -
MRT67307, a dual IKKε/TBK1 inhibitor, inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 blocks mTOR-dependent autophagy.
-
NSC 95397 inhibits MKP-1 and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway.
-
PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1 in ovarian cancer. Depletion of BMI-1 by PTC-028 induces caspase-mediated apoptosis
-
DS21360717 is a potent and orally active FER tyrosine kinase inhibitor, with an IC50 of 0.49 nM. DS21360717 has anti-cancer activity.
-
LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively.
-
BAY1238097 is a selective inhibitor of BET binding to histones and has strong anti-proliferative activity through down-regulation of c-Myc levels.
-
CCT020312, the G1/S checkpoint activator, is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
-
MRT-83, a Potent Smoothened Antagonist, has Potential to Treat Hh-pathway Related Diseases
2019-07-10
MRT-83 is a potent antagonist of Smo, with an IC50 in the nanomolar range. MRT-83 antagonizes the up-regulation of Ptc transcription. -
MS023 is a selective inhibitor of human type I PRMTs inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, 3, 4, 6, and 8, respectively.
-
S55746 (BLC201) is an orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM.. S55746 (BLC201) has antitumor activity with low toxicity.
-
WYC-209 is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50 = 0.19 μM for mTRCs).
-
SBI-0206965 is a selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 and 711 nM for the highly related kinase ULK2 .
-
TPCA-1, a Direct Dual Inhibitor of STAT3 and NF-κB, Regresses Mutant EGFR-Associated NSCLC
2019-07-15
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding. -
NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a Kd of 16 nM and an IC50 of 27 nM (in Hela cells). Anti-tumor activity.
-
ERD-308 is a highly potent PROTAC degrader of ER for ER+ breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM.
-
JG-98, an Hsp70 inhibitor, binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities.
-
ARS-853 is a Selective KRAS (G12C) Inhibitor
2019-07-19
ARS-853 is a selective, covalent KRAS (G12C) inhibitor, with an IC50 of 2.5 μM. ARS-853 treatment also induces apoptosis in four KRASG12C mutant cell lines. -
ARS-1620 is an atropisomeric selective KRAS G12C inhibitor for KRAS-mutant cancer with desirable pharmacokinetics. A promising clinical candidate.
-
MZP-55 is a selective PROTAC degrader of BRD3/4, shows no obvious effect on BRD2. MZP-55 exhibits excellent activity in cancer research.
-
dBET6 is a potent PROTAC degrader of BET, shows high affinity to BRD4(1), and possess good efficacy in T cell acute lymphoblastic leukemia activity.
-
SAR-260301 is a selective PI3Kβ inhibitor with an IC50 of 23 nM. SAR-260301 is a potent and highly selective PI3Kβ inhibitor for melanoma.
-
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
GSK2643943A is a Novel DUB Inhibitor
2019-07-25
GSK2643943A is a novel deubiquitylating enzyme (DUB) inhibitor. GSK2643943A targets USP20/Ub-Rho and shows an IC50 of 160 nM. -
M-89 is a specific menin inhibitor, with a Kd of 1.4 nM. M-89 inhibits the Menin-MLL protein-protein interaction and has potential to treat MLL leukemia.
-
APG-115 is an orally active MDM2 protein inhibitor binding to MDM2 protein. APG-115 blocks the interaction of MDM2 and p53 and induces apoptosis.
-
MBM-55 is a potent, selective Nek2 inhibitor with an IC50 of 1 nM. MBM-55 shows antitumor activities and induces cell cycle arrest and apoptosis.
-
GSK3368715 is an orally active and SAM uncompetitive type I PRMT inhibitor that produces a shift in arginine methylation states.
-
MT-802 is a potent BTK degrader based on PROTAC technology, with a DC50 of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia.
-
Alobresib is an Orally Active BET Bromodomain Inhibitor for Uterine Serous Carcinoma Treatment
2019-07-31
Alobresib is a novel and potent BET bromodomain inhibitor for recurrent/chemotherapy resistant uterine serous carcinoma overexpressing c-Myc. -
GNE-207 is an orally bioavailable inhibitor of the bromodomain of CBP, with an IC50 of 1 nM, exhibits a selectively index of >2500-fold against BRD4 (1).
-
BI-0252 is an orally active, selective MDM2-p53 inhibitor with an IC50 of 4 nM and can induce tumor regressions in all animals of a mouse SJSA-1 xenograft.
-
ML367 is an ATAD5 Stabilization Inhibitor
2019-08-03
ML367 is a potent inhibitor of ATAD5 stabilization. It blocks DNA repair pathways, and suppresses phosphorylation of RPA32 and CHK1. -
DW14800 is a potent PRMT5 inhibitor, exhibits anti-cancer activity. DW14800 reduces H4R3me2s and H3R8me2s, and reduces symmetric dimethylarginine.
-
LSN 3213128 is a selective, nonclassical, orally bioavailable antifolate with anti-cancer activity. LSN 3213128 potently and specifically inhibits AICARFT.
-
CA-5f is a potent late-stage macroautophagy (autophagy) inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II and SQSTM1 protein.
-
ACBI1 is a PROTAC Degrader of BAF Complex
2019-08-07
ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2, SMARCA4 and PBRM1, with DC50s of 6 nM, 11 nM and 32 nM in MV-4-11 cells, respectively. -
TAK-659 is a highly potent, selective, reversible and orally available inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3).
-
dMCL1-2 is a potent and selective degrader of myeloid cell leukemia 1 (MCL1) based on PROTAC, which binds to MCL1 with a KD of 30 nM.
-
VERU-111 (ABI-231) is a potent and orally bioavailable α and β tubulin inhibitor, which displays strong antiproliferative activity.
-
JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells.
-
TTT-28 Antagonizes Multidrug Resistance by Selectively Inhibiting the Efflux Activity of ABCB1
2019-08-15
TTT-28 is a novel selective inhibitor of ABCB1 (P-gp/MDR1) with high efficacy and low toxicity, which selectively blocks the efflux function of ABCB1. -
MPT0B392 Induces Apoptosis via Inhibiting Tubulin Polymerization and Inducing c-JNK Activation
2019-08-16
MPT0B392 is a novel microtubule depolymerizing agent that triggers induction of the mitotic arrest and induces JNK activation, leading to apoptosis. -
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
NXT629 is a potent, selective, and competitive PPAR-α antagonist and shows high selectivity over other nuclear hormone receptor.
-
GNA002 is a highly potent, specific and covalent EZH2 inhibitor, which efficiently reduces EZH2-mediated H3K27 trimethylation.
-
BJE6-106 is a selective PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over PKCα. BJE6-106 induces caspase-dependent apoptosis.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
BI-4924 is a Selective PHGDH Inhibitor
2019-08-23
BI-4924 is a lipophilic and highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal. -
MS31 is a highly selective spindlin 1 inhibitor, which inhibits the interactions between SPIN1 and H3K4me3. MS31 is not toxic to nontumorigenic cells.
-
CP-10 is a Specific PROTAC Degrader of CDK6
2019-08-25
CP-10 is a PROTAC with highly selective, specific, and remarkable CDK6 degradation (DC50=2.1 nM), which has anti-cancer activity. -
AAPK-25 is a potent and selective Aurora kinases and Polo-like Kinases (PLK) dual inhibitor, which shows anti-tumor activity.
-
AMG 232 is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC50 of 0.6 nM. AMG 232 binds to MDM2 with a Kd of 0.045 nM.
-
RG7112 is a potent, selective, first clinical and orally active MDM2-p53 inhibitor, with a KD of 11 nM for binding to MDM2.
-
ARV-825 is a PROTAC, and acts as a potent BRD4 degrader, with Kds of 90 and 28 nM for BRD4 BD1 and BRD4 BD2, respectively.
-
GMB-475 is a PROTAC BCR-ABL1 degrader, overcomes BCR-ABL1-dependent drug resistance, targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau.
-
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
MI-773 is a potent MDM2 inhibitor (Ki, 0.88 nM), blocks p53-MDM2 interaction, and and leads to p53 accumulation, with anti-cancer activity.
-
CITCO is a selective agonist of constitutive androstane receptor, with an EC50 of 49 nM, with potent activity against brain tumor stem cells.
-
RRx-001 is a hypoxia-selective epigenetic agent, triggers apoptosis and overcomes drug resistance in multi myeloma cells.
-
MI-1061 is an Orally Active MDM2 Inhibitor
2019-09-04
MI-1061 is an orally bioavailable MDM2 inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53, induces apoptosis, and has anti-tumor activity -
dBET57 is a potent and selective degrader of BRD4BD1 based on the PROTAC technology and mediates recruitment to the CRL4CRBN E3 ubiquitin ligase.
-
FT113 is a potent and orally active fatty acid synthase inhibitor, with an IC50 of 213 nM for full-length recombinant human FAS, with anti-tumor activity.
-
SGC-iMLLT is a potent, selective MLLT1/3-histone interactions inhibitor and shows high binding activity towards MLLT1 YEATS domain and MLLT3 YD.
-
YUKA1 is a potent, selective and cell permeable KDM5A inhibitor, with an IC50 of 2.66 μM. YUKA1 exhibits anti-cancer activity.
-
MD-224 is a human MDM2 degrader based on the PROTAC concept. MD-224 induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
E3330, an APE1 Redox Inhibitor, Modulates Cell Migration and Invasion in Metastatic Cancer
2019-09-13
E3330 is a direct, orally active AP endonuclease 1 (APE1) inhibitor, which suppresses NF-κB DNA-binding activity. E3330 shows good anticancer properties. -
AOH1160, an Orally Active PCNA Inhibitor, Exhibits Efferctive Anti-cancer Activity with Low Toxicity
2019-09-14
AOH1160 is a potent, first-in-class, orally available PCNA inhibitor and exhibits broad-spectrum anti-cancer activity without causing unacceptable toxicity. -
WJ460 is a potent myoferlin (MYOF) inhibitor, which exerts anti-metastatic activity in the nanomolar range in breast cancer cells.
-
UPGL00004 is a allosteric glutaminase C inhibitor which strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines.
-
TL02-59 is a selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 also inhibits Lyn and Hck. TL02-59 suppresses AML cell growth.
-
IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1) R132 mutations.
-
DVD-445 is a potent peptidomimetic covalent TrxR1 inhibitor with an IC50 of 0.60 μM for rat TrxR1. DVD-445 has good anticancer application.
-
MPT0E028 is an orally active and selective histone deacetylase (HDAC) inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6.
-
VU0155069 is a selective phospholipase D1 inhibitor with an IC50 of 46 nM, which strongly inhibits the invasive migration of several cancer cell lines.
-
KPT-6566 is a Selective PIN1 Inhibitor
2019-09-23
KPT-6566 is a potent prolyl isomerase PIN1 inhibitor, covalently binds to the catalytic site of PIN1, selectively inhibits and degrades PIN1. -
BY27 is a potent, selective BET BD2 inhibitor, shows high BD1/BD2 selectivity for BRD2, BRD3, BRD4, and BRDT. BY27 has anti-cancer activity.
-
AZD0424 is a selective Src/Abl kinase inhibitor with potential antineoplastic activity. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells
-
SS-208 is a selective HDAC6 inhibitor, with an IC50 of 12 nM. SS-208 (25 mg/kg, ip) significantly reduces the tumor growth in melanoma murine model.
-
PTC596, an orally active and selective BMI-1 inhibitor, induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
-
CSRM617 is a selective inhibitor of ONECUT2 (OC2). CSRM617 induces apoptosis. Well tolerated in the prostate cancer mouse model.
-
BPK-29 disrupts the NR0B1 protein-protein interactions and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.
-
LDN-192960 is a potent Haspin and DYRK2 dual inhibitor. LDN-192960 may have potential therapeutic utility in treating cancer.
-
-
SCH772984 is a highly selective and ATP-competitive ERK inhibitor. SCH772984 shows robust efficacy in RAS- or BRAF-mutant cancer cells.
-
LY3214996 is a highly potent and selective ERK1 and ERK2 inhibitor and shows potent antitumor activities in cancer models with MAPK pathway alterations.
-
Ravoxertinib (GDC-0994) is an orally bioavailable ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
-
FR 180204 is an ATP-competitive and selective ERK inhibitor and inhibits ERK1 and ERK2 with IC50s of 0.51 μM and 0.33 μM, respectively.
-
CGS 15943 is an orally bioavailable adenosine receptor antagonist with low nanomolar range Ki values for human A1, A2A, A2B, and A3 adenosine receptors.
-
CG-200745 is a potent and pan HDAC inhibitor. CG200745 inhibits the deacetylation of histone H3 and tubulin, inducing p53 accumulation.
-
NV03 is a potent and selective antagonist of UHRF1-H3K9me3 interaction by binding to UHRF1 TTD with a Kd of 2.4 μM and has anticancer activity.
-
CD161 is a potent and orally bioavailable bromodomain and extra-terminal bromodomain inhibitor with an IC50 of 28.2 nM and a Ki of 8.2 nM for BRD4 BD1.
-
sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer in a dose dependent manner with an IC50 of 1.8 μM.
-
Tasisulam is an anticancer agent and induces apoptosis, which also inhibits mitotic progression and induces vascular normalization.
-
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM.
-
JTE-013 is a potent and specific S1P2 antagonist and increases the excitability of sensory neurons independently of the receptor.
-
OTS964 is an orally active, high affinity and selective TOPK inhibitor and is also a potent inhibitor of the cyclin-dependent kinase CDK11.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
FTI-2153 is a potent and highly selectiveof farnesyltransferase (FTase) inhibitor and a highly potent antagonist of oncogenic H-Ras signaling.
-
TVB-3166 is an orally-available, reversible, and selective FASN inhibitor and it induces apoptosis, and inhibits in-vivo xenograft tumor growth.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
ASLAN003 is an orally active and potent inhibitor of hDHODH with antitumor activity, and it has the potential to be a first-in-class drug candidate in AML.
-
MN58b, a selective choline kinase α (CHKα) inhibitor, results in inhibition of phosphocholine synthesis, induces of apoptosis, and has antitumoral activity.
-
JNJ-10198409 is an orally active PDGF-RTK inhibitor (IC50=2 nM). It also has potent activity against PDGFR-β (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM).
-
SU16f is a selective PDGFRβ inhibitor and significantly decreases the enhanced migratory ability of SGC-7901 cells by GC-MSC.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
MRTX849 is a potent, orally-available, and mutation-selective covalent inhibitor of KRASG12C with potential antineoplastic activity.
-
AG-825 is a selective and ATP-competitive ErbB2 inhibitor and leads to a decrease in ErbB2–nucleolin interaction, which suppresses tyrosine phosphorylation.
-
CP5V is a Specific PROTAC Degrader of Cdc20
2019-11-20
CP5V is a PROTAC, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. -
DS18561882 is a highly potent, sozyme-selective methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor with a good oral pharmacokinetic profile.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
S516 is a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM and has marked antitumor activity against murine and human solid tumors.
-
GNE-618 is a Orally Active NAMPT Inhibitor
2019-11-28
GNE-618 is an orally active NAMPT inhibitor and reduces tumor growth. GNE-618 depletes NAD levels and induces tumor cell death. -
MS645, a bivalent BET BrD inhibitor, affords a sustained repression of BRD4 transcriptional activity in solid-tumor cells.
-
PK11007 is a Mild Alkylating Agent with Anticancer Activity and induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels.
-
PI-273 can be used to treat breast cancer. PI-273 is a first reversibly and specific PI4KIIα inhibitor (IC50 = 0.47 μM) and induce cell apoptosis.
-
SD-36 is a Selective PROTAC STAT3 Degrader
2019-12-06
SD-36 is a potent, efficacious and selective PROTAC STAT3 degrader (Kd=50 nM) and achieves complete tumor regression in vivo. -
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13.SR-4835 can provoke triple-negative breast cancer (TNBC) cell death.
-
SI-109 is a potent STAT3 SH2 domain inhibitor and effectively inhibits the transcriptional activity of STAT3. SI-109 is the ligand of PROTAC degrader SD-36.
-
CMLD010509 is a Highly Specific Inhibitor of the Oncogenic MYC-Driven Translation Program
2019-12-10
CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins. -
BI-4020 is an orally active, and non-covalent EGFR tyrosine kinase inhibitor. It inhibits BaF3 and EGFR wt cell lines with low IC50 values.
-
Sotorasib, a first-in-class, selective KRAS G12C covalent inhibitor, irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state.
-
Telaglenastat is a first-in-class, reversible, orally bioavailable glutaminase 1 splice variants (KGA and GAC) inhibitor. It shows antitumor activity.
-
Alpelisib is a potent, selective, and orally active PI3Kα inhibitor (IC50=5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, p110δ, and p110β).
-
Niraparib is an Orally Active PARP Inhibitor
2019-12-18
Niraparib is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor. Niraparib has potent anti-cancer activity. -
MG-277 works as a PROTAC molecular glue, inducing degradation of a translation termination factor, GSPT1 to achieve its potent anticancer activity.
-
TK216 is a potent ETS inhibitor. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity.
-
DRF-1042 is an orally active derivative of Camptothecin and acts to inhibit DNA topoisomerase I with good anticancer activity.
-
UK 356618 is a Selective MMP-3 Inhibitor
2019-12-25
UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity. -
MS432 is a first-in-class and highly selective PD0325901-based VHL-recruiting PROTAC degrader for MEK1 and MEK2 with good anti-cancer activity.
-
PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with good anti-cancer activity. PI-828 mitigated radiation-induced apoptosis in NCCIT cells.
-
FPA-124 is a cell-permeable copper complex and a selective Akt inhibitor. FPA-124 induces apoptosis in multiple human cancer cells.
-
KB02-JQ1 is a highly potent and selective PROTAC BRD4 degrader that degrades nuclear proteins by engaging CUL4-DDB1 E3 ubiquitin ligases DCAF16.
-
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
D-I03 is a Selective RAD52 Inhibitor
2020-01-08
D-I03 is a selective RAD52 inhibitor, which specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation. -
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus.
-
CKI-7 is a potent CK1 and Cdc7 kinase inhibitor, which induces cytotoxicity of established leukemia and lymphoma cell lines.
-
GPP78 is a potent Nampt inhibitor. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells. GPP78 has anti-cancer and anti-tumor activity.
-
CC-223 is an orally bioavailable mTOR kinase inhibitor and demonstrates mTORC1/2 and growth inhibitory activity across a variety of tumor cell types.
-
COTI-2 is an orally available third generation activator of p53 mutant forms by inhibiting the PI3K/AKT/mTOR pathway. COTI-2 has has anti-cancer activity.
-
PI-103 is a Potent PI3K and mTOR Inhibitor
2020-01-17
PI-103 is a potent PI3K and mTOR inhibitor, it also inhibits DNA-PK. PI-103 exhibits antiproliferative properties in a panel of human cancer cell lines. -
CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with good anticancer activity.
-
AZD4547 is a Potent FGFR Family Inhibitor
2020-01-21
AZD4547 potently inhibits the FGFR family with low IC50s. AZD4547 inhibits FGF/FGFR downstream signaling through FRS2, PLCγ, and MAPK at the cellular level. -
A-366 is a potent G9a-inhibitor without affect other histone methyltransferases. A-366 significantly results in tumor growth inhibition in leukemia.
-
PF-573228 is a potent and selective FAK inhibitor and serves as a useful tool to dissect the functions of FAK in normal and cancer cells.
-
BCI-215 is a potent and tumor cell-selective DUSP-MKP inhibitor without affecting normal cells. Anti-migratory and proapoptotic activities in cancer cells.
-
PKI-166 is an orally active EGFR tyrosine kinase inhibitor and inhibits pancreatic cancers. Combined with Gemcitabine produces a decrease in tumor growth.
-
BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 is a structural genomics consortium (SGC) epigenetics probe.
-
SAR439859 is an orally active and selective estrogen receptor degrader. SAR439859 is a potent ER antagonist, with an EC50 of 0.2 nM for ERα degradation.
-
M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with antiangiogenic and antitumoral activity.
-
BRD7389 is a specific RSK family kinase inhibitor and is a small-molecule inducer of insulin expression in pancreatic α-cells.
-
MRT199665 is a potent, ATP-competitive, and selective MARK/SIK/AMPK inhibitor, and causes apoptosis in MEF2C-activated human AML cells.
-
AKOS-22, a VDAC1 Oligomerization and Apoptosis Inhibitor, Protects Against Mitochondrial Dysfunction
2020-02-15
AKOS-22 is a potent mitochondrial protein VDAC1 and apoptosis inhibitor. AKOS-22 protects against Mitochondrial Dysfunction. -
SB-218078, a Chk1 inhibitor, inhibits Chk1 phosphorylation of cdc25C with an IC50 of 15 nM, causeing apoptosis by DNA damage and cell cycle arrest.
-
HKI-357 is an irreversible EGFR and ERBB2 inhibitor and is effective in the treatment of EGFR-mutant non-small cell lung cancers resistant to Gefitinib.
-
BAY-985 is an orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 and IKKε, respectively.
-
DS-437 is a Dual PRMT5/7 Inhibitor
2020-02-25
DS-437 is a dualPRMT5/7 inhibitor, and is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. -
CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin, and retains inhibitory activity against Btk.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
6RK73 is a covalent irreversible and specific UCHL1 inhibitor,which specifically inhibits UCHL1 activity in breast cancer.
-
AGN194204 is an orally active and selective RXR agonist. AGN194204 is inactive against RAR and has anti-inflammatory and anticarcinogenic actions.
-
BI-9321 is a potent, selective and cellular active NSD3-PWWP1 domain antagonist, and specifically disrupts histone interactions of the NSD3-PWWP1 domain.
-
BPI-9016M is a dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses lung cancer cell lines growth, migration, and invasion.
-
MSN-125, a potent Bax and Bak oligomerization inhibitor, efficiently prevents mitochondrial outer membrane permeabilization.
-
F1324 is a potent and high-affinity peptidic inhibitor of BCL6 with anti-cancer activity. F1324 has strong inhibition activity against BCL6 PPI.
-
BTSA1 is a high affinity and orally active BAX activator and induces conformational changes to BAX leading to BAX-mediated apoptosis.
-
ZLDI-8 is an ADAM-17 inhibitor that makes tumor cells susceptible to anti-tumor agents and therefore overcoming the HCC multi-drug resistance process.
-
ZCL278 is a potent and selective Cdc42 inhibitor with anticancer and antiviral activity. ZCL278 targets Cdc42-ITSN interaction.
-
CID2950007 is an allosteric inhibitor that binds the guanine nucleotide-associated Cdc42 and induces ligand dissociation.
-
CID-1067700 is a pan GTPase inhibitor, and competitively inhibits Rab7. CID-1067700 is a competitive guanine nucleotide binding inhibitor.
-
Ro 90-7501, an Aβ42 fibril assembly inhibitor, inhibits PP5 in a TPR-dependent manner and has radiosensitizing effects on cervical cancer cells.
-
CM-272, a first-in-class, selective, substrate-competitive and reversible dual G9a/DNMTs inhibitor, inhibits cell proliferation and promotes apoptosis.
-
CCT367766, a PROTAC-based Pirin-targeting PDP, exhibits a moderate affinity for the CRBN-DDB1 complex and reveals a good affinity for Pirin and CRBN.
-
PS315 is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111.
-
JBJ-04-125-02 is a mutant-selective, allosteric and orally active EGFR inhibitor. JBJ-04-125-02 inhibits cancer cell proliferation.
-
DB1976 is a selenophene analog of DB270 and a potent and fully efficacious transcription factor PU.1 inhibitor with apoptosis-inducing effect.
-
CM10 is a potent and selective aldehyde dehydrogenase 1A family inhibitor and regulates metabolism and has anti-cancer activity.
-
E64FC26 is a highly potent pan-style inhibitor of the protein disulfide isomerase (PDI) family with anti-myeloma activities.
-
EB-3D, a selective ChoKα1 inhibitor, induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells, and shows antiproliferative activity.
-
NU1025 is a potent PARP inhibitor and potentiates the cytotoxicity of ionizing radiation drug. NU1025 has anti-cancer and neuroprotective activity.
-
Mobocertinib is a potent epidermal growth factor receptor (EGFR, ErbB1) inhibitor, which displays antineoplastic activity.
-
Mepazine is an effective MALT1 inhibitor. Antipsychotic and tranquilizing agent. Mepazine affects viability of ABC-DLBCL cells by enhancing apoptosis.
-
LBW242, a Smac mimetic, is a potent and orally active proapoptotic IAP inhibitor. LBW242 shows effects on mutant FLT3-expressing cells.
-
LCH-7749944 is a potent PAK4 inhibitor and effectively suppresses the proliferation of human gastric cancer cells and induces apoptosis.
-
TL13-112 is a PROTAC Degrader of ALK
2020-04-15
TL13-112 is a selective ALK-PROTAC degrader and inhibits ALK activity. TL13-112 is comprised of the conjugation of Ceritinib and the ligand pomalidomide . -
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
TP3011 is a potent DNA topoisomerase I inhibitor. Antitumor activities.Active metabolite of TP3076. TP3011 inhibits cancer cell proliferative activities.
-
TL13-12 is a Selective ALK-PROTAC Degrader
2020-04-21
TL13-12 can induce receptor tyrosine kinase anaplastic lymphoma kinase degradation in non small cell lung cancer cells. PROTAC ALK degrader. -
DC-5163 is a potent GAPDH inhibitor, can inhibit glycolysis pathway partially. DC-5163 selectively inhibits cancer cell proliferation and induces apoptosis.
-
BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor, which is highly effective in inhibiting Pten-null prostate cancer growth.
-
M2698 is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with anti-cancer activity. M2698 can cross the blood-brain barrier.
-
ARCC-4 is a low-nanomolar AR degrader, and effectively degrades clinically relevant AR mutants associated with antiandrogen therapy.
-
TAK-683 is a Potent Metastin/GPR54 Agonist
2020-04-29
TAK-683 is a full KISS1R agonist (IC50=170 pM) with improved metabolic stability. It has the potential for the study of hormone-dependent prostate cancer. -
AMG 511 is a potent and selective class I PI3K inhibitor. Suppresses PI3K signaling. Decreases in phosphorylated AKT at Ser473 in a dose-dependent manner.
-
PIK-75 is a reversible DNA-PK and p110α selective inhibitor. Impairs cell proliferation, survival, and tumor growth. Induce apoptosis.
-
BO-264, an orally active TACC3 inhibitor, specifically blocks the function of FGFR3-TACC3 fusion protein and has broad-spectrum antitumor activity.
-
MK-2206 is an orally active, highly potent and selective allosteric AKT inhibitor, with IC50s in the nanomolar range and antitumor activity.
-
CPTH2 is a potent histone acetyltransferase (HAT) inhibitor and selectively inhibits the acetylation of histone H3 by recombinant human Gcn5.
-
ONO-7475 is a selective and orally active novel Anexelekto (AXL) inhibitor. It sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs.
-
iFSP1 is a potent, selective FSP1inhibitor that induces ferroptosis in GPX4-knockout cells which overexpressed FSP1.
-
SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK. SB-633825 can inhibit cancer cell growth and angiogenesis.
-
Zotatifin is a potent and selective eIF4A inhibitor. Zotatifin effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis.
-
SNDX-5613 is a potent, selective, small molecule inhibitor of the Menin-MLL binding interaction for targeted therapy in MLL-rearranged leukemias.
-
OTS514 is a TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.
-
BAY1082439, an orally bioavailable, selective PI3K inhibitor, inhibits mutated forms of PIK3CA and is effective in treating prostate cancer with PTEN-loss.
-
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
TNO155 is an allosteric inhibitor of wild-type SHP2. TNO155 has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.
-
UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with anti-prostate cancer efficacy.
-
MYCMI-6 is a selective MYC:MAX protein interactions inhibitor, which blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain.
-
AKN-028 is an Orally Active FLT3 Inhibitor
2020-05-28
AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor and causes dose-dependent inhibition of FLT3 autophosphorylation. -
CGP77675 is an orally active and potent inhibitor of Src family kinases with anticancer activity. CGP77675 inhibits Src, EGFR, KDR, v-Abl, and Lck.
-
HSD1590 is potent ROCK inhibitor, with IC50s of 1.22 and 0.51 nM for ROCK1 and ROCK2, respectively. HSD1590 displays low cytotoxicity.
-
PD-161570 is a potent inhibitor of FGF-1R, PDGFR, EGFR, c-Src tyrosine kinases and inhibits PDGF-stimulated autophosphorylation and FGF-1R phosphorylation.
-
OT-82 is a selective inhibitor of NAMPT. Selectively toxic to cells of hematopoietic origin. OT-82 is a promising antineoplastic agent.
-
PD-089828 is an competitive inhibitor of FGFR-1/PDGFR-β/EGFR, and a noncompetitive inhibitor of c-Src tyrosine kinase with a long-lasting cellular activity.
-
TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with antitumor activity.
-
THZ-P1-2 is a Selective PI5P4K Inhibitor
2020-06-10
THZ-P1-2 is a potent and selective PI5P4K inhibitor and covalently targets PI5P4Kα/β/γ. THZ-P1-2 causes autophagy disruption and upregulates TFEB signaling. -
ZINC69391, a Rac1 inhibitor, interferes with Rac1-GEF interaction. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects.
-
CID44216842 is a potent Cdc42 selective guanine nucleotide binding lead inhibitor. Cdc42 plays important roles in cell cycle progression.
-
AZA1, a potent dual inhibitor of Rac1 and Cdc42, induces apoptosis and inhibits prostate cancer cells proliferation, migration and invasion.
-
HM03 is a potent and selective HSPA5 inhibitor with anticancer activity. HSPA5 plays a key role in monitoring protein transport through the cell.
-
XZ739 is a PROTAC BCL-XL Degrader
2020-06-18
XZ739 is a PROTAC BCL-XL Degrader. XZ739 is potent against various cancer cell lines. PROTAC is an emerging therapeutic modality. -
TNP-351, an Antifolate, is a Dihydrofolate Reductase (DHFR) Inhibitor. Antifolates serve medical science well in neoplastic and non-neoplastic diseases.
-
ASP4132 is an Orally Active AMPK Activator
2020-06-23
ASP4132 is an orally active, potent AMPK activator with anti-cancer activity and makes tumor regression in breast cancer xenograft mouse models. -
JCN037 is a potent, non-covalent, and brain-penetrant EGFR tyrosine kinase inhibitor. JCN037 has potent anti-cancer activity.
-
DI-82 is a potent deoxycytidine kinase (dCK) inhibitor. DI-82 is potent against hematological malignancies and other cancers.
-
MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor with anti-angiogenesis and anti-cancer activity.
-
RA-9 is a potent and selective proteasome-associated DUBs inhibitor with favorable toxicity profile and anticancer activity.
-
DI-87, an orally active and selective dCK inhibitor, has antitumor activity and is used in combination therapy against tumors expressing dCK.
-
XMU-MP-3, a noncovalent inhibitor that suppresses BTK kinase activity both in vitro and in vivo.
-
HLI373 represents a potential drug-able lead for the development of therapeutically efficacious inhibitors of Hdm2. Hdm2 is an ubiquitin protein ligase.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
GSK621 is a potent and specific AMPK activator and induces autophagy and apoptosis in acute myeloid leukemia (AML) cells.
-
Targapremir-210 binds miR-210’s Dicer processing site and modulates the miR-210 hypoxic circuit in triple-negative breast cancer cells and a mouse xenograft model.
-
LQZ-7I orally and effectively inhibits xenograft tumor growth and induces survivin loss in tumors.
-
M-808 is a highly potent and efficacious covalent Menin-MLL interaction inhibitor. M-808 has a binding IC50 value of 2.6 nM.
-
S2116 is a potent lysine-specific demethylase 1 (LSD1) inhibitor and increases H3K9 methylation, reciprocal H3K27 deacetylation at super-enhancer regions.
-
HJC0416 is a potent and orally active STAT3 inhibitor with an enhanced anticancer profile. HJC0416 is a promising anti-cancer agent for breast cancer study.
-
TH1834 is a specific Tip60 (KAT5) histone acetyltransferase (HAT) inhibitor. TH1834 induces apoptosis and increases DNA damage in breast cancer.
-
RA375, a RPN13 inhibitor, inhibits proteasome function in muscle. RA375 is highly active against cell lines of multiple myeloma and diverse solid cancers.
-
MRK-740 is a selective PRDM9 inhibitor. MRK-740 is more selective for PRDM9 than other histone methyltransferases and other non-epigenetic targets.
-
TAI-1 is an orally active and highly potent first-in-class Hec1 (Ndc80) inhibitor and disrupts Hec1-Nek2 protein interaction, leads to Nek2 degradation.
-
SR7826 is a potent, selective and orally active LIM kinase (LIMK) inhibitor. SR7826 is highly efficient in inhibiting cell-invasion/migration in PC-3 cells.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor with potent anti-tumor activity in the NIH3T3/TPR-Met and U-87 MG xenograft models.
-
GSK778 is a potent and selective inhibitor of bromodomain (BRD) BD1 and offers a super survival advantage in the aggressive MLL-AF9 AML model.
-
JX06 is a potent, selective and covalent inhibitor of PDK via covalently binding to a cysteine residue in an irreversible manner.
-
DM-01 is a EZH2 inhibitor with anticancer activity. DM-01 has significant ability to reduce the cellular H3K27me3 level in K562 cells.
-
MS117 is a potent, selective, and cell-active PRMT6 inhibitor. MS117 is an invaluable tool for testing biological and therapeutic hypotheses.
-
MCP110 is an inhibitor of Ras/Raf-1 interaction in human cancer cells. The Ras family GTPases play a central role in the growth factor signaling.
-
KCC-07 prevents binding of MBD2 to methylated DNA and activates BAI1 inducing anti-proliferative BAI1/p53/p21 signaling. Anticancer activity.
-
CYH33 is an orally active, highly selective PI3Kα inhibitor and inhibits phosphorylation of Akt, ERK with potent activity against solid tumors.
-
UC2288 is an Orally Active p21 Attenuator
2020-08-12
UC2288 is a cell-permeable p21 attenuator. UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels. -
SKI-178 is a potent SphK1 and SphK2 inhibitor and is cytotoxic in both drug sensitive and multi-drug resistant cancer cell lines.
-
SC-43 is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis.
-
ATH686 is a potent, selective, and ATP-competitive FLT3 inhibitor with an antileukemic effect. ATH686 induces apoptosis and inhibits cell cycle.
-
SP-146 is a potent Aurora B inhibitor (IC50=0.316 nM), and shows >2000 fold selectivity against FLT3 and KIT. SP-146 is used for the research of TNBC.
-
SBP-0636457 is a smac mimetic and small-molecule IAP antagonist. Act as potent TRAIL-sensitizing agents in a variety of cancer cell lines.
-
BM-1197 is a potent and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Antitumor activity.
-
JH295 is a potent, irreversible and selective Nek2 inhibitor. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1.
-
YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor and induces a strong cell-cycle arrest, inhibits E2F-driven gene expression.
-
BRD9500 is an Orally Active Phosphodiesterases 3 (PDE3) Inhibitor with Antitumor Activity
2020-08-27
BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor. BRD9500 is active in an SK-MEL-3 xenograft model of cancer. -
ZZW-115, a NUPR1 Inhibitor, Possesses Anticancer Activity via Inducing Necroptosis and Apoptosis
2020-08-29
ZZW-115 is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. ZZW-115 exerts anticancer activity. -
SM1-71, a potent TAK1 inhibitor. it is also a multi-targeted kinase inhibitor and has the potential to be a useful tool to for cancer research.
-
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with potent anti-cancer activity. IPI-9119 induces cell cycle arrest, apoptosis.
-
CAY10404 is a potent and highly selective COX-2 inhibitor. CAY10404 is a potent inhibitor of PKB/Akt and MAPK signalling pathways.
-
RJW100 is a Potent LRH-1 and SF-1 Agonist
2020-09-05
RJW100 is a potent LRH-1 and SF-1 agonist. RJW100 also causes strong activation of the miR-200c promoter and downregulates ZEB1 and ZEB2 proteins. -
Z-LEHD-FMK, an irreversible, selective caspase-9 inhibitor, protects some human cancer cell lines from TRAIL-induced apoptosis
-
CRT0044876 is a potent and selective APE1 inhibitor. CRT0044876 inhibits the AP endonuclease, 3′-phosphodiesterase and 3′-phosphatase activities of APE1.
-
EPI-001 is a selective inhibitor of Androgen Receptor (AR) and can inhibit transactivation of the AR amino-terminal domain (NTD).
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
MPT0G211, an orally active and selective HDAC6 inhibitor, ameliorates tau phosphorylation, and cognitive deficits in an Alzheimer’s disease model.
-
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 displays potent anti-myeloma, anti-thrombotic activity.
-
PU02, a derivative of 6-MP, is an allosteric antagonist of 5-HT3 receptor. PU02 possesses anti-cancer cativity by inducing aopotosis.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
AZD-9833 is a potent and orally active ER antagonist. AZD-9833 has the potential for the study of ER+ HER2-advanced breast cancer.
-
RapaLink-1, a third-generation bivalent mTOR inhibitor, potently blocking cancer-derived, activating mutants of mTOR. It can cross the blood-brain barrier.
-
CMLD012073, an Amidino-Rocaglates, is a Potent eIF4A Inhibitor. Amidino- and amino-rocaglates act as potent translation inhibitors and anti-cancer agents.
-
SJF620 is a Potent PROTAC BTK Degrader
2020-09-26
SJF620 is a potent PROTAC BTK degrader with improved pharmacokinetic properties. Contains a Lenalidomide analog for recruiting CRBN. -
Ilorasertib is a potent inhibitor of Aurora A, B, and C, FLT-3,and the VEGF and PDGF receptor kinases. Activity in acute myeloid leukemia.
-
EEDi-5285 is an exceptionally potent and orally active embryonic ectoderm development (EED) inhibitor with potent anti-cancer activity.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
AG-494 is a potent and selective EGFR tyrosine kinase inhibitor. AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGFR.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
A 419259 is a Potent Src Inhibitor
2020-10-08
A 419259 is a Src family kinases inhibitor with IC50s of 9 nM, 3 nM and 3 nM for Src, Lck and Lyn, respectively. A 419259 is used for cancer research. -
CMLD012612 is a potent eIF4A inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM.
-
D-3263 is an enteric-coated, orally bioavailable (transient receptor potential melastatin member 8) TRPM8 agonist with antineoplastic activity.
-
Giredestrant is an orally active and selective estrogen receptor (ER) antagonist with anti-tumor activity. Giredestrant is a non-steroidal ER ligand.
-
NEO2734 (EP31670) is an orally active p300/CBP and BET bromodomain selective inhibitor, with IC50 values of <30 nM for both p300/CBP and BET bromodomains.
-
Mavelertinib is a high-affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
BRD3731 is a Selective GSK3β Inhibitor
2020-10-21
BRD3731 is a selective GSK3β inhibitor. BRD3731 can be used for the research of a mood disorder, diabetes, and neurodegenerative disorder, etc. -
Telomestatin is a potent telomerase inhibitor and selectively facilitates the formation of intramolecular G-quadruplexes. ADC cytotoxin for cancer research.
-
BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC) and does not induce CDK6 and IKZF1/3 degradation with anti-cancer activity.
-
BC-LI-0186 is a selective inhibitor of LeuRS and RagD interaction (IC50=46.11 nM). BC-LI-0186 suppresses the activity of cancer-associated MTOR mutants.
-
BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC) and does not induce IKZF1/3 degradation with anti-cancer activity.
-
MSAB, a strongest and selective inhibitor of Wnt/β-catenin signaling activity, represents an effective strategy for cancers.
-
APS6-45 is an orally active tumor-calibrated inhibitor. A highly efficacious lead. Inhibits RAS/MAPK signaling and exhibits antitumor activity.
-
CCT369260 is an Orally Avtive B-cell Lymphoma 6 (BCL6) Inhibitor with Anti-Tumor Activity
2020-11-03
CCT369260 is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 exhibits an IC50 of 520 nM. -
KB02-SLF is a PROTAC-based nuclear FKBP12 degrader. KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase).
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
DT2216 is a potent and selective BCL-XL degrader based on PROTAC technology. DT2216 inhibits leukemia and has potent anti-cancer activity.
-
dTRIM24 will be a useful tool to further probe the function of TRIM24 by rapid chemical depletion in hematopoietic cancers and other biological contexts.
-
ZXH-3-26 is a Selective PROTAC BRD4 Degrader
2020-11-17
ZXH-3-26 is a Selective PROTAC BRD4 Degrader and allows pharmacologic targeting of BRD4 without significant inhibition or degradation of BRD2/3. -
BETd-260 is a Potent PROTAC BET Degrader
2020-11-18
BETd-260 is a highly potent, efficacious, and promising BET degrader. -
SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology by recruiting VHL E3 ubiquitin ligase. SIAIS178 has anticancer activity.
-
GNE-987, a potent chimeric BET degrader, exhibits picomolar cell BRD4 degradation activity. GNE-987 can be used in PROTAC-Antibody Conjugate (PAC).
-
BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with cereblon ligands to hijack E3 ligases for PTK2 degradation.
-
dFKBP-1 induces potent and dose-dependent degradation of FKBP12 in 293FT-WT cells. A facile and general new strategy to control target protein stability.
-
UNC6852 is a chemical degrader that targets polycomb repressive complex 2 (PRC2). Anti-proliferative in diffuse large B cell lymphoma cell lines.
-
VZ185 is a highly selective, potent, and rapid dual degrader with a slight preference for BRD9 over BRD7.
-
PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor. Antitumor activity.
-
MZP-54 is a Selective BRD3/4 PROTAC Degrader
2020-12-02
MZP-54 is a PROTAC that would link together specific VHL ligand and BET bromodomain ligand. MZP-54 induces degradation of BRD3/4. -
H3B-6545 is a selective estrogen receptor covalent antagonist and prevents bone loss in ovariectomized Sprague-Dawley rats.
-
ADPM06 is a Novel Nonporphyrin Photodynamic Therapeutic (PDT) Sensitizer and Induces Apoptosis
2020-12-05
ADPM06 is a nonporphyrin PDT agent. ADPM06 exhibits IC50 values in the micro-molar range in human tumor cells and induces apoptosis. -
CC-90010 is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors and non-Hodgkin's lymphoma.
-
GNE-371, a Chemical Probe for the Second Bromodomains of TFIID Subunit 1 and TFIID Subunit 1-Like
2020-12-09
GNE-371 is a selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and TFIID subunit 1-like. -
VERU-111 inhibits the expression of tubulin βIII and βIV over other isotypes, which supports the ability of VERU-111 to surmount drug resistance.
-
BMS-P5 is an Orally Active PAD4 Inhibitor
2020-12-12
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model -
ML132, a potent and selective caspase 1 inhibitor with a unique selectivity pattern, is responsible for the proteolytic activation of IL-1β and IL-18.
-
CHDI-390576, a potent and CNS penetrant class IIa HDAC inhibitor, show selectivity over class I HDACs, HDAC8 and the class IIb HDAC6 isoform.
-
SAR-020106 is an ATP-competitive CHK1 inhibitor with an IC50 of 13.3 nM for hCHK1. SAR-020106 can enhance antitumor activity with selected anticancer drugs.
-
EMI56 is a Superior Mutant EGFR Inhibitor
2020-12-19
EMI56 is a Superior Mutant EGFR InhibitorLung Cancer, Non-Small Cell Lung Cancer A drug discovery platform to identify compounds that inhibit EGFR triple mutants. -
CTPI-2 is a SLC25A1 inhibitor. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. Antitumor activity.
-
BI-3802, a BCL6 degrader, inhibits the BCL6 BTB domain. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1.
-
DMU-212 Possesses Antimitotic, Anti-Proliferative, Antioxidant and Apoptosis Promoting Activities
2020-12-24
Activation of ERK1/2 is required for the antimitotic activity of the Resveratrol analogue DMU‐212 in human melanoma cells. -
PND-1186 is a FAK inhibitor and selectively promotes tumor cell apoptosis in three-dimensional environments. Acts as an anti-cancer therapy.
-
AZ9482 is a Triple PARP1/2/6 Inhibitor
2021-01-05
AZ9482 is a triple PARP1, PPAR2 and PPAR6 inhibitor, with IC50 values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively. -
CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), respectively.
-
APG-1387 is a bivalent SMAC mimetic and an IAP antagonist. APG-1387 induces apoptosis with anti-cancer activity.
-
WL47, a high-affinity cavolin-1 (CAV1) ligand (Kd=23 nM), act as a potent and selective disrupter of CAV1 oligomers.
-
NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor with potent tumor suppressive efficacies.
-
CJ-2360 is an ALK inhibitor with IC50s of 2.2-8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively.
-
NSC 80467, a potent DNA damaging agent, selectively inhibits survivin, and preferentially inhibits DNA synthesis.
-
G5-7, an orally active and allosteric JAK2 inhibitor. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect.
-
R59949 is a pan DGK inhibitor with an IC50 of 300 nM. R59949 activates PKC by enhancing the levels of the endogenous ligand diacyl glycerol.
-
ML786 is an orally bioavailable Raf inhibitor, inhibits V600EΔB-Raf, wt B-Raf, and C-Raf. It also inhibits Abl-1, DDR2, EPHA2, KDR, and RET.
-
NSC-105808, a potent, specific DNA2 nuclease inhibitor, inhibits HR repair, DSB end resection and suppresses proliferation of cancer cells.
-
Afatinib is an irreversible EGFR family inhibitor and shows potent activity against wild-type and mutant forms of EGFR and HER2.
-
Senaparib, a selective and orally active PARP1/2 inhibitor, has great potential as a monotherapy as well as in combination with other agents.
-
CMLD-2 is Inhibits HuR and Induces Apoptosis
2021-01-20
CMLD-2, a HuR -ARE interaction inhibitor, competitively binds HuR protein and induces apoptosis. CMLD-2 has potent anti-cancer activity. -
NU6102 is a Potent CDK1 and CDK2 Inhibitor
2021-01-21
NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. -
JH-XI-10-02, a highly Potent CDK8 Degrader, modulates the CDK8 protein levels. A viable therapeutic strategy in cancer.
-
ICCB280, a inducer of C/EBPα, exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis.
-
NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective CECR2 inhibitor with potent anti-cancer activity.
-
BI99179 is a Selective Type I FASN Inhibitor
2021-01-28
FASN is a key enzyme for lipogenesis and highly expressed in lipogenic tissues. BI99179 is a Selective Type I FASN Inhibitor. -
The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFβ and causing cell cycle arrest
-
Triciferol combines VDR agonism and HDAC inhibition to enhance the cytostatic and cytotoxic activities of 1,25D.
-
Fasentin inhibits GLUT-1 and GLUT-4 transporters. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity.
-
PINT87aa, a Potential Tumor-Suppressive Peptide, Directly Interacts with the PAF1 Complex
2021-02-04
PINT87aa, a potential tumor-suppressive peptide, directly interacts with the PAF1 complex and inhibits mRNA transcriptional elongation. -
KS15 is an inhibitor of the cryptochromes and clockbmal1 heterodimer interaction.
-
dCBP-1 is a potent and selective degrader of p300/CBP based on PROTAC. dCBP-1 is exceptionally potent at killing multiple myeloma cells.
-
Tuxobertinib (BDTX-189) is a small molecule ATP-competitive inhibitor against a family of allosteric EGFR and HER2 mutations.
-
Piclidenoson (IB-MECA) is an A3 adenosine receptor (A3AR) agonist. Piclidenoson is used for the research of cancer, inflammatory diseases and COVID-19.
-
PF 477736 (PF 00477736) is a Chk1 inhibitor. Breaching the DNA damage checkpoint. PF-00477736 combines with Gemcitabine to abrogates cell cycle arrest.
-
CXD101 is a selective and orally active class I HDAC inhibitor for advanced cancer.
-
AKI603 is a potent Aurora kinase inhibitor. AKI603 attenuates breast tumor-initiating cells and overcomes drug resistance.
-
NSC 33994 is a Selective JAK2 Inhibitor
2021-02-18
NSC 33994 (G6) is a selective JAK2 inhibitor. NSC 33994 reduces the levels of pJAK2 in both a dose- and time-dependent manner. -
PR-619 is a Broad-Range DUB Inhibitor
2021-02-20
PR-619, a broad-spectrum deubiquitinating enzyme (DUB) inhibitor, induces ER stress and ER-stress related apoptosis. -
Barasertib (AZD1152), a Pro-Drug of Barasertib-hQPA, is a Highly Selective Aurora B Inhibitor
2021-02-23
Barasertib (AZD1152) is a pro-drug of Barasertib-hQPA. A selective Aurora B kinase inhibitor. Provides a potential treatment for multiple myeloma. -
ML390 is a Potent DHODH Inhibitor
2021-02-24
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor and is an inducer of myeloid differentiation. -
PF-06843195 is a Selective PI3Kα Inhibitor
2021-02-25
PF-06843195 is a selective PI3Kα inhibitor. The Kis of PF-06843195 for PI3Kα and PI3Kδ are less than 0.018 nM and 0.28 nM, respectively. -
TAS-119 is an orally active, selective inhibitor of Aurora kinase A. A clinical candidate for efficacy testing in combination with taxanes.
-
AES-135 is a Potent HDAC Inhibitor
2021-03-03
AES-135, a potent HDAC inhibitor, demonstrates high cytotoxicity in a variety of cancer cell lines, most notably in pancreatic tumor lines. -
NAZ2329 is an allosteric, noncompetitive and reversible inhibitor of R5 RPTP subfamily and PTPRZ/PTPRG with anti-cancer activity.
-
GW806742X, an ATP mimetic and a potent MLKL inhibitor, retards MLKL membrane translocation and inhibits necroptosis.
-
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
DTHIB is a Direct and Selective Heat Shock Factor 1 (HSF1) Inhibitor. Selectively accelerates the degradation of nuclear HSF1.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor for a variety of disorders. Possesses antitumor and neuroprotective activity.
-
IACS-13909 is a Selective and Orally Active SHP2 Inhibitor. Overcomes tumor resistance to Osimertinib. Targeting SHP2. Therapeutic strategy.
-
IMT1 is a first-in-class specific and noncompetitive human POLRMT inhibitor for mitochondrial transcription disorders related diseases.
-
Z-LE(OMe)TD(OMe)-FMK is a Selective Caspase-8 Inhibitor. Caspase-8 is a cysteine protease for Fas-induced apoptosis and lymphocyte activation.
-
BIM-23190, a somatostatin analog, is a selective SSTR2 and SSTR5 agonist. BIM-23190 can be used in the study for cancer and acromegaly.
-
Conglobatin inhibits proliferation and induces apoptosis by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
YUM70 inhibits GRP78. Induces endoplasmic reticulum stress-mediated apoptosis. Pancreatic cancer. Acts as a novel anticancer agent.
-
DBPR112 is an orally active furanopyrimidine-based EGFR (WT and L858R/T790M) inhibitor with significant antitumor efficacy.
-
UZH1a is a Selective METTL3 Inhibitor
2021-03-25
UZH1a, a potent and selective METTL3 inhibitor can be used for epitranscriptomic modulation of cellular processes with antitumor activity. -
Olafertinib is a Third-Generation EGFR TKI
2021-03-27
Olafertinib acts as a promising third-generation EGFR inhibitor. Olafertinib has the potential for NSCLC research. -
Elimusertib is a potent, orally available and selective ATR inhibitor. Elimusertib has potent anti-tumor activity.
-
FLTX1, a Fluorescent Tamoxifen Derivative, Specifically Labels Intracellular Binding Sites (ER)
2021-03-31
FLTX1 is a fluorescent Tamoxifen (Tx) derivative that specifically labels intracellular Tx-binding sites (estrogen receptors). -
Rineterkib, an orally active RAF and ERK1/2 inhibitor, has activity in multiple MAPK activated cancer cells and xenograft models.
-
DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). DC_AC50 can be used for cancer research.
-
LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM.
-
PF-06260414 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) and has the potential for muscle weakening.
-
Stafib-1 is the First Selective Inhibitor of STAT5b SH2 Domain. Anticancer agent. STAT5b acts as a target for tumor therapy.
-
LDN193189 is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3, with weaker effects on ALK4, ALK5 and ALK7.
-
Retro-2 is an inhibitor of retrograde protein trafficking at the endosome-trans-Golgi network interface. Retro-2 induces cell autophagy
-
APS-2-79 is a MEK inhibitor. Stabilization of the KSR inactive state. An effective strategy to target other pseudokinases.
-
BMS-354825 is a dual Src and Abl kinase inhibitor. Antitumor activity. Orally active in the chronic myelogenous leukemia.
-
Miransertib is an orally active, selective and allosteric Akt inhibitor. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor.
-
L-Moses is the first potent, selective, and cell-active PCAF Brd inhibitor. L-Moses disrupts PCAF-Brd histone H3.3 interaction.
-
MS049 is a potent, selective dual inhibitor of PRMT4 and PRMT6. MS049 reduces levels of Med12me2a and H3R2me2a in HEK293 cells.
-
LYN-1604 is a Potent ULK1 Activator
2021-04-24
LYN-1604, a potent ULK1 activator, induces cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. -
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist. SB-332235 inhibits acute and chronic models of arthritis in the rabbit.
-
AZD1208 is a potent, selective, ATP-competitive, and orally active pan-Pim kinase inhibitor. AZD1208 inhibits acute myeloid leukaemia.
-
ML-00253764 is a brain penetrant nonpeptidic melanocortin receptor 4 (MC4R) antagonist with a Ki/IC50 of 0.16 µM/0.103 µM, respectively.
-
Rosabulin is a Potent Microtubule Inhibitor
2021-05-01
Rosabulin is a small molecule vascular disrupting agent, with potential antimitotic and antineoplastic activities. -
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
A-674563 is an orally active and selective Akt1 inhibitor. A-674563 induces G2 cell cycle arrest and apoptosis in STS cells.
-
Pirtobrutinib, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.
-
SHP394 acts as a Potent, Selective, and Orally Efficacious SHP2 Inhibitor. SHP2 is a multifunctional therapeutic target.
-
MR837 is an Inhibitor of NSD2-PWWP1
2021-05-11
MR837 is a potent inhibitor of NSD2 (WHSC1)-PWWP1 protein-protein interaction. MR837 can bind with human NSD2. -
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
SIS3 is a selective Smad3 phosphorylation inhibitor and inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.
-
PROTAC MDM2 degrader MD-222 is highly potent and effective in inducing degradation of MDM2 and in activating wild-type p53 in cells.
-
BI-3406 is a selective, orally bioavailable SOS1 inhibitor that binds to the catalytic domain of SOS1, preventing the interaction with KRAS.
-
GSK973, a selective, orally bioavailable inhibitor of the BD2s of the BET family, shows good potency against BRD2 BD2, BRD3 BD2 and BRDT BD2.
-
DT-061 is an Orally Active PP2A Activator
2021-05-21
DT-061 is an Orally Active PP2A Activator. PP2A inhibition is a druggable MEK inhibitor resistance mechanism. -
Lonafarnib is a potent and orally active farnesyl transferase inhibitor, and it inhibits the activities of H-ras, K-ras and N-ras.
-
FTI-277 is a farnesyl transferase inhibitor, selectively blocks oncogenic Ras signaling. It inhibits hepatitis delta virus infection.
-
PHT-7.3 is a Selective Inhibitor of Connector Enhancer of Kinase Suppressor of Ras 1 (Cnk1)
2021-05-27
PHT-7.3 is a selective inhibitor of Cnk1 pleckstrin homology (PH) domain. PHT 7.3 blocks the growth of mutant KRAS cells and tumors. -
Lenalidomide, a CRBN ligand, is an orally active immunomodulator that effective treatment for myelodysplastic syndrome and multiple myeloma.
-
Trilaciclib is a CDK4/6 inhibitor with IC50s of 1 nM/4 nM for CDK4/6, respectively. Use for chemotherapy-induced myelosuppression in vivo.
-
SMAP-2 is an orally active PP2A activator. SMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines.
-
LJI308 inhibits the phosphorylation of RSK and YB-1 after irradiation, treatment with EGF, and in cells expressing a KRAS mutation.
-
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
CC-90011 is a potent, selective, reversible and orally active LSD1 inhibitor that induces AML and SCLC cells differentiation.
-
Elacestrant is an orally available selective estrogen receptor degrader (SERD). Elacestrant is an effective breast cancer cell antagonist.
-
PTC-209, a specific BMI-1 inhibitor, irreversibly impairs colorectal cancer-initiating cells (CICs) and impairs the tumor microenvironment.
-
NU9056 is a selective Tip60 (KAT5) histone acetyltransferase inhibitor. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5.
-
DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM.
-
Acolbifene is a 4th generation SERM with potent and pure anticarcinogenic properties in the mammary gland and uterus.
-
ARV-110 is an orally active, specific androgen receptor (AR) PROTAC degrader. ARV-110 can be used for the research of prostate cancer.
-
CCI-007, a selective MLL-r leukemia cell lines inhibitor, and inhibits the viability of CALM-AF10 and SET-NUP214 leukemia.
-
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor and inhibits SIX1-mediated breast cancer metastasis.
-
Golvatinib (E-7050) is an inhibitor of c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively. Can be used for cancer research.
-
Vorasidenib is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor.
-
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
Rociletinib is a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
-
Venadaparib is a selective and orally active PARP1/2 inhibitor with significant in vitro and in vivo activities in multiple cancer models.
-
LP-261 is a potent and orally active anti-mitotic agent and shows an inhibition of in vitro tubulin polymerization with an EC50 of 3.2 μM.
-
Capivasertib is an orally active AKT inhibitor with pharmacodynamic activity in multiple solid and hematologic tumors.
-
Proxalutamide (GT0918) is an orally active potent androgen receptor (AR) antagonist. And Proxalutamide (GT0918) plays important roles in the study of prostate cancer and COVID-19.
-
SG3199, an ADC Cytotoxin, is a Cytotoxic DNA Minor Groove Interstrand Crosslinking PDB Dimer
2021-07-12
SG3199, a PBD dimer, is a warhead in next-generation ADCs with potently cytotoxic and a very short half-life. -
BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC). BSJ-4-116 exhibits potent antiproliferative effects.
-
GL0388 activates Bax and induces Bax-mediated apoptosis. GL0388 suppresses breast cancer xenograft tumor growth in vivo.
-
Lumiracoxib is a COX-2 inhibitor. Lumiracoxib acts as nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities.
-
SJ6986 is a selective and orally active GSPT1/GSPT2 degrader, displaying selectivity over classical IMiD neosubstrates, such as IKZF1/3
-
DP-C-4 is a CRBN-Based dual PROTAC for EGFR and PARP could provide an effective study for cancer diseases.
-
ABBV-744 is a first-in-class, orally active and selective BET BDII inhibitor could provide an effective study for prostate cancer.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
GGTI-2154 is a potent and selective inhibitor of GGTase I and has the potential for the research of cancer.
-
XY028-140 is a potent and selective PROTAC-based CDK4/6 degrader, which can inhibit RB-E2F signaling and reduce CDK4 and CDK6 protein levels.
-
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR. Nimotuzumab is a strong antitumor drug.
-
Pelcitoclax (APG-1252) is a Bcl-2/Bcl-xl Inhibitor with Antineoplastic and Pro-Apoptotic Effects
2021-07-28
Pelcitoclax has potent anti-tumor effects through ntrinsic mitochondrial pathway of apoptosis in cancer cells. -
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
DCH36_06 is a Selective p300/CBP Inhibitor
2021-07-31
DCH36_06 is a potent and selective p300/CBP inhibitor with strong anti-tumor activities both in vivo and in vitro. -
Aderbasib is a potent and orally active inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity in vivo.
-
NRX-2663 is a potent enhancer of the interaction between β-catenin SCFβ-TrCP, potentiates the ubiquitylation of mutant β-Catenin by β-TrCP.
-
M3258 is an orally bioavailable, potent, reversible, and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor.
-
MRTX9768 is an Orally Active PRMT5 Inhibitor
2021-08-07
MRTX9768 is an orally active PRMT5 inhibitor and designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors. -
E67-2 is a Selective KIAA1718 Jumonji Domain Inhibitor with Low toxicity and is a potent compound of cancer research.
-
SIM1 is a PROTAC Based BET Family Degrader
2021-08-11
SIM1 is a potent von Hippel-Lindau (VHL)-based trivalent PROTAC capable of degradation for all BET family members. -
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 induces cell cycle arrest and apoptosis with anti-cancer activity.
-
PHPS1 is a Selective Shp2 Inhibitor
2021-08-14
PHPS1 is a potent and selective Shp2 inhibitor. PHPS1 reveals a significant decrease in atherosclerotic plaque size. -
UMB298 is a selective CBP/P300 bromodomain inhibitor and could provide an effective study for acute myeloid leukemia.
-
VT-107 is a potent and pan-TEAD auto-palmitoylation inhibitor. VT-107 can inhibit the proliferation of NF2-deficient mesothelioma cells.
-
IV-361 is an orally active, potent, and selective CDK7 inhibitor. IV-361 exhibits excellent anti-tumor activity.
-
HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven many breast cancers.
-
Z-VAD-FMK is a cell-permeant, irreversible pan-caspase inhibitor, which prevents apoptosis in many different cell types.
-
Rapamycin is a Specific mTOR Inhibitor
2021-08-25
Rapamycin is a specific inhibitor of mTOR, an autophagy activator, an immunosuppressant, with anti-inflammatory and anti-tumor activities. -
Staurosporine is an ATP-competitive protein kinases inhibitor and is a potent compound of cancer research.
-
LY294002, a broad-spectrum inhibitor of PI3K (IC50s ranging 0.5-0.97 μM for PI3Kα, PI3Kδ, and PI3Kβ), is an apoptosis inducer.
-
Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II. Trichostatin A exhibits anti-tumor activity.
-
Fulvestrant is a pure antiestrogen and a potent estrogen receptor (ER) antagonist. Fulvestrant induces autophagy and has antitumor efficacy.
-
Iberdomide (CC-220) is an orally active cereblon (CRBN) E3 ligase modulator (CELMoD) with antitumor and immunostimulatory activities。
-
Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
-
Everolimus (RAD001), a Rapamycin Derivative, is a Selective and Orally Active mTOR1 Inhibitor
2021-09-07
Everolimus (RAD001), a Rapamycin derivative, is a selective and orally active mTOR1 inhibitor with anticancer activities. -
SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan and inhibits DNA and RNA synthesis.
-
Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor with good anticancer activity.
-
Sorafenib (Bay 43-9006) is an orally active Raf inhibitor and induces autophagy and apoptosis with anti-tumor activity.
-
ARQ 531 is a potent, ATP-competitive, reversible non-covalent and orally active BTK inhibitor, with anti-tumor activities.
-
Wortmannin is a potent, selective, irreversible and orally active PI3K inhibitor, with anticancer effects.
-
Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 and induces apoptosis.
-
GSK2606414 is an orally available PERK inhibitor and is a potent compound of cancer and neurological diseases.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor with antitumor activity.
-
Infigratinib is a potent inhibitor of the FGFR family, with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1/2/3/4, respectively.
-
Sapanisertib is an orally available, potent, and highly selective mTORC1/2 inhibitor demonstrating promise in numerous malignancies.
-
Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer.
-
Ganetespib (STA-9090) is a HSP90 Inhibitor
2021-10-14
Ganetespib is a unique Hsp90 inhibitor that exhibits potent and sustained antitumor effects in a broad range of malignancies. -
Atuveciclib (BAY-1143572) is a highly selective, oral PTEFb/CDK9 inhibitor with potent antitumor activity.
-
Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, disrupting the formation of actin polymers.
-
Saracatinib is a potent Src inhibitor (IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk) and has anti-invasive activities.
-
Quizartinib (AC220) is an Orally Active and Highly Selective FLT3 Tyrosine Kinase Inhibitor
2021-10-24
Quizartinib (AC220) is an orally active, highly selective, and potent second-generation type II FLT3 tyrosine kinase inhibitor. -
Brusatol (NSC 172924) is a Nrf2 Inhibitor
2021-10-26
Brusatol inhibits the Nrf2 signaling pathway by reducing the protein level of Nrf2, with anticancer activities. -
SB 258719 is a selective 5-HT7 receptor antagonist and can be used for the research of cancer and neurological disease.
-
CX-5461 is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis with potent antitumor activity.
-
Daunorubicin is a topoisomerase II inhibitor with a wide spectrum of anticancer activity and anti-HBV effect.
-
MB710 is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1 μM.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
IMD-0354 is a Selective IKKβ Inhibitor
2021-11-09
IMD-0354 is a selective IKKβ inhibitor and potently inhibits NF-κB activity. IMD0354 has antitumor activity. -
Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis. Anisomycin is a JNK activator.
-
Crizotinib is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Anti-tumor activity.
-
Oltipraz is a Nrf2 Inhibitor
2021-11-18
Oltipraz is a potent Nrf2 activator. Oltipraz has an inhibitory effect on HIF-1α activation in a time-dependent manner, the IC50 is 10 μM. -
Cyclopamine is a potent Hedgehog (Hh) pathway antagonist and a selective Smo inhibitor with antitumor activity.
-
A 83-01 is an inhibitor of ALK5/4/7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5/4/7, respectively.
-
PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity. Leukemia (T-ALL).
-
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
Fadrozole is a potent, selective, and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM. Can be used for cancer research.
-
Troglitazone is a potent PPARγ agonist with antitumor activies. Troglitazone has the potential for the research of the pancreatic cancer.
-
Spautin-1 is a specific and potent autophagy inhibitor which inhibits ubiquitin-specific peptidases, USP10 and USP13.
-
Flavopiridol is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
-
Lonidamine, an antitumor agent and an indazole derivative, interferes with energy-yielding processes in cancer cells.
-
CBL0137 is an inhibitor of the histone chaperone, FACT. CBL0137 activates p53 and inhibits NF-κB with EC50s of 0.37 and 0.47 µM, respectively.
-
AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM.
-
MRTX1133, a selective, first-in-class inhibitor of KRAS G12D, selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells.
-
Zebularine is a potent DNA methyltransferase inhibitor with anti-tumor activity. Zebularine also inhibits cytidine deaminase.
-
MS4322 is a first-in-class PRMT5 degrader and a valuable chemical tool for exploring the PRMT5 functions in vitro and in vivo.
-
Apitolisib is a potent Class I PI3 kinase and mTORC1/2 inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, respectively.
-
Almonertinib is an orally available, third-generation EGFR TKI with selectivity for EGFR-sensitizing and T790M resistance mutations.
-
ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor and has the potential for acute myeloid leukemia (AML) research.
-
Alda-1 is a potent ALDH2 Agonist
2021-12-30
Alda-1 ameliorates H2O2-induced Achilles tendinopathy. Alda-1 could be used for preventing Achilles tendinopathy. -
Bestatin is a broad-spectrum and competitive aminopeptidase and leukotriene A4 hydrolase inhibitor, with anticancer effects.
-
Repotrectinib is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib has anti-cancer activity.
-
Deguelin acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis.
-
XL092 is a potent inhibitor of the activity of Axl, Mer and C-Met kinase with IC50s of <10 nM, respectively. Anti-tumor Activity.
-
Dovitinib is a multi-targeted tyrosine kinase inhibitor. Dovitinib inhibits cell proliferation and has potent antitumor activity.
-
Rucaparib is a PARP Inhibitor
2022-01-13
Rucaparib is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3). Rucaparib has the potential for CRPC research. -
β-Lapachone, a topoisomerase I inhibitor, induces apoptosis by inhibiting cell cycle progression. β-Lapachone has anti-inflammatory effect.
-
Tirabrutinib is a Selective BTK Inhibitor
2022-01-18
Tirabrutinib is a selective and novel inhibitor of BTK, Tirabrutinib prevents B-cell receptor signaling and impeding B-cell development. -
SD-1029 is a JAK2/STAT3 Activation Inhibitor
2022-01-22
SD-1029, a JAK2/STAT3 activation inhibitor, can inhibit STAT3 nuclear translocation and JAK2 phosphorylation. -
VU0359595 is a Selective PLD1 Inhibitor
2022-01-26
VU0359595 is a potent and selective PLD1 inhibitor, and VU0359595 shows >1700-fold selective for PLD1 over PLD2. -
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Zingerone is a natural orally active nontoxic methoxyphenol potent anti-inflammatory, antidiabetic, antioxidize, and anti-tumor properties.
-
ML-099 is a pan Ras-related GTPases activator. ML-099 can activate Rac1, cell division cycle 42, Ras, Rab7, and Rab-2A.
-
IACS-15414, a potent and orally active SHP2 inhibitor, exhibits significant anti-tumor efficacy in mouse xenograft model.
-
GS-493 is a selective SHP2 inhibitor and blocks cellular motility and growth of cancer cells in vitro and in vivo.
-
HM43239 is a potent, selective, and orally active FLT3 inhibitor and shows effectiveness in AML with FLT3 mutations.
-
PFM39 is a potent and selective MRE11 exonuclease inhibitor, and does not inhibit endonuclease, nuclease activity.
-
Hesperadin, an ATP competitive inhibitor of Aurora A/B, inhibits Aurora B with an IC50 of 250 nM. A broad-spectrum influenza antiviral.
-
VAL-083 is an alkylating agent that creates N7 methylation on DNA, VAL-083 exhibits antitumor activity in vitro and in vivo.
-
Lomeguatrib is a highly potent MGMT inactivator, improves the therapeutic effect of alkylating agents in a number of tumour models.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
MS170 is a PROTAC AKT Degrader
2022-02-27
MS170 is a CRBN-recruiting degrader, the AKT proteolysis targeting chimera (PROTAC) degrader. -
Avitinib is a potent, irreversible and orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
-
Rigosertib (ON-01910), a multi-kinase inhibitor, inhibits PLK1 (IC50=9 nM), and induces G2/M arrest in cell cycle and apoptosis.
-
PX-12 is an irreversible inhibitor of Trx-1 and inhibits the growth, migration, and invasion of colorectal cancer cell lines.
-
Chelerythrine is a potent inhibitor pf protein kinase C with anti-cancer activity.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
Linzagolix is a potent, non-peptide, and orally active GnRH antagonist used for the research of endometriosis and uterine myomas.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Mirin is a potent MRN complex inhibitor. Mirin prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity.
-
Monastrol, a potent and cell-permeable inhibitor of the mitotic kinesin Eg5, has potential for cancer research.
-
FH535 is a potent inhibitor of Wnt/β-catenin and PPAR.
-
GNE-149 is an orally bioavailable full antagonist of estrogen receptor α. GNE-149 has potent antitumor activity.
-
Bafetinib is an orally active dual Abl/Lyn tyrosine kinase inhibitor. Bafetinib suppresses the growth of Ph+ leukemia cells.
-
Pirarubicin, an anthracycline antibiotics, is a topoisomerase II Inhibitor.
-
WAY 316606 is an inhibitor of the secreted protein sFRP-1.
-
Ulixertinib is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases.
-
Nimbolide, a triterpene derived from the leaves and flowers of neem, induces apoptosis through inactivation of NF-κB.
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Reversine is a potent, ATP-competitive Aurora kinases inhibitor. Reversine is a potential anticancer agent for ALL.
-
Tivantinib is a selective and orally active inhibitor of c-MET. Tivantinib can be used for the research of cancer.
-
Oprozomib (PR-047) is an orally active peptide epoxyketone proteasome inhibitor.
-
Embelin is a Nonpeptidic XIAP Inhibitor
2022-05-05
Embelin is a potent inhibitor of nonpeptidic XIAP. -
Splitomicin is a cell-permeable, potent inhibitor of SIR2. Splitomicin inhibits the aggregation of human platelets.
-
Bisantrene is topoisomerase II poisons and DNA intercalators. Bisantrene intercalates with and disrupts the configuration of DNA.
-
Epothilone B is a Microtubule Stabilizer
2022-05-10
Epothilone B, a non-taxane-related and nonneurotoxic microtubule stabilizer, can be used for the research of breast cancer. -
Pimasertib is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor with antitumor activies.
-
5-Azacytidine is a DNMT inhibitor. 5-Azacytidine can be used for the research of myelodysplastic syndrome.
-
Epoxomicin is an epoxyketone-containing natural product and a selective and irreversible proteasome inhibitor. Cross the blood-brain barrier.
-
Vistusertib is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.
-
Seliciclib, a potent, selective and orally active CDKs inhibitor, preferentially inhibits CDK2, CDK7 and CDK9.
-
Temoporfin, a photosensitizer agent, can be used for the research of squamous cell carcinoma of the head and neck.
-
Namodenoson (CF-102) is a selective A3 adenosine receptor (A3AR) agonist.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Ascochlorin Mediates Anti-tumor Effects through the Suppression of STAT3 Signaling Cascade
2022-06-05
Ascochlorin, an isoprenoid antibiotic, mediates its anti-tumor effects predominantly through the suppression of STAT3 signaling cascade. -
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
β-Amanitin is a cyclic peptide toxin, inhibits eukaryotic RNA polymerase II and III. It inhibits DNA transcription, and protein synthesis.
-
LTX-315 is an oncolytic peptide with potent anticancer activity.
-
Actinomycin D (Dactinomycin) is an autophagy activator inhibiting DNA repair with an IC50 of 0.42 μM.
-
Pitstop 2 is a clathrin inhibitor which inhibits clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin.
-
DS17701585 is a highly selective and orally active EP300 and CBP inhibitor and DS17701585 can be used for cancer research.
-
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin can be used for leukemia research.
-
Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
-
CQ211 is a selective RIOK2 inhibitor (Kd=6.1 nM). CQ211 exhibits anti-proliferation inhibition activity against multiple cancer cell lines.
-
FPDT is an anti-glioblastoma agent. Besides, FPDT shows anti-proliferative activity for GBM cells and astrocytes.
-
SBI-581 is an orally active and selective serine-threonine kinase TAO3 inhibitor with potent antitumor activity.
-
AZD7254 is a potent and orally active Smoothened (SMO) inhibitor, against sonic Hh protein (shh), with strong anti-cancer effects.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
RKI-1313 is a Potent ROCK1/2 inhibitor
2022-07-09
RKI-1313 is a potent ROCK inhibitor and shows little effect on the phosphorylation levels of ROCK substrates, migration, invasion. -
LDN-211904 oxalate is a potent and selective EphB3 inhibitor and combines with cetuximab can overcome cetuximab resistance.
-
Pulrodemstat is a potent, selective, reversible and orally active LSD1 inhibitor, with anticancer effects.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
PSB-SB-487 is a Potent GPR55 Antagonist
2022-07-21
PSB-SB-487, a Coumarin derivative, is a potent GPR55 antagonist, and is also a partial CB2 receptor agonist. -
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
Panobinostat, a potent and orally active non-selective HDAC inhibitor, exhibits antineoplastic activities.
-
DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis.
-
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with IC50s <5 nM , possessing anticancer activity.
-
ML-097 is a pan Ras-related GTPases activator that can activate Rac1, cell division cycle 42, Ras, and Rab7.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
PU-H54 is a potent purine-based (PU) Grp94-selective inhibitor. PU-H54 has the potential for the research of breast cancer.
-
Vamotinib is a novel, potent and selective BCR-ABL tyrosine kinase inhibitor that can induce apoptosis in chronic myelogenous leukemia cells.
-
BI-1622 is an orally active, potent and highly selective HER2 inhibitor, and shows antiproliferative and anti-tumor activity.
-
BNS-22 is a potent and selective inhibitor of TOP2α and TOP2β that exhibits anti-proliferative activities.
-
Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
-
FL118 is a survivin inhibitor and a camptothecin analogue. FL118 has the potential for the research of cancer.
-
BM-1074 is a potent and specific Bcl-2 and Bcl-xL inhibitor and shows antiproliferative and anti-tumor activity.
-
MS159 is a frist-In-class nuclear receptor binding SET NSD2 PROTAC degrader for multiple myeloma research.
-
DC-S239 is a potent and selective SET7 Inhibitor, and DC-S239 shows antiproliferative activity for some cancer cells.
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
ARV-471 is an oral estrogen receptor PROTAC degrader for breast cancer. ARV-471 robustly degrades ER in ER-positive breast cancer cell lines.
-
AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6.
-
BLU2864 is an orally active ATP-competitive PRKACA inhibitor. BLU2864 can be used in cancer and polycystic kidney disease research.
-
SPH5030 is a potent, selective, irreversible and orally active HER2 Inhibitor and shows anti-cancer activity.
-
LCS3 is a potent and reversible inhibitor of GSR and TXNRD1 with anti-tumour activity by non-competitive inhibition of the enzyme activity.
-
EAI001 is a potent, selective mutant EGFR allosteric inhibitor. EAI001 has the potential for research on cancer.
-
G12Si-5, a potent, selective and reversible covalent inhibitor of the K-Ras G12S, can be used for the research of cancer.
-
Simmiparib is a highly potent and orally active PARP1 and PARP2 inhibitor with IC50s of 1.75 nM and 0.22 nM, respectively. Antitumor effect.
-
TK4g is a potent JAK inhibitor and can be used for studies of lymphatic-related diseases and leukemic cancers.
-
ARD-69 is a potent PROTAC androgen receptor degrader and induces degradation of AR protein in AR-positive prostate cancer cell lines.
-
CP681301 is a Potent CDK5 Inhibitor
2022-09-26
CP681301 is a potent CDK5 inhibitor, inhibits glioma stem cells self-renewal and shows anti-tumor activity. -
SHR2415 is a highly potent, selective and orally active ERK1 and ERK2 inhibitor with IC50 values of 2.8 and 5.9 nM, respectively.
-
EM127 is a SMYD3 Covalent Inhibitor
2022-10-01
EM127 is a potent and selectivity SMYD3 covalent inhibitor and impairs methyltransferase activity, can be used in SMYD3 positive tumours. -
BT5528 is a bicyclic peptide toxin conjugate, an EphA2 activator. BT5528 shows potent anti-tumor activity.
-
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
PM-81I is a Potent STAT6 Inhibitor
2022-10-08
PM-81I is a potent STAT6 inhibitor that has potential for the research of allergic lung disease, allergic rhinitis and cancer. -
EPI-7170 is an AR N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR-Vs.
-
GR-46611 is a 5-HT1D Receptor Agonist
2022-10-11
GR-46611 is a potent 5-HT1D receptor agonist and has the potential for the research of epilepsy and inhibits bladder activity. -
AZ31 is a potent, highly selective, and orally active ATM inhibitor, and is also a potent radiosensitizer in vitro.
-
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF) with potent anti-cancer activity.
-
Coleon-U-quinone is a potent P-gp inhibitor. It inhibits P-glycoprotein (P-gp) activity and reverts doxorubicin (DOX) resistance.
-
Purinostat mesylate is a potent and selective inhibitor of HDAC. Purinostat mesylate can be used for the research of lymphoblastic leukemia.
-
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
Golcadomide is a potent and orally active CRBN E3 ligase modulator with immunomodulating and antineoplastic activities.
-
GNE-9815 is a highly selective pan-RAF inhibitor, can be used to research KRAS mutant cancers
2022-10-24
GNE-9815 is a highly selective, pan-RAF inhibitor with good oral bioavailability and is used for cancer research. -
MPM-1, a marine Eusynstyelamides mimic, is a potent anticancer agent. MPM-1 causes perturbation of autophagy in cancer cells.
-
RP-6685 is a potent, selective and orally active DNA Polθ inhibitor with an IC50 value of 5.8 nM. RP-6685 shows antitumor activity.
-
Zilovertamab is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling.
-
CAM 833, a potent and selective inhibitor of the BRCA2-RAD51 interaction, and has the potential for the cancer research.
-
SOR-C13 is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. SOR-C13 is used for Advanced Solid Tumors Research
-
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research
2022-11-05
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease. -
JNJ-9350 is an inhibitor of spermine oxidase (SMOX). JNJ-9350 also inhibits polyamine oxidase (PAO). JNJ-9350 has anti-cancer activity.
-
LY3177833 is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer
-
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
BI-0474 is a Potent KRAS G12C inhibitor
2022-11-14
BI-0474 is a potent KRAS G12C inhibitor and exhibits good anti-proliferative activity against NCI-H358 cells carrying the G12C mutation. -
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
GN25 is a specific inhibitor of p53-Snail binding and shows anti-tumor effect against K-Ras-mutated cancer.
-
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 shows potent antitumor activity.
-
JBJ-09-063 is a mutant-selective allosteric EGFR inhibitor. JBJ-09-063 can be used for EGFR-mutant lung cancer research.
-
Abexinostat, a potent and broad-spectrum inhibitor of histone deacetylases, can be used for the research of cancer.
-
JS25 is a selective and covalent BTK inhibitor in hematological cancer. JS25 has blood brain barrier crossing property.
-
STF-31 is a potent ans selective inhibitor of GLUT1 that inhibit glucose uptake in renal cell carcinoma (RCC) 4 cells.
-
Reversin 121, a P-glycoprotein Inhibitor, Reverses P-glycoprotein-Mediated Multidrug Resistance
2022-12-01
Reversin 121 is a potent P-glycoprotein inhibitor that reverses P-glycoprotein-mediated multidrug resistance. -
Spiruchostatin A is a potent HDAC inhibitor that can induce apoptosis and has anticancer activity uesd for leukemia studies.
-
CYD-2-11 is a selective Bax agonist with antitumor activities in vitro and vivo and the inducing of cell apoptosis.
-
U7D-1 is a selective USP7 PROTAC degrader. U7D-1 induces apoptosis in Jeko-1 cells and shows anticancer activity.
-
Targefrin is a potent EphA2-targeting agent, acts as an antagonist, and can be used to research pancreatic cancer.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Olutasidenib (FT-2102) is an orally active, brain penetrant inhibitor of mutant IDH1. Olutasidenib is used for AML or MDS Research.
-
Mitonafide, a potent cytostatic agent, can inhibit DNA and RNA synthesis. Mitonafide is a potent antitumor agent.
-
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b and has the potential for the research of Large B-cell lymphomas (LBCL).
-
A947 is a selective SMARCA2 (PROTAC). A947 also is a moderately selective SMARCA2 degrader. A947 can be used for the research of cancer.
-
Adagrasib (MRTX849) is an orally available, and mutation-selective covalent inhibitor of KRAS G12C. Can be used for NSCLC research.
-
NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R).
-
CYD-4-61 is a novel Bax activator. It induces cytochrome c release, mitochondrial membrane penetration, consequently leads to cell apoptosis.
-
Rohinitib is a potent and specific eIF4A inhibitor that induce apoptosis of AML cell lines and shows anti-AML effects in vivo.
-
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human IGF1R. Ganitumab can be used in research of cancer.
-
AManzamine A is an orally active β-carboline alkaloid effective against HSV-1, Cancer, and Malaria.
-
SJ988497 is a cell permeable PROTAC JAK2 degrader that degrades JAK2 in vitro and in vivo, and shows anticancer activity against leukemia.
-
D6808 is a highly selective and potent c‑Met inhibitor. D6808 can be used for the research of NSCLC and gastric cancers
-
MMRi62, a Ferroptosis inducer targeting MDM2-MDM4. MMRi62 shows a P53-independent pro-apoptotic activity against PDAC cells.
-
TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP. TD1092 inhibits NF-κB pathway and epithelial-mesenchymal transition (EMT).
-
Xentuzumab is an anti-IGF-1/2 mAb, also targets to INSR-A. Xentuzumab inhibits tumor proliferation and induces apoptosis.
-
Tigatuzumab, a humanized IgG1 anti-DR5 monoclonal antibody, is aTRAIL-R2 agonist, with potent anticancer effects.
-
OTS193320 is a potent SUV39H2 methyltransferase activity inhibitor. OTS193320 triggers apoptotic cell death.
-
FA16 is a specific and metabolically stable ferroptosis inducer. It inhibits system Xc-, results in tumor progression suppression.
-
SIAIS100 is a Potent BCR-ABL PROTAC Degrader
2023-01-10
SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC50 value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML). -
Benufutamab is a DR5-specific agonistic IgG1 antibody (Hx-DR5-01 and Hx-DR5-05), with potent antitumor effects.
-
Salviolone is a natural diterpene identified from Salvia miltiorrhiza roots with an anti-melanoma activity.
-
YX-2-107 is a PROTAC that selectively degrades CDK6.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
YL-939 was a potent inhibitor of iron death and significantly improved liver injury in a model of iron death-related acute liver injury.
-
Amivantamab is an EGFR-MET bispecific monoclonal antibody for the treatment of non-small cell lung cancer.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TWEAK with potent antitumor activity.
-
Coibamide A is an N-methyl-stabilized cytotoxic depsipeptide with antiproliferative activity. Coibamide A induces autophagosome accumulation.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
SZUH280, a potent and selective PROTAC HDAC8 degrader, ,shows antitumor activity in an A549 nude mouse model.
-
Talacotuzumab is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure.
-
Lexatumumab is a TRAIL-R2 agonist antibody that can induce apoptosis. It shows stronger efficacy when combined with other anticancer agents.
-
MS8815 is a selective EZH2 PROTAC degrader. MS8815 can be used for the research of triple-negative breast cancer (TNBC),
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
ML-SA5 is a potent TRPML1 cation channel agonist with some anticancer activity and can inhibit tumour growth.
-
MC2590 is a potent pyridine-containing HDAC inhibitor and modulates pro- and anti-apoptotic microRNAs toward apoptosis induction.
-
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
Asunercept (APG101) is a soluble CD95-Fc fusion protein targeting CD95L.
-
Ferristatin is a potent iron transport inhibitor and shows antiviral potency and anti-MTase (methyltransferase) activity.
-
Elacestrant (RAD1901) is an orally available selective estrogen receptor degrader. Elacestrant used for Breast cancer research.
-
Opnurasib (JDQ-443) is a structurally novel, potent, and selective covalent oral inhibitor of KRAS G12C that exhibits antitumor activity.
-
BPDA2 is a competitive active site SHP2 inhibitor and suppresses SHP2-mediated signaling and breast cancer cell phenotypes.
-
ARN24139 is a potential topoisomerase II (topoII) inhibitor that inhibits cancer cell proliferation and is useful in cancer research.
-
Talotrexin (PT523), a classic antifolate, is an RFC (reduced folate carrier) specific inhibitor and selectively inhibits RFC transport.
-
RLA-5331 is an iron activator containing anti-androgen. RLA-5331 is used for metastatic castrated tolerant prostate cancer (mCRPC) research.
-
SH-BC-893 is an orally active sphingolipid analog. It can be used for the research of cancer and metabolism-related diseases.
-
SG-094 is a potent TPC2 inhibitor with antiproliferative effects. SG-094 can be used for the research of cancer.
-
Cetuximab is a potent human anti-EGFR monoclonal antibody. Besides, Cetuximab also shows anti-tumor activity.
-
Navitoclax (ABT-263) is an Orally Active Bcl-2 Inhibitor for Chronic Lymphocytic Leukemia Research
2023-03-06
Navitoclax is an orally active Bcl-2 inhibitor targeting to Bcl-xL, Bcl-2, Bcl-w, with anti-tumor activity in vitro and in vivo. -
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
SU056, a YB-1 Inhibitor, Induces Cell-cycle Arrest, Apoptosis and Inhibits Cell Migration in Cancer
2023-03-09
SU056 is a YB-1 inhibitor that induces cell cycle arrest, apoptosis and inhibits cell migration of cancer cells. -
Sotorasib is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor, which inhibits tumor growth in mice.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo. -
Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
-
Izalontamab is an EGFR/HER3 Bi-specific monoclonal antibody. Besides, Izalontamab has the potential for the research of cancer.
-
Palbociclib is a potent, selective and orally active CDK4 and CDK6 inhibitor with strong anti-cancer activity.
-
MC0704 is a STAT3 inhibitor (IC50=2.13 μM), which can be used for the research of metastatic triple-negative breast cancer (mTNBC).
-
MPT0B014 is a potent tubulin polymerization inhibitor and induces cancer cell apoptosis in a dose-dependent manner.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Enzyme
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-16658B | Z-VAD-FMK |
Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.
|
|
853
|
| HY-100381 | Nigericin sodium salt |
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.
Source: Streptomyces hygroscopicus |
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
258
|
| HY-16658 | Z-VAD(OMe)-FMK |
|
211
|
|
| HY-13205 | Belnacasan |
Belnacasan (VX-765) is an orally bioactive proagent of VRT-043198, which is a potent and selective inhibitor of IL-converting enzyme (ICE)/caspase-1 with Kis of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively. Belnacasan (VX-765) inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC50 of ~0.7 μM.
|
|
181
|
| HY-B2176B | ATP dimagnesium |
ATP (Adenosine 5'-triphosphate) dimagnesium is a central component of energy storage and metabolism in vivo. ATP dimagnesium provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP dimagnesium is an important endogenous signaling molecule in immunity and inflammation. ATP dimagnesium can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP dimagnesium has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
178
|
| HY-B2176I | ATP disodium salt, 100 mM Solution, PCR Grade |
ATP (Adenosine 5'-triphosphate) disodium salt, 100 mM Solution, PCR Grade is a central component of energy storage and metabolism in vivo. ATP disodium salt, 100 mM Solution, PCR Grade provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium salt, 100 mM Solution, PCR Grade is an important endogenous signaling molecule in immunity and inflammation. ATP disodium salt, 100 mM Solution, PCR Grade can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP disodium salt, 100 mM Solution, PCR Grade has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
168
|
| HY-B0075 | Melatonin |
Melatonin is a hormone made by the pineal gland that can activate melatonin receptor and inhibit PANoptosis. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress.
|
Melatonin Receptor
Autophagy
Mitophagy
Endogenous Metabolite
Apoptosis
PANoptosis
Ligands for Target Protein for PROTAC
Histone Acetyltransferase
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Viral Infection
Neurodegenerative Disease
Digestive System Inflammation
SARS-CoV-2 Infection
|
149
|
| HY-100573 | Necrosulfonamide |
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
|
Mixed Lineage Kinase
Necroptosis
Pyroptosis
Caspase
NOD-like Receptor (NLR)
Keap1-Nrf2
TNF Receptor
Interleukin Related
NO Synthase
Heme Oxygenase (HO)
Digestive System Disease
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Depression
Digestive System Inflammation
Cardiovascular Disease
Parkinson's Disease
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
147
|
| HY-12466 | Z-DEVD-FMK |
Z-DEVD-FMK is a specific and irreversible caspase-3 inhibitor with an IC50 of 18 μM.
|
|
139
|
| HY-12305 | Q-VD-OPh |
|
117
|
|
| HY-19696 | Tauroursodeoxycholate |
Colorectal Cancer
Prostate Cancer
Liver Cancer
Viral Infection
Neurodegenerative Disease
Pain
Digestive System Inflammation
Glucose Metabolism
Obesity
|
111
|
|
| HY-L003 | Apoptosis Compound Library |
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.
MCE designs a unique collection of 3,650 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.
|
|
90
|
| HY-L015 | PI3K/Akt/mTOR Compound Library |
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.
MCE owns a unique collection of 1,149 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.
|
|
90
|
| HY-K1073 | Annexin V-FITC/PI Apoptosis Detection Kit |
MCE Annexin V-FITC/PI Apoptosis Detection Kit provides a rapid and convenient method to detect cell apoptosis and necrosis. After staining, live cells show little or no fluorescence (Annexin V-/PI-), early apoptosis cells show green fluorescence(Annexin V+/PI-), late apoptosis cells and necrosis cells show red and green fluorescence (Annexin V+/PI+). |
|
89
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-L014 | NF-κB Signaling Compound Library |
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.
MCE owns a unique collection of 1,801 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.
|
|
85
|
| HY-L051 | Ferroptosis Compound Library |
Ferroptosis is a novel type of cell death program that is distinct from apoptosis, necroptosis and autophagy. It is dependent on iron and reactive oxygen species (ROS) and is characterized by lipid peroxidation. As a novel type of cell death, ferroptosis has distinct properties and recognizing functions involved in physical conditions or various diseases including cancers, neurodegenerative diseases, acute renal failure, etc.
MCE carefully collected a unique collection of 1,255 ferroptosis signaling pathway related compounds with ferroptosis-inducing or -inhibitory activity. MCE Ferroptosis Compound Library is a useful tool to study ferroptosis mechanism as well as related diseases.
|
|
84
|
| HY-L059 | Pyroptosis Compound Library |
Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.
MCE designs a unique collection of 2,034 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.
|
|
84
|
| HY-L075 | Anti-Lung Cancer Compound Library |
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
|
84
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L085 | Anti-Parkinson's Disease Compound Library |
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.
MCE offers a unique collection of 2,199 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.
|
|
83
|
| HY-L133 | Cuproptosis Compound Library |
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".
The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.
Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.
Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.
MCE supplies a unique collection of 446 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.
|
|
83
|
| HY-L135 | Cancer Stem Cells Compound Library |
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.
Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.
MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.
|
|
83
|
| HY-L155 | Mitochondrial Toxicity Compound Library |
Mitochondria, as the main place of energy supply in life, is essential to maintain normal life activities. Mitochondrial dysfunction is associated with common diseases, such as cardiovascular diseases, neurodegenerative diseases, diabetes and cancer. The heart, brain and liver rely heavily on mitochondrial function as the main organs for drug metabolism. In addition, mitochondria is also a target of many drugs, some of which induce organotoxicity by inducing mitochondrial toxicity.
MCE contains 545 mitochondrial toxic compounds, which can be used as tool compounds for drug development and disease mechanism research.
|
|
83
|
| HY-L156 | Autoimmune Disease Compound Library |
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).
MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.
|
|
83
|
| HY-L161 | Cytokine Inhibitors Library |
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.
MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.
|
|
83
|
| HY-L162 | Cell Death Library |
Cell death plays a crucial role in the development of the body and the maintenance of internal balance to prevent the development of diseases. According to the regulation of the involved processes, cell death can be defined as programmed and non-programmed death. Programmed cell death (PCD) can be divided into lytic cell death and nonlytic cell death, mainly including apoptosis, necrotic apoptosis and Pyroptosis. Non-Programmed cell death (Non-PCD) generally refers to necrosis. In stark contrast to Accidental Cell Death (ACD), Regulatory Cell Death (RCD) relies on specialized molecular mechanisms. Cell death includes internal apoptosis, external apoptosis, necrotic apoptosis, ferroptosis, pyroptosis, lysosome-dependent cell death, etc.
MCE designs a unique collection of 3,860 cell death compounds, covering multiple targets, such as Apoptosis, Ferroptosis, Pyroptosis, Necroptosis, etc. It is a useful tool for screening cell death drugs.
|
|
83
|
| HY-L162M | Cell Death Inhibitor Library Mini |
Cell death is a core biological process that maintains homeostasis in multicellular organisms, playing a dual role in life activities. On one hand, cell death participates in physiological processes such as cell renewal and damage repair through precise regulation; on the other hand, it actively eliminates damaged, infected, or cancerous cells, thereby blocking pathological progression and preserving organism health. Cell death not only ensures the normal development and growth regulation of organisms but is also closely associated with the occurrence and development of various diseases. Numerous studies have shown that specific types of programmed cell death play critical roles in disease progression, providing an important theoretical basis for developing novel therapeutic strategies by regulating cell death pathways.
MCE offers 23 types of commonly used cell death inhibitors, such as apoptosis, ferroptosis, pyroptosis, and cuproptosis, suitable for use as positive controls in the study of novel cell death mechanisms.
|
|
83
|
| HY-L164 | Serine/Threonine Kinase Inhibitor Library |
Protein serine/threonine kinases (PSKs) are protein kinases that use ATP as a high-energy donor molecule to transfer phosphate groups to serine/threonine residues of target protein. As an important signal transduction regulator, serine/threonine kinases can affect the function of target proteins by disrupting enzyme activity or binding of target proteins to other proteins. Serine/threonine kinases are involved in the regulation of immune response, cell proliferation, differentiation, apoptosis and other physiological processes. Serine/threonine kinase inhibitors are an important class of compounds that have been widely studied in cancer, chronic inflammation, autoimmune diseases, aging and other diseases.
MCE designs a unique collection of 2,276 serine/threonine kinase inhibitors, mainly targeting the receptor PKA, Akt, PKC, MAPK/ERK, etc, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases, anti-autoimmune diseases and anti-aging compounds.
|
|
83
|
| HY-L168 | Extracellular Vesicles (EVs) Compound Library |
Extracellular vesicles (EVs) are small membrane binding structures that are released from cells into the surrounding environment and play a crucial role in mediating and regulating intercellular communication related to physiological and pathological processes. EVs are lipid membrane vesicles composed of proteins, lipids, and nucleic acids. EVs can be divided into several types based on their source, such as extracellular vesicles, microcapsules, and apoptotic vesicles. The size range of exosomes is 30-150nm, which are endocrine in multi vesicular endosomes (MVEs); microvesicles (50-1000nm) are secreted directly through extracellular interactions, thereby releasing plasma membrane vesicles. In contrast, apoptotic bodies are usually larger, ranging in size from 1 to 5 μ m. This is generated during programmed cell death. EV plays a crucial role in transmitting information between cells and influencing the behavior and function of receptor cells.
MCE designs a unique collection of 707 small molecules related to extracellular vesicles (EVs). It is a good tool to be used for research on metabolize, cancer and other diseases.
|
|
83
|
| HY-L174 | Macrophage Related Compound Library |
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.
MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L175 | Inflammasomes related Compound Library |
Inflammasomes are classic pattern recognition receptors for natural immune responses. Inflammasomes are polymeric protein complexes that regulate inflammatory responses and pyrolytic cell death, thereby exerting the host's defense against microorganisms. Inflammasomes sensors are associated with adapter proteins, activating inflammatory caspase-1, releasing inflammatory cytokines and inducing cell death, endowing the host with defense against pathogens. NLRP1, NLRP3, NLRC4, AIM2, and pyrin are considered typical inflammasomes because they convert cysteine asparaginase-1 into catalytically active capsaicin-1. In addition to infectious diseases, the importance of inflammasomes is also related to various clinical diseases, such as autoimmune diseases, neurodegeneration and metabolic disorders, and the development of cancer. Therefore, it is necessary to strictly regulate the activation and function of inflammasomes to avoid accidental host tissue damage while inducing pathogens to kill the inflammatory response.
MCE designs a unique collection of 178 inflammasomes related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L219 | Antimicrobial Peptides Library |
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development.
MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
|
|
83
|
| HY-L237 | Pattern Recognition Receptors Library |
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.
MCE has cataloged 338 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
|
|
83
|
| HY-L948 | PD-1/PD-L1 Lead-like Library |
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
|
|
83
|
| HY-13755 | Sulforaphane |
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties.
|
|
79
|
| HY-N0822 | Shikonin |
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
74
|
| HY-101297 | Z-IETD-FMK |
Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell permeable caspase-8 inhibitor. Z-IETD-FMK is also a granzyme B inhibitor.
|
|
73
|
| HY-17363 | Dimethyl fumarate |
Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Colorectal Cancer
Viral Infection
Obesity
Lung Fibrosis
|
65
|
| HY-B1081A | Oxidopamine hydrobromide |
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
|
Dopamine Receptor
Autophagy
Mitophagy
COX
PGE synthase
Interleukin Related
p38 MAPK
Apoptosis
Caspase
|
50
|
| HY-N0674 | Dehydrocorydaline |
Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.
|
Inflammation or Immune System Disease
Lung Cancer
Breast Cancer
Prostate Cancer
Pancreatic Cancer
Ovarian Cancer
Parasitic Infection
Neurodegenerative Disease
Pain
|
47
|
| HY-K1078 | One Step TUNEL Apoptosis Detection Kit (FITC) |
MCE One Step TUNEL Apoptosis Detection Kit (FITC) provides a rapid and convenient method to detect cell apoptosis. After staining cells with this kit, live cells have no fluorescence, apoptosis cells show green fluorescence. |
|
43
|
| HY-14654 | Aspirin |
Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.
|
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Non-Small Cell Lung Cancer
SARS-CoV-2 Infection
Obesity
Rheumatoid Arthritis
|
38
|
| HY-P9902 | Pembrolizumab |
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
37
|
| HY-K1071 | Cell Cycle and Apoptosis Analysis Kit (PI staining) |
MCE Cell Cycle and Apoptosis Analysis Kit (PI staining) provides a convenient method to detect cell cycle and cell apoptosis. |
|
31
|
| HY-N0171 | Beta-Sitosterol (purity>80%) |
Beta-Sitosterol (purity≥80%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
|
|
25
|
| HY-N0171A | Beta-Sitosterol (purity>98%) |
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
|
Bacterial
Apoptosis
Reactive Oxygen Species (ROS)
MDM-2/p53
Caspase
PARP
MMP
Bcl-2 Family
HIF/HIF Prolyl-Hydroxylase
TNF Receptor
Interleukin Related
NF-κB
mTOR
Lactate Dehydrogenase
CDK
Glutathione Peroxidase
SOD
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Bacterial Infection
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Glucose Metabolism
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
25
|
| HY-P9903 | Nivolumab |
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Triple-Negative Breast Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
|
23
|
| HY-N0143A | Phlorizin dihydrate |
Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities.
|
|
18
|
| HY-N0052 | Sanguinarine |
Sanguinarine (Sanguinarin), a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate apoptosis via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.
|
|
16
|
| HY-P0081 | Bax inhibitor peptide V5 |
|
|
16
|
| HY-N0052A | Sanguinarine chloride |
Sanguinarine (Sanguinarin) chloride, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate apoptosis via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.
|
|
16
|
| HY-17536 | Selinexor |
Selinexor (KPT-330) is an analog of KPT-185 (HY-15611). Selinexor is an orally active, selective CRM1 inhibitor that inhibits tumor growth by inducing PANoptosis.
|
|
14
|
| HY-P80246 | NLRP3 Antibody (YA266) |
|
13
|
|
| HY-N0373 | Licochalcone B |
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction.
|
Digestive System Disease
Lung Cancer
Depression
Autoimmune Disease
Digestive System Inflammation
Alzheimer's Disease
|
12
|
| HY-P80566 | Bcl-2 Antibody (YA590) |
|
12
|
|
| HY-12290 | Arg-Gly-Asp-Ser |
|
10
|
|
| HY-P3211 | Nangibotide |
Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Autoimmune Disease
Digestive System Inflammation
Cardiovascular Disease
Obesity
|
8
|
| HY-P3211A | Nangibotide TFA |
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
|
|
8
|
| HY-N0052C | Sanguinarine (gluconate) |
Sanguinarine (Sanguinarin) gluconate, a benzophenanthridine alkaloid, can stimulate apoptosis via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.
|
|
7
|
| HY-139414 | Lysophosphatidylcholines |
|
7
|
|
| HY-K1079 | One Step TUNEL Apoptosis Detection Kit (Cyanine 3) |
MCE One Step TUNEL Apoptosis Detection Kit (Cyanine 3) provides a rapid and convenient method to detect cell apoptosis. After staining cells with this kit, live cells have no fluorescence, apoptosis cells show red fluorescence. |
|
7
|
| HY-N0417 | Cucurbitacin E |
Cucurbitacin E is a CDK1 inhibitor that significantly inhibits the activity of the cyclin B1/CDC2 complex. Cucurbitacin E also induces PANoptosis in adrenocortical carcinoma cells in a ZBP1-dependent manner. Cucurbitacin E exhibits synergistic effects with Mitotane (HY-13690); when used in combination, they effectively eliminate tumors.
|
Breast Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
Glucose Metabolism
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
|
6
|
| HY-N0780 | Isoalantolactone |
Isoalantolactone is an apoptosis inducer, which also acts as an alkylating agent.
|
|
6
|
| HY-N0816 | Polyphyllin VI |
Polyphyllin VI, an active saponin, possess anti-cancer activities. Polyphyllin VI induces G2/M cell cycle arrest and triggers apoptosis. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer.
|
|
6
|
| HY-N0605 | Ginsenoside Rh2 |
|
6
|
|
| HY-P81878 | Phospho-MLKL (Ser358) Antibody (YA1623) |
Phospho-MLKL (Ser358) Antibody (YA1623) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MLKL (Ser358).
Host: Rabbit; Reactivity: Human |
|
5
|
| HY-K1070 | Apoptosis and Necrosis Assay Kit |
MCE Apoptosis and Necrosis Assay Kit provides a rapid and convenient method to detect cell apoptosis and necrosis. |
|
5
|
| HY-N0596 | Panaxadiol |
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities.
|
Inflammation or Immune System Disease
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Obesity
|
4
|
| HY-N1535 | Ponicidin |
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a Kd value of 135 nM. Ponicidin inhibits the JAK2/STAT3 pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer.
|
|
4
|
| HY-D0014 | Brilliant blue G-250 |
Brilliant Blue G-250 is a dye commonly used for the visualization of proteins separated by SDS-PAGE, offering a simple staining procedure and high quantitation. In the Bradford protein assay, protein concentrations are determined by the absorbance at 595 nm due to the binding of Brilliant Blue G-250 to proteins. Brilliant Blue G-250 is a safe highly selective P2×7R antagonist with promising consequent inactivation of NLRP3 inflammasome.
|
|
4
|
| HY-B2123 | Lactose |
Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
SARS-CoV-2 Infection
Obesity
|
4
|
| HY-P81169A | PD-1 Antibody(YA3401) |
|
4
|
|
| HY-N1431A | Tabersonine hydrochloride |
Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer.
|
NOD-like Receptor (NLR)
NF-κB
CDK
p38 MAPK
Cytochrome P450
Akt
Interleukin Related
Apoptosis
PI3K
Caspase
|
3
|
| HY-P0034 | Ac-DEVD-CMK |
|
3
|
|
| HY-N0839 | Quillaic acid |
|
3
|
|
| HY-N6893 | Ergolide |
Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE2) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia.
|
|
3
|
| HY-N1431 | Tabersonine |
Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer.
|
NOD-like Receptor (NLR)
NF-κB
CDK
p38 MAPK
Cytochrome P450
Akt
Interleukin Related
Apoptosis
PI3K
Caspase
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
3
|
| HY-N1939 | Icariside I |
Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape.
|
Apoptosis
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
STAT
CDK
Bcl-2 Family
Aryl Hydrocarbon Receptor
JAK
Caspase
IFNAR
PD-1/PD-L1
Metabolic or Endocrine Disease
Lung Cancer
Breast Cancer
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Autoimmune Disease
Digestive System Inflammation
|
3
|
| HY-P0034A | Ac-DEVD-CMK TFA |
Ac-DEVD-CMK (Caspase-3 Inhibitor III) TFA is a selective and irreversible caspase-3 inhibitor. Ac-DEVD-CMK TFA significantly inhibits apoptosis induced by high levels of glucose or 3,20-dibenzoate (IDB; HY-137295). Ac-DEVD-CMK TFA can be used in a variety of experimental approaches to inhibit apoptosis.
|
|
3
|
| HY-78263 | MNS |
MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells.
|
|
3
|
| HY-32350 | Ercalcitriol |
Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
|
|
3
|
| HY-N0639 | Punicalin |
Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity.
|
|
3
|
| HY-126741 | Azadirachtin |
Azadirachtin is an oral active triterpenoid compound with anticancer, antimalarial, anti-inflammatory, and insecticidal activities. Azadirachtin induces cell apoptosis through the mitochondrial pathway (by inhibiting Bcl-2/Bax ratio or activating Apaf-1 and caspase-3) or through death receptors (by inhibiting TNFR activation). Additionally, Azadirachtin exerts its anti-inflammatory effects by inhibiting NF-кB signaling pathway activation, and it exhibits insecticidal activity by inducing apoptosis in insect cells.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Parasitic Infection
Depression
Pain
Digestive System Inflammation
Obesity
|
3
|
| HY-107430 | Oxythiamine |
Oxythiamine (Hydroxythiamin), an analogue of anti-metabolite, can suppress the non-oxidative synthesis of ribose and induce cell apoptosis. Oxythiamine is a thiamine antagonist and inhibits transketolase (TK). Oxythiamine inhibits cancer cell apoptosis and inhibits cell proliferation.
|
|
3
|
| HY-W010155 | Tryptophol |
Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces apoptosis and cleavage of caspase-8. Tryptophol inhibits Cunninghamella blakesleeana biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy.
|
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Digestive System Disease
Bacterial Infection
Digestive System Inflammation
Cardiovascular Disease
|
3
|
| HY-P7395 | PD-1 Protein, Human (CHO, Fc) |
PD-1 Protein is an important immune regulatory molecule expressed on the surface of activated immune cells. By binding to its ligands (PD-L1/PD-L2), the PD-1 Protein exerts immunosuppressive effects. PD-1 Protein can be used in the research of tumors, autoimmune diseases, and other conditions. PD-1 protein, Human (CHO, Fc) is a recombinant PD-1 protein expressed by CHO cells and carries a C-hFc tag.
Species: Human; Source: CHO |
|
3
|
| HY-P702574 | MLKL Protein, Human (His) |
MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL Protein, Human (His) is the recombinant human-derived MLKL protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
3
|
| HY-P3434 | Ac-FEID-CMK |
Ac-FEID-CMK is a potent zebrafish-specific GSDMEb-derived peptide inhibitor.
Ac-FEID-CMK can attenuate the mortality and kidney injury during septic shock. Ac-FEID-CMK inhibits pyroptosis and attenuates septic AKI (acute kidney injury) in vivo. Ac-FEID-CMK can suppress the caspy2-mediated noncanonical inflammasome pathway.
|
|
2
|
| HY-P3434A | Ac-FEID-CMK TFA |
Ac-FEID-CMK TFA is a potent zebrafish-specific GSDMEb-derived peptide inhibitor.
Ac-FEID-CMK TFA can attenuate the mortality and kidney injury during septic shock. Ac-FEID-CMK TFA inhibits pyroptosis and attenuates septic AKI (acute kidney injury) in vivo. Ac-FEID-CMK TFA can suppress the caspy2-mediated noncanonical inflammasome pathway.
|
|
2
|
| HY-P2259 | TAT-GluA2 3Y |
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction.
|
|
2
|
| HY-N0546 | Ligustroflavone |
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Colorectal Cancer
Prostate Cancer
Cardiovascular Disease
Glucose Metabolism
Obesity
Lung Fibrosis
|
2
|
| HY-N1990 | Gypenoside XLIX |
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation.
|
PPAR
Sirtuin
Keap1-Nrf2
Toll-like Receptor (TLR)
NF-κB
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
Apoptosis
Pyroptosis
Autophagy
Neurological, Eye or Ear Disease
Atherosclerosis and Inflammation
Acute Lung Injury
Cardiomyopathy
Liver Injury
|
2
|
| HY-W016412 | Coenzyme Q0 |
Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling.
|
Apoptosis
Autophagy
EGFR
Akt
mTOR
Caspase
Bcl-2 Family
Reactive Oxygen Species (ROS)
PARP
COX
NO Synthase
TNF Receptor
Interleukin Related
MMP
NF-κB
|
2
|
| HY-N0244 | Theaflavin-3'-gallate |
Theaflavin-3'-gallate is a monomer of theaflavins found in black tea, which has anti-UVB damage activity and inhibits cell apoptosis and necroptosis. Theaflavin-3'-gallate acts as a pro-oxidant and induces oxidative stress in cancer cells, inhibiting xanthine oxidase (OX), with an IC50 of 7.6 μM.
|
|
2
|
| HY-N0171R | Beta-Sitosterol (Standard) |
Beta-Sitosterol (Standard) is the analytical standard of Beta-Sitosterol. This product is intended for research and analytical applications. Beta-Sitosterol (purity≥80%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
|
|
2
|
| HY-P10102 | Kp7-6 |
Kp7-6 is a Fas mimetic peptide and also a Fas/FasL antagonist. Kp7-6 specifically binds to Fas and FasL, disrupts receptor complexes, and blocks downstream apoptosis signaling pathways. Kp7-6 inhibits the phosphorylation of ERK1-2, induces the phosphorylation of IκBα, and activates NF-κB. Kp7-6 inhibits the activation of caspase-8, caspase-3 and JNK, and suppresses human amylin-induced β-cell apoptosis. Kp7-6 inhibits FasL-induced lymphoid cytotoxicity and apoptosis. Kp7-6 reduces local tumor FasL expression, increases CD8+Fas+ T cell infiltration, and decreases tumor volume in pancreatic neuroendocrine tumor models. Kp7-6 prevents concanavalin A-induced liver injury in mice. Kp7-6 is applicable to research related to type 2 diabetes, concanavalin A-induced hepatitis and pancreatic neuroendocrine tumors.
|
|
2
|
| HY-119109 | Laminaran |
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
Source: Eisenia Bicyclis |
|
2
|
| HY-125859 | Peroxidase, Horseradish |
Peroxidase, Horseradish actively involves in oxidizing reactive oxygen species, innate immunity, hormone biosynthesis and pathogenesis of several diseases.
|
|
2
|
| HY-125857 | Cytochrome C |
Cytochrome C is a multi-functional enzyme involving in life and death decisions of the cell. Cytochrome C is essential in mitochondrial electron transport and intrinsic type II apoptosis.
|
|
2
|
| HY-P7396 | PD-1 Protein, Human (HEK293, His) |
|
2
|
|
| HY-P72717 | CD5L Protein, Mouse (HEK293, His) |
The CD5L protein is primarily expressed by macrophages and regulates inflammatory responses in infection or atherosclerosis. CD5L is incorporated into adipocytes via CD36-mediated endocytosis, thereby inhibiting lipid droplet size and affecting lipolysis. CD5L Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD5L protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Mouse; Source: HEK293 |
|
2
|
| HY-P71436 | ZBP1 Protein, Human (His) |
ZBP1 is an important innate sensor that defends against viruses by recognizing Z-RNA structures and inducing PANoptosis. It binds Z-RNA through TNF-α family members and stimulates RIPK3 and MLKL to activate necroptosis. ZBP1 Protein, Human (His) is the recombinant human-derived ZBP1 protein, expressed by E. coli , with C-6*His labeled tag.
Species: Human; Source: E. coli |
|
2
|
| HY-P704200 | RIPK1 Protein, Mouse (C-His) |
RIPK1 Protein, Mouse (C-His) is the recombinant mouse-derived RIPK1 protein, expressed by E. coli, with C-6*His tag.
Species: Mouse; Source: E. coli |
|
2
|
| HY-P86158 | Cleaved N-terminal GSDMD Antibody (YA5850) |
Cleaved N-terminal GSDMD Antibody (YA5850) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cleaved N-terminal GSDMD. GSDMD exists in multiple protein isoforms: the ~53 kDa GSDMD precursor, the ~35 kDa cleaved GSDMD-N fragment, and the ~22 kDa cleaved GSDMD-C fragment. This antibody specifically detects the ~35 kDa GSDMD-N fragment produced following GSDMD cleavage at Asp275.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
2
|
| HY-P80624 | Cleaved-Caspase 8 Antibody (YA792) |
Cleaved-Caspase 8 Antibody (YA792) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cleaved-Caspase 8.
Host: Mouse; Reactivity: Human, Mouse, Rat |
|
2
|
| HY-P80227 | MLKL Antibody (YA289) |
|
2
|
|
| HY-P80679 | AMID/FSP1 Antibody |
AMID/FSP1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to AMID/FSP1.
Host: Rabbit; Reactivity: Human, Mouse, Monkey |
|
2
|
| HY-P85810 | GSDMD (N-terminal) Antibody (YA5502) |
GSDMD (N-terminal) Antibody (YA5502) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GSDMD.
Host: Mouse; Reactivity: Human, Mouse, Rat |
|
2
|
| HY-P83706 | GSDMD Antibody (YA3443) |
GSDMD Antibody (YA3443) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GSDMD.
Host: Rabbit; Reactivity: Human |
|
2
|
| HY-K1072 | Cell Apoptosis Analysis Kit (Hoechst staining) |
MCE Cell Apoptosis Analysis Kit (Hoechst staining) provides a rapid and convenient method to detect cell apoptosis. |
|
2
|
| HY-15306S | Eltrombopag-13C4 |
Eltrombopag-13C4 (SB-497115-13C4) is 13C-labeled Eltrombopag. Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells.
|
|
1
|
| HY-141567 | Pseudouridine 5'-triphosphate |
Pseudouridine 5'-triphosphate (Pseudo-UTP) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate can be used for the research of vaccinia virus infection.
|
|
1
|
| HY-B0298AS | Clemastine-d5 fumarate |
Clemastine (HS-592; Meclastine)-d5 fumarate is the deuterium labeled Clemastine fumarate. Clemastine fumarate is an orally active, blood-brain barrier-permeable H1 histamine receptor (H1 histamine receptor) antagonist with potent antiallergic effects. Clemastine fumarate also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes. In addition to antihistamine effects, Clemastine fumarate exhibits multiple pharmacological activities, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, exerting anti-apoptotic and neuroprotective effects, and suppressing inflammation .
|
Isotope-Labeled Compounds
mAChR
p62
IKK
Apoptosis
Keap1-Nrf2
mTOR
Histamine Receptor
Pyroptosis
Autophagy
|
1
|
| HY-N3417 | Kongensin A |
Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent HSP90 inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications.
|
|
1
|
| HY-P10387A | RSM3 TFA |
RSM3 TFA is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 TFA reduces the m6A modification level of SLC31A1 and the global RNA methylation level. RSM3 TFA upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 TFA is applicable to the research of preeclampsia and cancer.
|
|
1
|
| HY-N6689 | Destruxin A |
Destruxin A is a fungal cyclopeptide with insecticidal and antiviral activities. Destruxin A has a certain inhibitory effect on leukemia cells in vitro. Destruxin A can also specifically inhibit the innate immune response of Drosophila melanogaster, making the flies more susceptible to bacterial infections.
Source: Metarhizium anisopliae |
|
1
|
| HY-133948 | 1-Monopalmitolein |
1-Palmitoleoyl glycerol is a biologically active monoacylglycerol. It increases daunomycin accumulation, shown to inhibit P-glycoprotein in Caco-2 cells. 1-Palmitoleoyl glycerol induces thymocyte apoptosis.
|
|
1
|
| HY-P3496 | Pep19-2.5 |
Pep19-2.5 is an synthetic and antitoxin peptide, blocks the intracellular endotoxin signaling cascade. Pep19-2.5 inhibits signaling of lipopeptides (LP) and lipopolysaccharides (LPS) mediated by transmembrane and cytosolic pattern recognition receptors (PRRs). The signaling cascades lead to inflammation and cell pyroptosis.
|
|
1
|
| HY-N6777 | Penicillic acid |
Penicillic acid is a polyketide mycotoxin produced by several species of Aspergillus and Penicillium. Penicillic acid exhibits cytotoxicity in rat alveolar macrophages (AM) in vitro. Penicillic acid inhibits Fas ligand-induced apoptosis by blocking self-processing of caspase-8.
Source: Penicillium |
|
1
|
| HY-P10387 | RSM3 |
RSM3 is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 reduces the m6A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer.
|
|
1
|
| HY-N5084 | Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside |
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
|
|
1
|
| HY-N8572 | 3',4'-Dimethoxyflavone |
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Cardiovascular Disease
|
1
|
| HY-P1169 | Ac-IETD-AFC |
|
|
1
|
| HY-D1056H | Lipopolysaccharides, from S. marcescens |
Lipopolysaccharides, from S. marcescens (Serratia marcescens) are lipopolysaccharide endotoxins and TLR-4 activators derived from Serratia marcescens, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. marcescens exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from S. marcescens induce NF-κB activation in mouse cells via Toll-like receptor (TLR4)/MD-2. The lipopolysaccharides of S. marcescens can induce apoptosis in host immune cells, thereby suppressing the host's innate immunity.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use. |
|
1
|
| HY-N6253 | Pinoresinol |
|
1
|
|
| HY-P99934 | Eftozanermin alfa |
Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with Kds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies.
|
|
1
|
| HY-N3415 | Kumatakenin |
Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a Kd value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5 to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis.
|
|
1
|
| HY-W013579 | (S)-(+)-Carvone |
(S)-(+)-Carvone is an orally active natural product. (S)-(+)-Carvone increases the activity of antioxidant enzymes (SOD, CAT) and ROS, reduces the levels of oxidative stress markers (MDA, AChE), reduces the secretion of proinflammatory cytokines (IL-1β, IL-4, IL-6, IL-10), and downregulates NLRP3. (S)-(+)-Carvone increases the activities of caspase-8, -9 and -3. (S)-(+)-Carvone induces apoptotic death. (S)-(+)-Carvone has antimanic-like effect, liver protection and anticancer activity against skin cancer. (S)-(+)-Carvone improves memory and arthritis.
|
Environmental Pollutants
Interleukin Related
SOD
Caspase
NOD-like Receptor (NLR)
Apoptosis
Reactive Oxygen Species (ROS)
Cancer
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
1
|
| HY-141567A | Pseudouridine 5'-triphosphate trisodium solution (100 mM) |
Pseudouridine 5'-triphosphate (Pseudo-UTP) trisodium solution (100 mM) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate trisodium solution (100 mM) enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate trisodium solution (100 mM) can be used for the research of vaccinia virus infection.
|
|
1
|
| HY-119976 | Boscalid |
Boscalid is a succinate dehydrogenase (SDHI) inhibitor with antifungal activity. Boscalid binds to the ubiquinone-binding site of fungal mitochondrial complex II, blocks ATP production and aerobic respiration, exhibits good control efficacy against a variety of plant fungal diseases including gray mold, sclerotinia rot and powdery mildew, and is widely used for disease control in agriculture. Boscalid induces apoptosis, altered lipid metabolism, mitochondrial dysfunction, respiratory impairment, oxidative stress, ROS accumulation and neurodevelopmental disorders in zebrafish. Boscalid reduces foraging ability, shortens median death time and causes chronic toxicity in exposed honeybees. Boscalid also possesses genotoxicity, cytotoxicity, elevated mitochondrial superoxide levels and early-stage apoptosis.
|
|
1
|
| HY-N0218 | Benzoylmesaconine |
Benzoylmesaconine is a monoester-type alkaloid and is the most abundant component of Wutou decoction, which is widely used in China for rheumatoid arthritis. Benzoylmesaconine exhibits potent anti-inflammatory properties by inhibiting NF-κB. Benzoylmesaconine can suppress NLRP3 inflammasome activation by inhibiting IL-1β secretion and GSDMD-N protein expression. Benzoylmesaconine reduces intracellular K+ efflux and disrupts NLRP3 inflammasome assembly.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
Rheumatoid Arthritis
|
1
|
| HY-P9928A | Alirocumab (anti-PCSK9) |
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.
Species: Human |
|
1
|
| HY-P10149 | Ac-IEPD-CHO |
Ac-IEPD-CHO is a reversible granzyme B inhibitor with a Ki of 80 nM. Ac-IEPD-CHO is also a caspase-8 inhibitor.
|
|
1
|
| HY-N2414 | Periplogenin |
Periplogenin is an orally active cardiac glycoside found in Cortex periplocae. Periplogenin can induce ROS production and necroptosis and cause G0/G1 phase arrest. Periplogenin can inhibit pyroptosis by regulating the NLRP3/Caspase-1/GSDMD signaling. Periplogenin suppresses growth of prostate carcinoma cells by docking to an ATP1A1 protein pocket and forming a hydrogen bond with T804. Periplogenin can be used for the researches of cancer, inflammation and immunology, such as prostate carcinoma, rheumatoid arthritis and psoriasis.
|
Reactive Oxygen Species (ROS)
Necroptosis
Pyroptosis
Interleukin Related
Caspase
NOD-like Receptor (NLR)
|
1
|
| HY-P5381 | gp91 ds-tat |
gp91 ds-tat, a biological active peptide, is a NADPH oxidase 2 (Nox2) inhibitor. gp91 ds-tat blocks NADPH oxidase-dependent superoxide production. gp91 ds-tat ameliorates high glucose-induced increase in total ROS, LPOs and iron levels. gp91 ds-tat inhibits homocysteine (Hcy)-induced activation of NLRP3 inflammasomes and restores Hcy-inhibited lysosomal TRPML1 channel activity. gp91 ds-tat improves cerebrovascular and cognitive function in APP/PS1 mice. gp91 ds-tat can be used for the study of Alzheimer’s disease (AD), glomerular inflammation and cardiovascular disease.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
1
|
| HY-116084S | Trimethylamine N-oxide-d9 |
Trimethylamine N-oxide-d9 is the deuterium labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.
|
|
1
|
| HY-P99044 | Sabatolimab |
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.
Species: Human |
|
1
|
| HY-N3005 | Britannin |
Britannin is an NLRP3 inhibitor with an IC50 of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics.
|
|
1
|
| HY-P1137 | 10Panx |
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].
|
|
1
|
| HY-W041892 | Dimethyl itaconate |
Dimethyl itaconate induces innate immune memory (trained immunity), and exhibits immunomodulatory property. Dimethyl itaconate inhibits the activation of microglia, reduces the neuroinflammation and synaptic structural damage. Dimethyl itaconate regulates the composition of intestinal flora.
|
|
1
|
| HY-N2397 | 9''-Methyl salvianolate B |
9''-Methyl salvianolate B (MSB) is a blood-brain barrier-permeable inhibitor with high affinity for g5Rp, with a Kd value of 117 nM against African swine fever virus (ASFV) g5Rp. 9''-Methyl salvianolate B also acts as a ZBP1 inhibitor. It exhibits strong binding affinity to key proteins in the PPARγ/NF-κB pathway. 9''-Methyl salvianolate B blocks the interaction between ASFV g5Rp and host proteins eIF5A or RPS15. It restores hypusination modification of eIF5A, promotes autophagy (Autophagy), and inhibits ASFV replication. 9''-Methyl salvianolate B effectively disrupts ZBP1-mediated PANoptosome assembly. It effectively alleviates myocardial ischemia/reperfusion injury. 9''-Methyl salvianolate B can be used in studies related to African swine fever.
|
|
1
|
| HY-Y1881B | Copper sulfate pentahydrate, for cell culture, 98% |
Copper sulfate pentahydrate, for cell culture, 98% is a biochemical reagent. Copper sulfate pentahydrate, for cell culture, 98% reduces the production of ROS and the expression levels of MyD88 as well as c-Rel genes. Copper sulfate pentahydrate, for cell culture, 98% decreases the activities of T-SOD, CAT, and GSH, increases the activities of caspase-3, caspase-8, and caspase-9. Copper sulfate pentahydrate, for cell culture, 98% is cytotoxic to various cells.
|
|
1
|
| HY-P9928 | Alirocumab |
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.
Species: Human |
|
1
|
| HY-P790108 | NLRP3 Protein, Human (His) |
The NLRP3 protein acts as a sensor in the NLRP3 inflammasome, which is activated in response to membrane defects. It forms a complex with CASP1 and PYCARD/ASC, promotes the release of IL1B, IL18 and GSDMD, and induces pyroptosis. NLRP3 Protein, Human (His) is the recombinant human-derived NLRP3, expressed by E. coli, with C-6*His labeled tag.
Species: Human; Source: E. coli |
|
1
|
| HY-P70639 | PD-1 Protein, Mouse (HEK293, Fc) |
The PD-1 protein is expressed on antigen-activated T cells and can induce and maintain immune tolerance to itself.PD-1 binds to CD274/PDCD1L1 and CD273/PDCD1LG2, transmits inhibitory signals, inhibits T cell activation and regulates immune responses.PD-1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Mouse; Source: HEK293 |
|
1
|
| HY-P7537 | BCL2 Protein, Human (His) |
BCL2 Protein regulates the mitochondrial membrane permeability, and inhibits the caspase activity, thereby suppressing the apoptosis in various cell types. BCL2 Protein interacts with BECN1 and AMBRA1, and inhibits the autophagy. BCL2 Protein, Human (His) is the human-derived resombinant BCL2 Protein that is expressed in in E. coli with a His tag at the C-terminus.
Species: Human; Source: E. coli |
|
1
|
| HY-P72101 | BCL2 Protein, Mouse (His) |
BCL2 protein crucially regulates cell death by controlling mitochondrial membrane permeability. It interacts with caspases in a feedback loop, inhibiting their activity. BCL2 prevents cytochrome c release from mitochondria and binds to apoptosis-activating factor (APAF-1). BCL2 Protein, Mouse (His) is the recombinant mouse-derived BCL2 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Mouse; Source: E. coli |
|
1
|
| HY-P71598 | NLRP3 Protein, Mouse (His-SUMO) |
The NLRP3 protein acts as a sensor in the NLRP3 inflammasome, which is activated in response to membrane defects caused by pathogens or damage signals. It assembles the inflammasome complex, including NLRP3, CASP1, and PYCARD/ASC. NLRP3 Protein, Mouse (His-SUMO) is the recombinant mouse-derived NLRP3 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Species: Mouse; Source: E. coli |
|
1
|
| HY-P73344A | PD-1 Protein, Human (HEK293, hFc) |
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1, Human (HEK293, hFc) is the recombinant human-derived PD-1 protein, expressed by HEK293, with Tag Free labeled tag.
Species: Human; Source: HEK293 |
|
1
|
| HY-P73724 | PD-1 Protein, Mouse (HEK293, His-Fc) |
PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-hFc, C-8*His labeled tag.
Species: Mouse; Source: HEK293 |
|
1
|
| HY-P80468 | Phospho-MLKL (Ser345) Antibody (YA174) |
Phospho-MLKL (Ser345) Antibody (YA174) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MLKL (Ser345).
Host: Rabbit; Reactivity: Mouse |
|
1
|
| HY-P84982 | PD-L1 Antibody (YA4674) |
|
1
|
|
| HY-P87843 | AIM2 Antibody (YA7528) |
|
1
|
|
| HY-P80006 | AIF Antibody (YA636) |
AIF Antibody (YA636) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AIF.
Host: Rabbit; Reactivity: Human, Mouse |
|
1
|
| HY-P86069 | Phospho-MLKL(S358) Antibody (YA5761) |
Phospho-MLKL(S358) Antibody (YA5761) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Phospho-MLKL(S358).
Host: Mouse; Reactivity: Human |
|
1
|
| HY-K1075 | Annexin V-PE Apoptosis Detection Kit |
MCE Annexin V-PE Apoptosis Detection Kit provides a rapid and convenient method to detect cell apoptosis and necrosis. After staining, live cells show little or no fluorescence, apoptosis cells and necrosis cells show red fluorescence. |
|
1
|
| HY-K1093 | VF 647A-Annexin V/PI Apoptosis Detection Kit |
MCE VF 647A-Annexin V/PI Apoptosis Detection Kit can be utilized to detect the level of cell apoptosis. |
|
1
|
| HY-116084S1 | Trimethylamine-N-oxide-13C3 |
Trimethylamine-N-oxide-13C3 is the 13C-labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.
|
Isotope-Labeled Compounds
NOD-like Receptor (NLR)
Reactive Oxygen Species (ROS)
TGF-beta/Smad
Endogenous Metabolite
|
/
|
| HY-150659S | ATP-d14 disodium |
ATP-d14 (Adenosine 5'-triphosphate-ATP-d14) sodium is the d14-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
/
|
| HY-N0596R | Panaxadiol (Standard) |
Panaxadiol (Standard) is the analytical standard of Panaxadiol. This product is intended for research and analytical applications. Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities.
|
|
/
|
| HY-N10312 | Yadanzigan |
Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice.
|
|
/
|
| HY-D3537 | AF 430 Annexin V |
AF 430 Annexin V is an AF 430-labeled annexin V, used to label early apoptotic cells and detect the occurrence of apoptosis (Ex/Em = 425/542 nm).
|
|
/
|
| HY-N0660R | Jujuboside B (Standard) |
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway. Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.
|
Reference Standards
ERK
p38 MAPK
Akt
PI3K
11β-HSD
STING
VEGFR
Ferroptosis
Autophagy
Apoptosis
Keap1-Nrf2
Caspase
PARP
AMPK
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
Colorectal Cancer
Leukemia/Lymphoma/Myeloma
Depression
Non-Small Cell Lung Cancer
|
/
|
| HY-182066 | Photosensitizer-9 |
Photosensitizer-9 is an iridium (III)-based photosensitizer with anti-melanoma activity. Photosensitizer-9 exhibits significant phototoxicity (IC50=0.98 μM) and an ideal phototoxicity index (PI=3.05). Under light irradiation, Photosensitizer-9 generates large amounts of intracellular •OH in an oxygen-independent manner. Photosensitizer-9 mediates photodynamic therapy under hypoxic conditions and synergistically activates PANoptosis (by upregulating cleaved Caspase-3, GSDMD-N, p-MLKL), ferroptosis (by disrupting the GSH-GPX4-LPO axis), apoptosis, pyroptosis and necroptosis in melanoma cells. Photosensitizer-9 induces immunogenic cell death by promoting the release of damage-associated molecular patterns under hypoxic conditions and increases the maturation rate of dendritic cells. Photosensitizer-9 reduces tumor volume in melanoma-bearing mice. Photosensitizer-9 is applicable to relevant studies on melanoma.
|
|
/
|
| HY-P11624 | PP-60 |
PP-60 is an apoptosis inducer. PP-60 inhibits the proliferation of cancer cells and induces cancer cell apoptosis. PP-60 exerts anti-tumor effects in nude mouse liver tumor models. PP-60 is applicable to research related to cancers such as liver cancer, lung cancer, and prostate cancer.
|
|
/
|
| HY-N0168S | Hesperetin-d3 |
|
/
|
|
| HY-P4222 | IETD-CHO |
IETD-CHO (Caspase-8-IN-1) is a potent caspase-8 inhibitor.
|
|
/
|
| HY-D3549 | APC Annexin V |
|
/
|
|
| HY-138071 | 8α-Tigloyloxyhirsutinolide 13-O-acetate |
8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo.
|
|
/
|
| HY-P10977 | Tat-ASIC1a (1-20) (mouse, rat) |
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease.
|
|
/
|
| HY-P11607 | CyLip-10 |
CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection.
|
|
/
|
| HY-179386 | PARP1/EZH2-IN-1 |
PARP1/EZH2-IN-1 is a selective PARP1 and EZH2 dual inhibitor. PARP1/EZH2-IN-1 has IC50s of 28 nM, 414 nM and 74 nM for PARP1, PARP2 and EZH2, respectively. PARP1/EZH2-IN-1 inhibits the proliferation and migration of TNBC cells (triple-negative breast Cancer cells). PARP1/EZH2-IN-1 induces PANoptosis (Apoptosis, Pyroptosis and Necroptosis), increases the level of reactive oxygen species (ROS), and activates related inflammatory pathways. PARP1/EZH2-IN-1 can be used in triple-negative breast cancer research.
|
PARP
Histone Methyltransferase
Apoptosis
Pyroptosis
Necroptosis
Reactive Oxygen Species (ROS)
PANoptosis
|
/
|
| HY-175030 | TNI-97 |
TNI-97 is a selective and orally active HDAC6 inhibitor, with an IC50 of 0.2 nM. TNI-97 potently inhibited TNBC cell MDA-MB-453 growth and clonogenicity. TNI-97 induces PANoptosis including apoptosis, necroptosis and pyroptosis in MDA-MB-453 cells. TNI-97 shows antitumor activity in the mice carrying the MDA-MB-453 xenograft or carrying murine-derived TNBC cell allografts. TNI-97 can be used for the study of triple-negative breast cancer.
|
|
/
|
| HY-P1380 | Difopein |
Difopein is a 14-3-3 protein inhibitor. Difopein acts as an apoptosis inducer, regulates apoptosis-related proteins, downregulates Bcl-2, upregulates Bax, activates caspase-9 and caspase-3, and induces nuclear fragmentation, membrane-enclosed apoptotic bodies and DNA ladder formation. Difopein serves as a tumor growth inhibitor, which inhibits the proliferation of glioma cells and induces their apoptosis in in vivo nude mouse models. Difopein is applicable to glioma-related research.
|
|
/
|
| HY-B0006S2 | Carvedilol-d5 |
Carvedilol-d5 is deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome.
|
|
/
|
| HY-W791671 | Aspergillus giganteus α-sarcin |
|
/
|
|
| HY-144277 | RIPK1-IN-12 |
RIPK1-IN-12 is a potent RIPK1 inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC50 values of 1.6 and 2.9 nM, respectively.
|
|
/
|
| HY-P11707 | FS1 peptide |
FS1 peptide is a synthetic BH3 mimetic peptide that shows potential in enhancing NK cell-mediated cancer immunity. FS1 peptide targets anti-apoptotic BCL-2 family proteins, triggers the release of cytochrome c, and thereby promotes apoptosis (Apoptosis). FS1 peptide can be used for NK cell-based immunological research.
|
|
/
|
| HY-D3556 | R-PE Annexin V |
R-PE Annexin V is a R-PE-labeled annexin V, used to label early apoptotic cells and detect the occurrence of apoptosis (Ex/Em = 496/578 nm).
|
|
/
|
| HY-P10939 | Ac-DMLD-CMK |
Ac-DmLD-CMK is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DmLD-CMK binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DmLD-CMK alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity.
|
|
/
|
| HY-P10950 | PD-L1 inhibitory peptide |
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers.
|
|
/
|
| HY-P11580 | Pap12-6-10 |
Pap12-6-10 is an MD-2 ligand that binds to the hydrophobic pocket of MD-2 to inhibit the dimerization of the TLR4/MD-2 complex and downstream inflammatory signal transduction. Pap12-6-10 also binds to LPS to permeabilize bacterial cell membranes and induce oxidative stress, leading to bacterial death. Pap12-6-10 regulates LPS-induced inflammatory responses through the TLR4 signaling pathway and exhibits antibacterial activity against multidrug-resistant Gram-negative bacteria. Pap12-6-10 shows low tendency to induce drug resistance and low preclinical cytotoxicity, and it prevents organ damage in a mouse model of sepsis. Pap12-6-10 can be used for research related to Gram-negative sepsis and carbapenem-resistant Acinetobacter baumannii infections.
|
|
/
|
| HY-P992349 | DXL625 |
DXL625 is an autophilic CD20-targeting agent. DXL625 triggers downstream apoptosis signaling pathways dependent on intact lipid rafts and extracellular Ca2+. DXL625 induces caspase-mediated apoptosis in cancer cells and selectively targets cells in the actively proliferative S phase. DXL625 mediates complement-dependent cytotoxicity in cancer cells and primary B lymphocytes. DXL625 can be used in research related to Burkitt's lymphoma and B-cell lymphoma.
Species: Human |
|
/
|
| HY-P3867 | Hypocretin (70-98), human |
Hypocretin (70-98), human is a polypeptide that is capable of binding to an orexin receptor OX1R and promotes apoptosis.
|
|
/
|
| HY-D3169 | IETDC |
IETDC is a caspase 8-responsive fluorescent probe. IETDC is cleaved by activated caspase 8 to release D-cysteine, which then reacts with 6-hydroxy-2-cyanobenzothiazole (HCBT) to form firefly luciferin in situ. IETDC must be used in conjunction with PCL-2 (HY-D3168) to detect the co-existence of hydrogen peroxide and caspase 8. IETDC is applicable to studies related to acute inflammation.
|
|
/
|
| HY-P11383 | AIM2-derived decapeptide |
|
/
|
|
| HY-P99442 | Apolizumab |
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro.
Species: Human |
|
/
|
| HY-P991305 | AGEN-1571 |
|
/
|
|
| HY-N6777S | Penicillic acid-13C8 |
Penicillic acid-13C8 is the 13C-labeled Penicillic acid (HY-N6777). Penicillic acid is a polyketide mycotoxin produced by several species of Aspergillus and Penicillium. Penicillic acid exhibits cytotoxicity in rat alveolar macrophages (AM) in vitro. Penicillic acid inhibits Fas ligand-induced apoptosis by blocking self-processing of caspase-8.
|
|
/
|
| HY-N21740 | Furohyperforin |
Furohyperforin is a natural product isolated from Hypericum perforatum L., possessing neuroprotective and antidepressant activities. Furohyperforin acts as an NLRP3 inflammasome inhibitor and also exhibits inhibitory effects on recombinant CYP3A4. Furohyperforin exerts neuroprotective effects against corticosterone-induced neuronal damage. Furohyperforin inhibits the NLRP3 inflammasome cascade and its downstream IL‑1β and GSDMD signaling pathways, and also reduces serum corticosterone levels in mice, regulating HPA axis function. Furohyperforin is applicable for depression-related research.
|
|
/
|
| HY-P5169 | LVGRQLEEFL (mouse) |
LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
|
|
/
|
| HY-P2291 | Beta-defensin 103 isoform X1, pig |
Beta-defensin 103 isoform X1, pig is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
|
|
/
|
| HY-P10285S | d-KLA Peptide-d30 |
d-KLA Peptide (D-(KLAKLAK)2)-d30 is the deuterium labeled d-KLA Peptide (HY-P10285). d-KLA Peptide, KLA peptide (HY-P5345) isomer, is a pro-apoptosis peptide. d-KLA Peptide can specifically target mitochondria and induce apoptosis by destroying the mitochondrial membrane. d-KLA Peptide increases caspase 3/7 activity, exerts proapoptotic activity and enhances antitumor efficacy in mouse melanoma models.
|
|
/
|
| HY-N15380 | 4,4′-Secalonic acid D |
4,4′-Secalonic acid D (Compound 12) is a PARP1 inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting PARP1. 4,4′-Secalonic acid D has anti-tumor activity.
Source: Paraconiothyrium sp. |
|
/
|
| HY-P10656 | Ac-DEVDD-TPP |
Ac-DEVDD-TPP is a porphyrin derivative that can be converted into D-TPP by caspase-3 cleavage and laser irradiation. The formed porphyrin nanofibers can effectively induce Apoptosis and Pyroptosis. Ac-DEVDD-TPP has antitumor activity.
|
|
/
|
| HY-D3538 | AF 488 Annexin V |
AF 488 Annexin V is an AF 488-labeled annexin V, used to label early apoptotic cells and detect the occurrence of apoptosis (Ex/Em = 470/520 nm).
|
|
/
|
| HY-P3151A | Gliadin p31-43 TFA |
Gliadin p31-43 TFA is an undigested gliadin peptide. Gliadin p31-43 TFA induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 TFA can be used for celiac disease research.
|
|
/
|
| HY-P1813 | PSA1 (141-150) |
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
|
|
/
|
| HY-P992518 | Pumitamig (Mouse IgG2a) |
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
|
|
/
|
| HY-N7917 | Tenacigenoside A |
Tenacigenoside A is a multidrug resistance reversal agent and apoptosis inducer that selectively acts on P-glycoprotein and apoptosis-related proteins (BCL2, BCL-XL, BID). Tenacigenoside A exerts its key activity by regulating the expression of apoptosis-related proteins and inhibiting P-gp function, thereby inhibiting tumor cell proliferation, inducing tumor cell apoptosis, and reversing multidrug resistance in tumors. Tenacigenoside A can be used in research on malignant tumors such as lymphoma.
|
|
/
|
| HY-N10417 | Apoptosis inducer 5 |
|
/
|
|
| HY-P10370 | d-(KLAKLAK)2, Proapoptotic Peptide |
d-(KLAKLAK)2, as an antibacterial and anti-tumor polypeptide, is a representative of the antimicrobial peptide group, and also has good anticancer properties. d-(KLAKLAK)2 is able to kill bacteria by damaging their cell membranes, causing cell contents to leak out. d-(KLAKLAK)2 can also inhibit tumor cell proliferation by causing mitochondrial swelling and mitochondrial membrane destruction, triggering apoptosis (programmed cell death).
|
|
/
|
| HY-D3550 | Biotin Annexin V |
Biotin Annexin V is a Biotin-labeled annexin V, used to label early apoptotic cells and detect the occurrence of apoptosis.
|
|
/
|
| HY-D3534 | 5X Annexin Binding Buffer |
5X Annexin Binding Buffer is a concentrated buffer specifically designed for apoptosis detection. It promotes the binding of Annexin V to phosphatidylserine.
|
|
/
|
| HY-P11581 | MNP2 |
MNP2 is a NLRP3-ASC interaction inhibitor. MNP2 selectively binds to the PYD domain of ASC (Ka=149 nM) and blocks ASC-PYM binding (Ka=58 nM), thereby inhibiting the interaction between ASC and NLRP3 and suppressing the formation of the NLRP3 inflammasome. MNP2 inhibits IL-1β release and caspase-1 maturation, and reduces the efflux of potassium and chloride ions. MNP2 prevents mitochondrial damage and reactive oxygen species production, and significantly decreases NLRP3 inflammasome formation in neurodegenerative pathologies induced by β-amyloid, Tau protein and α-synuclein. MNP2 is applicable for the research of neurodegenerative diseases.
|
|
/
|
| HY-P992051 | Anti-CD103 Antibody (hCD103.01A) |
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-168927 | Apoptosis inducer 36 |
Apoptosis inducer 36 (Compound 42) exhibits anti-leukemic activity through reduction of leukemia stem cells (LSCs) and induction of differentiation. Apoptosis inducer 36 inhibits the proliferation of AML cells, arrests cell cycle at G1 phase, and induces PANoptosis including apoptosis, pyroptosis and necrosis. Prodrug of apoptosis inducer 36 exhibits orally active antitumor efficacy in mouse model.
|
|
/
|
| HY-W768895 | Sanguinarine chloride-13C,d3 |
Sanguinarine chloride-13C,d3 (Sanguinarin chloride-13C,d3) is the deuterium labeled Sanguinarine chloride (HY-N0052A). Sanguinarine (Sanguinarin) chloride, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate apoptosis via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.
|
|
/
|
| HY-D3535 | AF 350 Annexin V |
AF 350 Annexin V is an AF 350-labeled annexin V, used to label early apoptotic cells and detect the occurrence of apoptosis (Ex/Em = 346/445 nm).
|
|
/
|
| HY-D3555 | Fluorescein Annexin V |
Fluorescein Annexin V is a Fluorescein-labeled annexin V, used to label early apoptotic cells and detect the occurrence of apoptosis (Ex/Em = 488/525 nm).
|
|
/
|
| HY-B0621S | Triclabendazole-d3 |
Triclabendazole-d3 is the deuterium labeled Triclabendazole (HY-B0621). Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica.
|
|
/
|
| HY-16658BG | Z-VAD-FMK (GMP) |
Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.
|
|
/
|
| HY-N12941 | Macarangin |
Macarangin can be isolated from propolis. Macarangin has DPPH radical-scavenging activity and shows anti-inflammatory activities via inhibiting the activation process of NLRP3 inflammasome.
Source: Kenyan propolis |
|
/
|
| HY-B0116S | Stavudine-d4 |
Stavudine-d4 is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis.
|
Isotope-Labeled Compounds
Reverse Transcriptase
HIV
Nucleoside Antimetabolite/Analog
NOD-like Receptor (NLR)
Autophagy
Apoptosis
|
/
|
| HY-P992376 | huXBR1-402 |
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis).
Species: Human |
|
/
|
| HY-W007328S | 5-Methoxyindole-d3 |
5-Methoxyindole-d3 is the deuterated-labeled 5-Methoxyindole (HY-W007328). 5-Methoxyindole is an L-tryptophan metabolite with antifungal activity, and also serves as a pharmaceutical intermediate. Metabolites of 5-Methoxyindole exhibit COX-2 inhibitory, anti-inflammatory and anti-tumor activities. 5-Methoxyindole induces morphological distortion of hyphae and conidia, ROS accumulation, apoptosis and cell death in Gaeumannomyces graminis. 5-Methoxyindole can be used in studies related to fungal infections and organic synthesis.
|
Isotope-Labeled Compounds
Endogenous Metabolite
Drug Intermediate
Fungal
Reactive Oxygen Species (ROS)
Apoptosis
|
/
|
| HY-W010201S1 | Citronellol-d3 |
Citronellol-d3 ( (±)-Citronelloll-d3) is the deuterium labeled Citronellol (HY-W010201). Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis.
|
p62
Isotope-Labeled Compounds
Apoptosis
TNF Receptor
Necroptosis
PI3K
Autophagy
Atg8/LC3
Fungal
ERK
Reactive Oxygen Species (ROS)
|
/
|
| HY-D3536 | AF 405 Annexin V |
AF 405 Annexin V is an AF 405-labeled annexin V, used to label early apoptotic cells and detect the occurrence of apoptosis (Ex/Em = 405/435 nm).
|
|
/
|
| HY-W722562 | Trimethylamine oxide-15N |
Trimethylamine oxide-15N is the deuterium labeled Trimethylamine N-oxide (HY-116084). Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.
|
|
/
|
| HY-P991634 | IBI-325 |
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
Species: Human |
|
/
|
| HY-N20662 | (+)-Neoalbaconol |
(+)-Neoalbaconol is a selective Akt/PDK1 inhibitor (with an IC50 of 10 μM against hPDK1). (+)-Neoalbaconol selectively inhibits cancer cell proliferation, and induces energy depletion, apoptosis, autophagy and necroptosis in cancer cells. In addition, (+)-Neoalbaconol downregulates cIAP1/2 and TRAFs to activate non-canonical NF-κB and promote TNFα transcription, blocks EGFR-mediated VEGF production and receptor activation, and mediates cell necrosis via the RIPK3-ROS-dependent pathway. (+)-Neoalbaconol can be used in research related to nasopharyngeal carcinoma, melanoma, breast cancer and gastric cancer.
Source: Dictyopteris divaricata Okam |
|
/
|
| HY-P5142 | ω-Hexatoxin-Hv1a |
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons.
|
|
/
|
| HY-P5640 | Tritrpticin |
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia.
|
|
/
|
| HY-W724344 | Cetalkonium-d5 chloride |
Cetalkonium-d5 chloride (Benzyldimethylhexadecylammonium-d5 chloride) is the deuterium labeled Cetalkonium chloride (HY-B1597). Cetalkonium chloride is an ammonium antiseptic agent used in many topical agents for infections of mouth, throat and eye. Cetalkonium chloride acts as anti-inflammatory amphiphilic agent. Cetalkonium chloride is a cationic surfactant, that improves the precorneal residence time and bioavailability of drugs. Cetalkonium chloride interacts with the negative charges on the bacterial cell membrane, disrupts the integrity of the cell membrane, causes leakage of cell contents and ultimately leading to bacterial death.
|
|
/
|
| HY-D3168 | PCL-2 |
PCL-2 is a reactive oxygen species (ROS)-responsive fluorescent probe. PCL-2 reacts with ROS to release 6-hydroxy-2-cyanobenzothiazole (HCBT), which then reacts with D-cysteine to form firefly luciferin in situ. PCL-2 must be used in conjunction with IETDC (HY-D3169) to detect the co-existence of hydrogen peroxide and caspase 8. PCL-2 is applicable to studies related to acute inflammation.
|
|
/
|
| HY-20457G | TL8-506 (GMP) |
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
|
|
/
|
| HY-P992351 | ELB021 |
ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8+ T cell-mediated cytotoxicity. Independent of PD-1 regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection.
Species: Human |
|
/
|
| HY-P4890 | Relaxin H3 (human) |
Relaxin H3 (human) is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
|
RXFP Receptor
Reactive Oxygen Species (ROS)
Pyroptosis
Caspase
Interleukin Related
TGF-beta/Smad
AMPK
Apoptosis
|
/
|
| HY-122292 | Celastramycin A |
Celastramycin A is an antibiotic isolated from Streptomyces MaB-QuH-8, which exhibits antimicrobial activity against series of gram-negative bacteria and mycobacteria, with MICs between 0.05-3.1 μg/ml. Celastramycin A exhibits immunosuppressing efficacy in ex vivo Drosophila through immune deficiency pathway (IC50 of 0.008 μg/ml), inhibits the immunoresponse in human innate immunity through TNF-α signaling, inhibits IL-8 production in HUEVCs with IC50 of 0.06 μg/ml.
Source: Drosophila |
|
/
|
| HY-P2291A | Beta-defensin 103 isoform X1, pig TFA |
Beta-defensin 103 isoform X1, pig TFA is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
|
|
/
|
| HY-N6714R | Alternariol (Standard) |
Alternariol (Standard) is the analytical standard of Alternariol. This product is intended for research and analytical applications. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
|
|
/
|
| HY-N2902 | Artocarpin |
Artocarpin is an orally active apoptosis inducer. Artocarpin targets NF-κB, Erk1/2, p38 MAPK, AktS473, p53, Akt 1 kinase and Akt 2 kinase. Artocarpin induces reactive oxygen species (ROS) production, mediates p53-dependent and p53-independent apoptotic signaling pathways, induces G1-phase cell cycle arrest, and triggers autophagic cell death. Artocarpin exerts cytotoxic and bactericidal effects on cancer cells, reduces bacterial load, and exhibits anti-inflammatory, analgesic and anti-angiogenic activities.
|
|
/
|
| HY-16569B | Colchicine,suitable for plant cell culture |
Colchicine,suitable for plant cell culture, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine,suitable for plant cell culture can be used for plant cell culture.
|
|
/
|
| HY-P2457 | rCRAMP (rat) |
rCRAMP (rat) is the rat cathelin-related antimicrobial peptide. rCRAMP (rat) contributes to the antibacterial activity in rat brain peptide/protein extracts. rCRAMP (rat) is a potential key player in the innate immune system of rat CNS.
|
|
/
|
| HY-P10715 | Fmoc-KCRGDK |
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
|
|
/
|
| HY-N20708 | Chiisanogenin |
Chiisanogenin is an orally active triterpenoid. Chiisanogenin reduces postprandial blood glucose by promoting GLUT4 translocation and glucose uptake via activation of the IRS-1/PI3K/Akt signaling pathway. Chiisanogenin binds to MLKL and inhibits its phosphorylation and oligomerization, maintains lysosomal integrity, restores autophagic flux, and suppresses NLRP3 inflammasome activation and pyroptosis. Chiisanogenin inhibits xanthine oxidase activity and regulates oxidative stress and ion pump activity. Chiisanogenin binds to or inhibits PKA, H+/K+-ATPase and β-glucuronidase. Chiisanogenin possesses multiple pharmacological activities, including broad-spectrum antibacterial activity, anticancer, anti-inflammatory, antirheumatic, renoprotective, cardioprotective and antiarrhythmic effects. Chiisanogenin can be used in research related to type 2 diabetes, rheumatoid arthritis, myocardial injury, hepatocellular carcinoma and ventricular arrhythmia.
|
|
/
|
| HY-178762S | RIPK1-IN-35 |
RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC50 of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis.
|
|
/
|
| HY-N12905 | Celastramycin A (isomer) |
Celastramycin A isomer is an isomer of Celastramycin A (HY-122292), an antibiotic against Gram-negative bacteria and Mycobacterium tuberculosis with an MIC of 0.05-3.1 μg/mL. Celastramycin A exerts immunosuppressive effects in Drosophila ex vivo via the immunodeficiency pathway (IC50 of 8 ng/mL), inhibits human innate immune responses via the TNF-α pathway, and inhibits IL-8 production in HUEVC with an IC50 of 60 ng/mL.
Source: Streptomyces strains |
|
/
|
| HY-N0546R | Ligustroflavone (Standard) |
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
|
|
/
|
| HY-17355BS | Dexpramipexole-d3 dihydrochloride |
Dexpramipexole-d3 ((R)-Pramipexole-d3) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Nav1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.
|
Reactive Oxygen Species (ROS)
Isotope-Labeled Compounds
Glutathione Peroxidase
Ferroptosis
Apoptosis
Sodium Channel
Mitophagy
Autophagy
ATP Synthase
NOD-like Receptor (NLR)
PINK1/Parkin
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
/
|
| HY-N8380 | (-)-Latifolin |
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities.
|
|
/
|
| HY-N12482 | Callicarboric acid A |
NLRP3-IN-27 (compound 1) is an inhibitor of NLRP3 with an IC50 value of 0.74 μM. NLRP3 reduces inflammasome-induced pyroptosis in J774A.1 cells. NLRP3-IN-27 can be isolated from Callicarpa arborea Rox.
|
|
/
|
| HY-N1939R | Icariside I (Standard) |
Icariside I (Standard) is the analytical standard of Icariside I (HY-N1939). This product is intended for research and analytical applications. Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape.
|
Reference Standards
Apoptosis
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
STAT
CDK
Bcl-2 Family
Aryl Hydrocarbon Receptor
JAK
Caspase
IFNAR
PD-1/PD-L1
|
/
|
| HY-P5407 | HD5 |
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
|
Colorectal Cancer
Small Cell Lung Cancer
Epithelial Ovarian Cancer
SARS-CoV-2 Infection
HPV Infection
|
/
|
| HY-B1971S1 | Deltamethrin-d6 |
Deltamethrin-d6 (Decamethrin-d6) is deuterium labeled Deltamethrin. Deltamethrin (Decamethrin) is an orally active synthetic pyrethroid insecticide. Deltamethrin induces oxidative stress and results in inflammation and apoptosis via inhibiting Nrf2/HO-1 pathway. Deltamethrin has an anticancer effect by inducing apoptosis. Deltamethrin can be used extensively in pest control.
|
Isotope-Labeled Compounds
NF-κB
Calcium Channel
Apoptosis
Bcl-2 Family
Endogenous Metabolite
Interleukin Related
Caspase
|
/
|
| HY-N16463 | QS-S2 |
|
|
/
|
| HY-111582G | BBIQ (GMP) |
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses.
|
|
/
|
| HY-N2414R | Periplogenin (Standard) |
Periplogenin (Standard) is the analytical standard of Periplogenin (HY-N2414). Periplogenin is an orally active cardiac glycoside found in Cortex periplocae. Periplogenin can induce ROS production and necroptosis and cause G0/G1 phase arrest. Periplogenin can inhibit pyroptosis by regulating the NLRP3/Caspase-1/GSDMD signaling. Periplogenin suppresses growth of prostate carcinoma cells by docking to an ATP1A1 protein pocket and forming a hydrogen bond with T804. Periplogenin can be used for the researches of cancer, inflammation and immunology, such as prostate carcinoma, rheumatoid arthritis and psoriasis.
|
Reference Standards
Reactive Oxygen Species (ROS)
Necroptosis
Pyroptosis
Interleukin Related
Caspase
NOD-like Receptor (NLR)
|
/
|
| HY-D2376 | BH-Vis |
BH-Vis is a two-photon fluorescent probe that inhibits cell plasma membrane (CPM). BH-Vis has great potential to accurately identify pyroptosis at the cellular level during AAA development in the mouse abdominal aortic aneurysm AAA model.
|
|
/
|
| HY-W010201S | Citronellol-d6 |
Citronellol-d6 is deuterated labeled Citronellol (HY-W010201). Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis.
|
|
/
|
| HY-32350S1 | Ercalcitriol-d3 |
Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
|
|
/
|
| HY-W653896 | Alternariol-d2 |
Alternariol-d2 is deuterium labeled Alternariol. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
|
|
/
|
| HY-N14116 | Garlic oil |
Garlic oil is an orally effective anti-inflammatory, antioxidant, and anticancer agent. Garlic oil inhibits the activation of NF-κB, NFκB2 and NLRP3 inflammasome, and induces the expression of GSTA1, HO-1 and NQO-1. Garlic oil reduces the Bcl-2/Bax protein ratio and activates NNK-induced apoptosis (apoptosis) in lung tissues. Garlic oil attenuates NNK-induced apoptosis in MRC-5 cells and reduces excessive ROS production. Garlic oil alleviates pyroptosis (pyroptosis) and exerts a protective effect against acute lung injury in mice. Garlic oil inhibits lung tumorigenesis in mice and improves small intestinal motility in rats with type 2 diabetes. Garlic oil can be used in research related to acute lung injury, lung cancer, peptic ulcer, type 2 diabetes and hypertension.
|
NF-κB
NOD-like Receptor (NLR)
Glutathione S-transferase
Heme Oxygenase (HO)
Quinone Reductase
Bcl-2 Family
Apoptosis
Reactive Oxygen Species (ROS)
Pyroptosis
|
/
|
| HY-P2076A | Dusquetide TFA |
Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
|
|
/
|
| HY-P990072 | Lipustobart |
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity.
Species: Human |
|
/
|
| HY-B0006S | Carvedilol-d3 |
Carvedilol-d3 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome.
|
|
/
|
| HY-P5834 | Boc-AEVD-CHO |
|
/
|
|
| HY-144002 | RIBI-529 |
RIBI-529 (RC-529) is a fully synthetic, low-toxicity TLR4 agonist vaccine adjuvant. RIBI-529 upregulates cell surface co-stimulatory molecules, receptors, cytokines and chemokines, and activates the innate immune system. RIBI-529 enhances short-term CD4+ T cell clonal expansion, division, and ex vivo survival under growth factor withdrawal conditions. RIBI-529 enhances humoral and cell-mediated adaptive immune responses, induces non-specific resistance against viral and bacterial pathogens, and skews responses toward a Th1 type, accompanied by Th2 responses.
|
|
/
|
| HY-153939S | Idasanutlin-d3-1 |
Idasanutlin-d3-1 (RG7388-d3-1) is the deuterated-labeled Idasanutlin (HY-15676). Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
|
Isotope-Labeled Compounds
MDM-2/p53
E1/E2/E3 Enzyme
Apoptosis
Pyroptosis
Reactive Oxygen Species (ROS)
Caspase
Musculoskeletal and Skin Disease
Colorectal Cancer
Melanoma
Neuroblastoma
Osteosarcoma
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
|
/
|
| HY-P3362 | Ac-IETD-AMC |
Ac-IETD-AMC is a fluorogenic caspase-8/granzyme B substrate containing the acetyl (Ac) moiety. Ac-IETD-AMC is frequently used to measure caspase-8 activity.
|
|
/
|
| HY-N11067 | Taccalonolide E |
|
/
|
|
| HY-P4890A | Relaxin H3 (human) TFA |
Relaxin H3 (human) TFA is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) TFA acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) TFA inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) TFA activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) TFA can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
|
RXFP Receptor
Reactive Oxygen Species (ROS)
Pyroptosis
Caspase
Interleukin Related
TGF-beta/Smad
AMPK
Apoptosis
|
/
|
| HY-P99886 | Pexelizumab |
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.
Species: Human |
|
/
|
| HY-P6084 | RP-220 |
RP-220 is a renalase peptide targeting NLRP3. RP220 has anti-inflammatory and anti-apoptotic activities. RP220 inhibits renal tubular epithelial cells apoptosis with alkaline insult by activating MAPK signaling pathway. RP220 significantly inhibits NLRP3 expression and reduces macrophage infiltration and kidney tissue damage in acute kidney injury (AKI) mice model. RP-220 can be uses for systemic lupus erythematosus (SLE) and its complication lupus nephritis (LN) research.
|
|
/
|
| HY-147889 | BBR-BODIPY |
BBR-BODIPY is a fluorescent probe that allows screening its interaction with the targeted cells. BBR-BODIPY induces apoptosis and changes the expression of apoptosis-related proteins.
|
|
/
|
| HY-P5169A | LVGRQLEEFL (mouse) TFA |
LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
|
|
/
|
| HY-P991126 | Ciltistotug |
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-P991125 | Cenzestotug |
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-P2275B | Peptide5 TFA |
Peptide5 TFA, a connexin 43 mimetic peptide, reduces animals swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 TFA also inhibits NLRP3 inflammasome, and is an anti-inflammatory agent.
|
|
/
|
| HY-W012480S1 | DL-Tryptophan-d8 |
DL-Tryptophan-d8 is the deuterium labeled DL-Tryptophan. DL-Tryptophan ((±)-Tryptophan) is an orally effective aryl hydrocarbon receptor (AhR) agonist. DL-Tryptophan reduces the expression of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, as well as liver injury markers aspartate aminotransferase and alanine aminotransferase, and alleviates hepatocyte apoptosis (apoptosis) in sepsis induced by cecal ligation and puncture. DL-Tryptophan can be used in the research of sepsis-related acute liver injury.
|
Isotope-Labeled Compounds
Endogenous Metabolite
Aryl Hydrocarbon Receptor
Interleukin Related
TNF Receptor
Apoptosis
|
/
|
| HY-P99709 | Lodapolimab |
Lodapolimab (LY3300054) is a fully human IgG1λ anti-PD-L1 monoclonal antibody, with an EC50 of 0.075 nM against hPD-L1 and an EC50 of 0.085 nM against cynomolgus monkey PD-L1. Lodapolimab induces naive T cell activation, enhances the T cell activation effect of anti-CTLA4 antibodies, promotes anti-tumor alloreactivity, regulates innate immune pathways, and induces characteristics of adaptive immune activation. Lodapolimab can be used in research related to high-grade serous ovarian cancer and other solid tumors.
Species: Human |
|
/
|
| HY-P11603 | SK56 |
SK56 is a GSDMD-NT pore inhibitor. SK56 inhibits pyroptosis (Pyroptosis) and the release of pyroptosis-related cytokines in macrophages and human peripheral blood leukocytes. SK56 prevents extensive cell death in human alveolar organoids in an organoid-macrophage co-culture model. SK56 prevents death from infectious shock induced by LPS (HY-D1056) or cecal ligation and puncture in mice. SK56 can be used in studies related to sepsis.
|
|
/
|
| HY-W747928 | (-)-Aspartic acid-d3 |
(-)-Aspartic acid-d3 ((R)-Aspartic acid-d3) is the deuterium labeled (-)-Aspartic acid (HY-42068). (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system.
|
|
/
|
| HY-42068R | (-)-Aspartic acid (Standard) |
(-)-Aspartic acid (Standard) is the analytical standard of (-)-Aspartic acid. This product is intended for research and analytical applications. (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system.
|
|
/
|
| HY-B1193S | Terfenadine-d3 |
Terfenadine-d3 ((±)-Terfenadine-d3) is the deuterium labeled Terfenadine. Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].
|
|
/
|
| HY-17536R | Selinexor (Standard) |
Selinexor (Standard) is the analytical standard of Selinexor. This product is intended for research and analytical applications. Selinexor (KPT-330) is an analog of KPT-185 (HY-15611). Selinexor is an orally active, selective CRM1 inhibitor that inhibits tumor growth by inducing PANoptosis.
|
|
/
|
| HY-P10217 | PD-1/PD-L1-IN-42 |
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-P5142A | ω-Hexatoxin-Hv1a TFA |
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) TFA is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a TFA blocks L-type voltage-dependent Ca2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a TFA causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a TFA is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons.
|
|
/
|
| HY-W008907 | 5'-O-Tritylthymidine |
5'-O-Tritylthymidine is an inhibitor of TK-2 and inhibits angiogenesis. 5'-O-Tritylthymidine targets FAK-Mdm-2 interactions, decreasing cell viability and increasing apoptosis.
|
|
/
|
| HY-100573S | Necrosulfonamide-d4 |
Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
|
Isotope-Labeled Compounds
Mixed Lineage Kinase
Necroptosis
Pyroptosis
Caspase
NOD-like Receptor (NLR)
Keap1-Nrf2
TNF Receptor
Integrin
NO Synthase
Heme Oxygenase (HO)
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-W145481A | D-Galacto-D-mannan |
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease.
|
|
/
|
| HY-P2320 | IDR-1 |
IDR-1 is an antimicrobial peptide that is active against Gram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and anti-infective properties, enhances the levels of monocyte chemokines, and attenuates pro-inflammatory cytokine release.
|
|
/
|
| HY-N9921 | Antcin A |
Antcin A is an orally active modulator of p53 and glucocorticoid receptor (GR), with an IC50 of 8.55 μM against human GR. Through transcriptional activation of p53, Antcin A induces miR-200c and inhibits ZEB1, regulates epithelial-mesenchymal transition markers, and suppresses cancer cell migration/invasion. Antcin A activates GR, inhibits Na+/K+-ATPase and NLRP3 inflammasome assembly, pyroptosis (pyroptosis) and pro-inflammatory cytokine release, reduces hepatic lipid deposition, improves liver function, and reverses metabolic changes induced by the SARS-CoV-2 spike protein. Antcin A can be used in research related to breast cancer, head and neck cancer, non-alcoholic fatty liver disease, and coronavirus disease 2019 (COVID-19).
Source: Antrodia cinnamomea |
Pyroptosis
NOD-like Receptor (NLR)
MDM-2/p53
Glucocorticoid Receptor
MicroRNA
Na+/K+ ATPase
SARS-CoV
|
/
|
| HY-N0822R | Shikonin (Standard) |
Shikonin (Standard) is the analytical standard of Shikonin. This product is intended for research and analytical applications. Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
|
|
/
|
| HY-P99938 | Pucotenlimab |
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor.
Species: Human |
|
/
|
| HY-P10862A | AH-D peptide TFA |
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
|
|
/
|
| HY-B0006S1 | Carvedilol-d4 |
Carvedilol-d4 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome.
|
|
/
|
| HY-B2176S4 | ATP-d14 dilithium |
ATP-d14 (Adenosine 5'-triphosphate-ATP-d14) dilithium is the d14-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
/
|
| HY-121362 | Evernic Acid |
Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections.
|
|
/
|
| HY-N6642 | Ankaflavin |
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects.
Source: Monascus |
|
/
|
| HY-P99618 | Fidasimtamab |
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer.
Species: Human |
|
/
|
| HY-P3486 | GADGVGKSAL |
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-P10862 | AH-D peptide |
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50 values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis. |
|
/
|
| HY-P3487 | GAGGVGKSA |
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-P990782 | Efzofitimod |
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD).
Species: Human |
|
/
|
| HY-B2123R | Lactose (Standard) |
Lactose (Standard) is the analytical standard of Lactose. This product is intended for research and analytical applications. Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
|
|
/
|
| HY-P99928 | Efprezimod alfa |
Efprezimod alfa (MK 7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome.
|
|
/
|
| HY-P99834 | Crefmirlimab |
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.
Species: Human |
|
/
|
| HY-17026S | Gemcitabine-13C,15N2 |
antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis.
|
|
/
|
| HY-P991122 | Besufetamig |
Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers.
Species: Human |
|
/
|
| HY-P99941 | Retifanlimab |
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA).
Species: Human |
|
/
|
| HY-P2208 | Z-IETD-AFC |
Z-IETD-AFC, a specific fluorescence substrate, can be used to determine the caspase-8 catalytic activity.
|
|
/
|
| HY-P990757 | Ragistomig |
|
/
|
|
| HY-P990901 | Aplitabart |
Aplitabart (IGM-8444) is a pentameric IgM death receptor 5 (DR5) agonist antibody with a KD of 85 nM and an apparent affinity of 11 pM. Aplitabart induces DR5 multimerization, thereby triggering cancer cell apoptosis via the extrinsic apoptotic pathway apoptosis. Aplitabart is applicable to cancer-related research such as colorectal cancer and gastric cancer.
Species: Human |
|
/
|
| HY-P10424 | OPBP-1 |
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-P3488 | GADGVGKSA |
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-W750342 | Tryptophol-d4 |
Tryptophol-d4 (Indole-3-ethanol-d4) is the deuterium labeled Tryptophol (HY-W010155). Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces apoptosis and cleavage of caspase-8. Tryptophol inhibits Cunninghamella blakesleeana biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-111954 | (+)-Erinacin A |
(+)-Erinacin A (Erinacine A) is a cyanoditerpenoid isolated from Hericium erinaceus with anticancer, anti-inflammatory and neuroprotective activities. (+)-Erinacin A can induce cancer cell death by activating extrinsic and intrinsic apoptosis pathways. (+)-Erinacin A can also inhibit the expression of NO synthase (iNOS) and the production of nitrotyrosine to exert inflammatory and neuroprotective effects, thereby reducing ischemic brain damage.
Source: Hericium erinaceus |
|
/
|
| HY-17363R | Dimethyl fumarate (Standard) |
Dimethyl fumarate (Standard) is the analytical standard of Dimethyl fumarate. This product is intended for research and analytical applications. Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
|
|
/
|
| HY-W012480S | DL-Tryptophan-d3 |
DL-Tryptophan-d3 is the deuterium labeled DL-Tryptophan. DL-Tryptophan ((±)-Tryptophan) is an orally effective aryl hydrocarbon receptor (AhR) agonist. DL-Tryptophan reduces the expression of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, as well as liver injury markers aspartate aminotransferase and alanine aminotransferase, and alleviates hepatocyte apoptosis (apoptosis) in sepsis induced by cecal ligation and puncture. DL-Tryptophan can be used in the research of sepsis-related acute liver injury.
|
Isotope-Labeled Compounds
Endogenous Metabolite
Aryl Hydrocarbon Receptor
Interleukin Related
TNF Receptor
Apoptosis
|
/
|
| HY-120833 | Ac-Ile-Glu-Thr-Asp-pNA |
|
/
|
|
| HY-N10319 | Artepillin C |
Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC50=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce necroptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation.
|
Digestive System Disease
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Pain
Digestive System Inflammation
Glucose Metabolism
Obesity
|
/
|
| HY-NP019 | Agkistrodon halys batroxobin |
Agkistrodon halys batroxobin is a thrombin-like serine protease. Agkistrodon halys batroxobin reduces the expression of Sirt1 and extracellular signal-regulated kinase activation in brain tissue. Agkistrodon halys batroxobin reduces cleaved caspase-3 expression and inhibits neuronal apoptosis in rat.
|
|
/
|
| HY-130494S | (±)11(12)-EET-d11 |
(±)11(12)-EET-d11 is the deuterium labeled (±)11(12)-EET. (±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective.
|
|
/
|
| HY-P3560 | Edratide |
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE).
|
|
/
|
| HY-N2993 | Polyporenic acid C |
Polyporenic acid C is a lanostane-type triterpenoid. Polyporenic acid C can be isolated from Poria cocos. Polyporenic acid C causes the cleavage of caspase-8 and caspase-3, as well as the cleavage of PARP. Polyporenic acid C reduces the phosphorylation level of Akt (Ser473), increases the phosphorylation of PTEN and p53 (Ser15), and activates JNK. Polyporenic acid C induces Apoptosis. Polyporenic acid C shows anticancer activity against non-small cell lung cancer.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Pain
Digestive System Inflammation
Parkinson's Disease
Obesity
Lung Fibrosis
|
/
|
| HY-113963 | Ac-IETD-CHO |
Ac- IETD- CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac- IETD- CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac- IETD- CHO also inhibits cytotoxic T lymphocytes induced cell death.
|
|
/
|
| HY-P99484 | Botensilimab |
|
/
|
|
| HY-N5025 | Bullatine A |
Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
/
|
| HY-P11058 | OVA(250-264) |
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
|
|
/
|
| HY-101092A | QS-21 |
|
/
|
|
| HY-17363S1 | Dimethyl fumarate-d2 |
Dimethyl fumarate-d2 is the deuterium labeled Dimethyl fumarate. Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
|
|
/
|
| HY-159114 | Whole Glucan Particles |
Whole Glucan Particles is a Dectin-1a agonist. Whole Glucan Particles activates the innate immune system to improve the function of macrophages, monocytes and other immune cells.
|
|
/
|
| HY-185057 | S-D-Lactoylglutathione |
S-D-Lactoylglutathione (S-Lactylglutathione; (R)-S-Lactoylglutathione) is a multifunctional metabolic intermediate of the glyoxalase system. S-D-Lactoylglutathione activates K+ efflux in bacteria by displacing inhibitory glutathione from KefGB channels, thereby acidifying the cytoplasm. In eukaryotic cells, S-D-Lactoylglutathione mediates S-glutathionylation as a substrate of glyoxalase 2. S-D-Lactoylglutathione serves as a sensitive metabolic biomarker for neodymium nitrate neurotoxicity; when used in combination with MSCs-exo, it upregulates glutathione levels, downregulates lactate dehydrogenase and Glo2 levels, and inhibits cellular inflammatory responses and pyroptosis. S-D-Lactoylglutathione can be used in research related to prostate cancer, breast cancer, non-small cell lung cancer, sepsis-associated encephalopathy, and neurotoxicity.
|
|
/
|
| HY-P99114 | Sugemalimab |
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.
Species: Human |
|
/
|
| HY-P10939A | Ac-DMLD-CMK TFA |
Ac-DMLD-CMK TFA is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DMLD-CMK TFA binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DMLD-CMK TFA alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity.
|
|
/
|
| HY-P990781 | Suciraslimab |
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-P1380A | Difopein TFA |
Difopein TFA is a 14-3-3 protein inhibitor. Difopein TFA acts as an apoptosis inducer, regulates apoptosis-related proteins, downregulates Bcl-2, upregulates Bax, activates caspase-9 and caspase-3, and induces nuclear fragmentation, membrane-enclosed apoptotic bodies and DNA ladder formation. Difopein TFA serves as a tumor growth inhibitor, which inhibits the proliferation of glioma cells and induces their apoptosis in in vivo nude mouse models. Difopein TFA is applicable to glioma-related research.
|
|
/
|
| HY-P99265 | Mapatumumab |
|
/
|
|
| HY-P10439 | CVRARTR |
CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research.
|
|
/
|
| HY-P10285 | d-KLA Peptide |
d-KLA Peptide (D-(KLAKLAK)2), KLA peptide (HY-P5345) isomer, is a pro-apoptosis peptide. d-KLA Peptide can specifically target mitochondria and induce apoptosis by destroying the mitochondrial membrane. d-KLA Peptide increases caspase 3/7 activity, exerts proapoptotic activity and enhances antitumor efficacy in mouse melanoma models.
|
|
/
|
| HY-W007328 | 5-Methoxyindole |
5-Methoxyindole is an L-tryptophan metabolite with antifungal activity, and also serves as a pharmaceutical intermediate. Metabolites of 5-Methoxyindole exhibit COX-2 inhibitory, anti-inflammatory and anti-tumor activities. 5-Methoxyindole induces morphological distortion of hyphae and conidia, ROS accumulation, apoptosis and cell death in Gaeumannomyces graminis. 5-Methoxyindole can be used in studies related to fungal infections and organic synthesis.
|
|
/
|
| HY-NP0196 | Mouse immunoglobulin G |
Mouse Immunoglobulin G (Mouse IgG) is the most abundant glycoprotein in mouse serum, which bridges innate and adaptive immune responses. A conserved asparagine-297 residue on each heavy chain contains an N-linked glycosylation site. Mouse Immunoglobulin G shares many glycosylation features with human IgG, but contains N-Glycolylneuraminic acid (HY-128965) instead of N-acetylneuraminic acid (HY-I0400). Mouse Immunoglobulin G is widely used as a negative isotype control, immunoassay coating protein and research standard in the life sciences.
|
|
/
|
| HY-N6714 | Alternariol |
Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
Source: fungi of the genus Alternaria |
|
/
|
| HY-N2909 | Aurantiamide |
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Alzheimer's Disease
Parkinson's Disease
Obesity
|
/
|
| HY-P3151 | Gliadin p31-43 |
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research.
|
|
/
|
| HY-P99270 | Tigatuzumab |
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer.
Species: Human |
|
/
|
| HY-P99299 | Lexatumumab |
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.
Species: Human |
|
/
|
| HY-P99791 | Orilanolimab |
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
Species: Human |
|
/
|
| HY-P99759 | Nogapendekin alfa (his tag) |
Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8+ T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma.
Species: Human |
|
/
|
| HY-P2076 | Dusquetide |
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
|
|
/
|
| HY-W020955 | Triphenylphosphinechlorogold |
Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I)) is a gold complex, Apoptosis inducer, and catalyst. Triphenylphosphinechlorogold exhibits high LOX inhibitory activity. Triphenylphosphinechlorogold induces cell cycle arrest and apoptosis. Triphenylphosphinechlorogold catalyzes the peroxidation of linoleic acid. A weak interaction exists between Triphenylphosphinechlorogold and DNA. Triphenylphosphinechlorogold displays antiproliferative activity against breast cancer cells.
|
|
/
|
| HY-B0075S1 | Melatonin-d3 |
Melatonin-d3 is the deuterium labeled Melatonin. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress.
|
|
/
|
| HY-107202GL | Polyinosinic-polycytidylic acid (GMP Like) |
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
|
|
/
|
| HY-P9992 | Pelgifatamab |
Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer.
Species: Human |
|
/
|
| HY-N0660 | Jujuboside B |
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway. Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.
|
Apoptosis
PARP
Caspase
AMPK
Autophagy
VEGFR
Keap1-Nrf2
STING
11β-HSD
Ferroptosis
PI3K
Akt
p38 MAPK
ERK
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
Breast Cancer
Colorectal Cancer
Leukemia/Lymphoma/Myeloma
Depression
Non-Small Cell Lung Cancer
|
/
|
| HY-P99555 | Tomaralimab |
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury.
Species: Human |
Cancer
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
/
|
| HY-P99480 | Bintrafusp alfa |
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer.
|
Non-Small Cell Lung Cancer
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
/
|
| HY-42068 | (-)-Aspartic acid |
(-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system.
|
|
/
|
| HY-NP0204 | MSA Protein |
MSA Protein (Mouse Serum Albumin) is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD).
|
|
/
|
| HY-P991049 | Atrosimab |
Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.
Species: Human |
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
Fatty Liver Disease
|
/
|
| HY-P99175 | KWAR 23 |
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
Species: Human |
|
/
|
| HY-P99203 | Cemiplimab |
|
/
|
|
| HY-P99396 | Spesolimab |
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways.
Species: Human |
|
/
|
| HY-P991097 | Pumitamig |
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
Species: Human |
|
/
|
| HY-P990688 | Xaluritamig |
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.
Species: Human |
|
/
|
| HY-P10408 | Candidalysin |
Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity
|
|
/
|
| HY-P70640 | PD-1 Protein, Mouse (HEK293, His) |
PD-1 Protein is an important immune regulatory molecule expressed on the surface of activated immune cells. By binding to its ligands (PD-L1/PD-L2), the PD-1 Protein exerts immunosuppressive effects. PD-1 Protein can be used in the research of tumors, autoimmune diseases, and other conditions. PD-1 Protein, Mouse (HEK293, His) is a recombinant PD-1 protein expressed by HEK293 cells and carries a C-6*His tag and glycosylation modification.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P71855 | RIPK3 Protein, Human (P.pastoris, His) |
RIPK3 is a kinase that controls necroptosis and apoptosis. In necroptosis, activated by TNF-α and ZBP1, RIPK3 phosphorylates MLKL, leading to membrane damage. RIPK3 Protein, Human (P.pastoris, His) is the recombinant human-derived RIPK3 protein, expressed by P. pastoris , with N-6*His labeled tag.
Species: Human; Source: P. pastoris |
|
/
|
| HY-P72718 | CD5L Protein, Human (HEK293, His) |
CD5L protein regulates lipid metabolism and lipolysis by promoting fatty acid endocytosis into adipocytes via the CD36 receptor. This process, crucial for maintaining lipid homeostasis, leads to the degradation of triacylglycerols into glycerol and free fatty acids. CD5L Protein, Human (HEK293, His) is the recombinant human-derived CD5L protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P70676 | PD-1 Protein, Cynomolgus (HEK293, His) |
PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Cynomolgus; Source: HEK293 |
|
/
|
| HY-P71853 | RIPK3 Protein, Mouse (P.pastoris, His) |
RIPK3 Protein, participates in programmed necrosis (necroptosis) and apoptosis, contributing to diverse cellular processes. RIPK3 Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived RIPK3 protein, expressed by P. pastoris , with N-6*His labeled tag.
Species: Mouse; Source: P. pastoris |
|
/
|
| HY-P704049A | GSDMD Protein, Human (C-His) |
GSDMD Protein, Human (C-His) is the recombinant human-derived GSDMD protein, expressed by E. coli, with C-6*His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P70525 | PD-1 Protein, Human (HEK293, mFc) |
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-mFc labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P704049 | GSDMD Protein, Human (His) |
GSDMD Protein, Human (His) is the recombinant human-derived GSDMD protein, expressed by E. coli, with N-6*His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P71708 | Caspase-8/CASP8 subunit p18 Protein, Human (His) |
The Caspase-8/CASP8 subunit p18 protein is a key thiol protease that acts as a molecular switch in programmed cell death processes, including apoptosis, necroptosis, and pyroptosis. It is essential for preventing tissue damage by inducing exogenous apoptosis by cleaving and activating effector caspases. Caspase-8/CASP8 subunit p18 Protein, Human (His) is the recombinant human-derived Caspase-8/CASP8 subunit p18 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P704188 | ZBP1 Protein, Human (His, Myc) |
ZBP1 is an important innate sensor that defends against viruses by recognizing Z-RNA structures and inducing PANoptosis. It binds Z-RNA through TNF-α family members and stimulates RIPK3 and MLKL to activate necroptosis. ZBP1 Protein, Human (His, Myc) is the recombinant human-derived ZBP1 protein, expressed by E. coli, with N-10*His and C-Myc labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P701768 | RIPK1 Protein, Human (sf9, His, GST) |
RIPK1 protein is a serine-threonine kinase that centrally regulates TNF-mediated apoptosis, necroptosis, and inflammatory pathways. Functionally, it plays a kinase-dependent role in the regulation of cell death and a kinase-independent scaffolding function in the control of inflammatory signaling and cell survival. RIPK1 Protein, Human (sf9, His, GST) is the recombinant human-derived RIPK1 protein, expressed by sf9 insect cells , with N-8*His, N-GST labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P704184 | ZBP1 Protein, Mouse (HEK293, His, Flag) |
ZBP1 Protein, Mouse (HEK293, His, Flag) is the recombinant mouse-derived ZBP1 protein, expressed by HEK293, with C-6*His & C-Flag tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P70766 | PD-1 Protein, Human (147a.a, HEK293, His) |
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (147a.a, HEK293, His) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P72816 | AIM2 Protein, Human (sf9, GST) |
AIM2 Protein, a member of the IFI20X/IFI16 family, exhibits potential regulatory functions in cell proliferation and tumorigenic reversion. Induced by interferon-gamma, AIM2 plays a key role in immune responses. Notably expressed in tissues like lymph node and appendix, AIM2 is a significant player in diverse cellular processes and immune-related functions. AIM2 Protein, Human (sf9, GST) is the recombinant human-derived AIM2 protein, expressed by Sf9 insect cells , with N-GST labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P71649 | GSDMC Protein, Human (His-SUMO) |
GSDMC protein serves as the precursor of pore-forming proteins and undergoes cleavage to release Gasdermin-C. This N-terminal moiety binds to the membrane, forming pores with an inner diameter of 10 to 15 nm and inducing pyroptosis. GSDMC Protein, Human (His-SUMO) is the recombinant human-derived GSDMC protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P7S2794 | IGF2BP1 Protein, Human (His) |
Species: Human; Source: E. coli |
|
/
|
| HY-P705693 | Caspase-10/CASP10 Protein, Human (His-GST) |
Caspase-10/CASP10 Protein, Human (His-GST) is an approximately 54.2 kDa caspase-10 protein with a His-GST-tag, expressed in E. coli. Caspase-10 belongs to the caspase family and involved in the execution-phase of cell apoptosis.
Species: Human; Source: E. coli |
|
/
|
| HY-P71191 | PDCD4 Protein, Human (His) |
PDCD4 inhibits translation initiation by disrupting the EIF4A1-EIF4G interaction and inhibiting EIF4A helicase activity. It regulates JUN kinase activation and downregulates MAP4K1, inhibiting invasion and tumorigenesis. PDCD4 Protein, Human (His) is the recombinant human-derived PDCD4 protein, expressed by E. coli , with C-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P705851 | MLKL Protein, Human (sf9, His-GST) |
MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL, Human (sf9, His-GST) is the recombinant human-derived MLKL protein, expressed by sf9 insect cells, with N-Avi labeled tag.
Species: Human; Source: sf9 insect cells |
|
/
|
| HY-P71019 | PDCD5 Protein, Human (His) |
PDCD5 Protein is implicated in apoptosis, highlighting its potential role in regulating programmed cell death and maintaining cellular homeostasis. Despite this functional attribution, the specific molecular interactions and pathways involving PDCD5 in apoptosis require further exploration for a comprehensive understanding of its significance in cellular fate determination and survival mechanisms. PDCD5 Protein, Human (His) is the recombinant human-derived PDCD5 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P70050 | CRADD Protein, Human |
As an adapter protein, CRADD forms a PIDDosome complex with PIDD1 and CASP2, activates CASP2 and initiates apoptosis. It also recruits CASP2 to the TNFR-1 signaling complex in the tumor necrosis factor-mediated pathway, interacting with RIPK1 and TRADD. CRADD Protein, Human is the recombinant human-derived CRADD protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P71717 | Apoptosis inhibitor 4/Birc5 Protein, Mouse (P.pastoris, His) |
Apoptosis inhibitor 4/Birc5 has the dual effects of promoting cell proliferation and inhibiting apoptosis. As an important component of the chromosomal channel protein complex (CPC), Birc5 coordinates chromosome alignment and segregation during mitosis and cytokinesis. Apoptosis inhibitor 4/Birc5 Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived Apoptosis inhibitor 4/Birc5 protein, expressed by P. pastoris , with N-His labeled tag.
Species: Mouse; Source: P. pastoris |
|
/
|
| HY-P7743 | Caspase-14/CASP14 Protein, Human (His) |
Caspase-14 Protein, Human (His) is an approximately 31.0 kDa caspase-14 protein with a His-flag. Caspase-14 is a seemingly non-apoptotic caspase involved in keratinocyte differentiation and cornification.
Species: Human; Source: E. coli |
|
/
|
| HY-P7856 | PDCD8/AIFM1 Protein, Human (His) |
PDCD8/AIFM1 protein has the dual functions of NADH oxidoreductase and apoptosis regulator, and translocates from the mitochondrial intermembrane space to the cytoplasm and nucleus in response to apoptotic stimuli. It acts through a caspase-independent pathway, inducing “parthanatos” characterized by fragmentation of chromosomal DNA. PDCD8/AIFM1 Protein, Human (His) is the recombinant human-derived PDCD8/AIFM1 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P702186 | AIM2 Protein, Human |
AIM2 protein is a key sensor in the AIM2 inflammasome, which can activate the inflammasome in response to cytoplasmic dsDNA, thereby inducing pyroptosis. This complex is triggered by pathogens or injury signals and plays a critical role in innate immunity and inflammation. AIM2 Protein, Human is the recombinant human-derived AIM2 protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P702187 | AIM2 Protein, Human (His) |
AIM2 protein is a key sensor in the AIM2 inflammasome, which can activate the inflammasome in response to cytoplasmic dsDNA, thereby inducing pyroptosis. This complex is triggered by pathogens or injury signals and plays a critical role in innate immunity and inflammation. AIM2 Protein, Human (His) is the recombinant human-derived AIM2 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P702223 | BCL2 Protein, Rat (Cell-Free, His) |
The BCL2 protein is critical for inhibiting apoptosis in different cellular systems and regulates cell death by controlling mitochondrial membrane permeability. BCL2 operates in a feedback loop with caspases, inhibiting caspase activity by preventing cytochrome c release and binding to apoptosis-activating factor (APAF-1). BCL2 Protein, Rat (Cell-Free, His) is the recombinant rat-derived BCL2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.
Species: Rat; Source: E. coli Cell-free |
|
/
|
| HY-P702935 | RIPK1 Protein, Rat (Active, sf9, GST) |
RIPK1 Protein, Rat (Active, sf9, GST) is the recombinant rat-derived RIPK1, expressed by Sf9 insect cells , with N-GST labeled tag. ,
Species: Rat; Source: Sf9 insect cells |
|
/
|
| HY-P702936 | RIPK1 Protein, Cynomolgus (Active, sf9, GST) |
RIPK1 Protein, Cynomolgus (Active, sf9, GST) is the recombinant cynomolgus-derived RIPK1, expressed by Sf9 insect cells , with N-GST labeled tag. ,
Species: Cynomolgus; Source: Sf9 insect cells |
|
/
|
| HY-P703061 | RIPK1 Protein, Cynomolgus (Active, 373a.a, sf9, GST) |
RIPK1 Protein, Cynomolgus (Active, 373a.a, sf9, GST) is the recombinant cynomolgus-derived RIPK1, expressed by Sf9 insect cells , with GST labeled tag.
Species: Cynomolgus; Source: Sf9 insect cells |
|
/
|
| HY-P703063 | RIPK1 Protein, Canine (Active, sf9, GST) |
RIPK1 Protein, Canine (Active, sf9, GST) is the recombinant dog-derived RIPK1, expressed by Sf9 insect cells , with GST labeled tag.
Species: Dog; Source: Sf9 insect cells |
|
/
|
| HY-P705636 | RIPK3 Protein, Human (Active, sf9, GST) |
RIPK3 is a kinase that controls necroptosis and apoptosis. In necroptosis, activated by TNF-α and ZBP1, RIPK3 phosphorylates MLKL, leading to membrane damage. RIPK3, Human (Active, sf9, GST) is the recombinant human-derived RIPK3 protein, expressed by Sf9 insect cells, with labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P706324 | RIPK3 Protein, Human (Active, 316a.a, sf9, His-GST) |
RIPK3 is a kinase that controls necroptosis and apoptosis. In necroptosis, activated by TNF-α and ZBP1, RIPK3 phosphorylates MLKL, leading to membrane damage. RIPK3, Human (Active, sf9, GST) is the recombinant human-derived RIPK3 protein, expressed by Sf9 insect cells, with labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P80273 | PD-L1 Antibody (YA235) |
|
/
|
|
| HY-P83326 | IGF2BP1 Antibody (YA3071) |
IGF2BP1 Antibody (YA3071) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGF2BP1.
Host: Rabbit; Reactivity: Human, Mouse |
|
/
|
| HY-P80049 | Caspase-8 Antibody (YA554) |
|
/
|
|
| HY-P86351 | RIP3 Antibody (YA6043) |
RIP3 Antibody (YA6043) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P87753 | Phospho-MLKL (Ser345) Antibody (YA7438) |
Phospho-MLKL (Ser345) Antibody (YA7438) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-MLKL (Ser345).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P81161 | CEBP-alpha Antibody |
CEBP-alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CEBP-alpha.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P80979 | HOPX Antibody (YA846) |
HOPX Antibody (YA846) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HOPX.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P86650 | NLRP3 Antibody (YA6342) |
|
/
|
|
| HY-P83816 | AIM2 Antibody (YA3513) |
|
/
|
|
| HY-P86230 | AIF Antibody (YA5922) |
AIF Antibody (YA5922) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AIF.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P86637 | ALIX Antibody (YA6329) |
ALIX Antibody (YA6329) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALIX.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P80313 | RIP Antibody (YA091) |
RIP Antibody (YA091) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P80534 | AIF Antibody (YA835) |
AIF Antibody (YA835) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to AIF.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P810290 | Phospho-RIP3 (S232) Antibody (YA9633) |
Phospho-RIP3 (S232) Antibody (YA9633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P810537 | Phospho-RIP3 (Ser232) Antibody (YA9807) |
Phospho-RIP3 (Ser232) Antibody (YA9807) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-RIP3 (Ser232).
Host: Rabbit; Reactivity: Mouse, Rat |
|
/
|
| HY-P86228 | MLKL Antibody (YA5920) |
|
/
|
|
| HY-P86835 | Caspase-8 (p18) Antibody (YA6528) |
|
/
|
|
| HY-P84575 | Caspase-8 Antibody (YA4272) |
|
/
|
|
| HY-P85727 | Caspase-8 Antibody (YA5419) |
|
/
|
|
| HY-P86141 | Caspase-8 Antibody (YA5833) |
|
/
|
|
| HY-P80624A | Cleaved-Caspase 8 Antibody (YA792)(PBS only) |
Cleaved-Caspase 8 Antibody (YA792) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cleaved-Caspase 8.
Host: Mouse; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P810290A | Phospho-RIP3 (S232) Antibody (YA9633)(PBS only) |
Phospho-RIP3 (S232) Antibody (YA9633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P83816A | AIM2 Antibody (YA3513)(PBS only) |
|
/
|
|
| HY-P84575A | Caspase-8 Antibody (YA4272)(PBS only) |
|
/
|
|
| HY-P810377 | PDCD6/ALG-2 Antibody (YA9697) |
PDCD6/ALG-2 Antibody (YA9697) is a Mouse-derived and non-conjugated IgG1 Monoclonal antibody, targeting to PDCD6/ALG-2.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P80534A | AIF Antibody (YA835)(PBS only) |
AIF Antibody (YA835) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to AIF.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P80979A | HOPX Antibody (YA846)(PBS only) |
HOPX Antibody (YA846) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HOPX.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P811373 | GSDMC Antibody |
GSDMC Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GSDMC.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P811716 | p-Mlkl (S345) Antibody (YA10187) |
p-Mlkl (S345) Antibody (YA10187) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to p-Mlkl (S345).
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P811716A | p-Mlkl (S345) Antibody (YA10187) (PBS only) |
p-Mlkl (S345) Antibody (YA10187) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to p-Mlkl (S345).
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P82858 | PAR4 Antibody (YA2603) |
|
/
|
|
| HY-P83326A | IGF2BP1 Antibody (YA3071)(PBS only) |
IGF2BP1 Antibody (YA3071) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGF2BP1.
Host: Rabbit; Reactivity: Human, Mouse |
|
/
|
| HY-P83706A | GSDMD Antibody (YA3443)(PBS only) |
GSDMD Antibody (YA3443) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GSDMD.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P85314 | PAR4 Antibody (YA5006) |
|
/
|
|
| HY-P85314A | PAR4 Antibody (YA5006)(PBS only) |
|
/
|
|
| HY-P85731 | Survivin/BIRC5 Antibody (YA5423) |
Survivin/BIRC5 Antibody (YA5423) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Survivin/BIRC5.
Host: Mouse; Reactivity: Human, Rat |
|
/
|
| HY-P85925 | PD-1 Antibody (YA5617) |
|
/
|
|
| HY-P86537 | Survivin/BIRC5 Antibody (YA6229) |
Survivin/BIRC5 Antibody (YA6229) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Survivin/BIRC5.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P87199 | Bik Antibody (YA6887) |
Bik Antibody (YA6887) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bik.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P87346 | PDCD7 Antibody (YA7029) |
PDCD7 Antibody (YA7029) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDCD7.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P80766A | NLRP3 Antibody(YA6868) |
|
/
|
|
| HY-P80766AA | NLRP3 Antibody(YA6868)(PBS only) |
|
/
|
|
| HY-P80906 | Survivin/BIRC5 Antibody (YA665) |
Survivin/BIRC5 Antibody (YA665) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Survivin/BIRC5.
Host: Mouse; Reactivity: Human, Rat |
|
/
|
| HY-P810728 | NLRP3 Antibody (YA9972) |
|
/
|
|
| HY-P810740 | Cleaved-RIP (Asp324) Antibody (YA9983) |
Cleaved-RIP (Asp324) Antibody (YA9983) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to Cleaved-RIP (Asp324).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-K1076 | Annexin V-mCherry Apoptosis Detection Kit |
Annexin V-mCherry Apoptosis Detection Kit provides a rapid and convenient method to detect cell apoptosis and necrosis. After staining, live cells show little or no fluorescence, apoptosis cells and necrosis cells show red fluorescence. |
|
/
|
| HY-K1091A | Biotin Apoptosis Detection Kit (TUNEL) |
MCE Biotin Apoptosis Detection Kit (TUNEL) can be used to detect apoptosis in cultured cells, as well as in frozen or paraffin sections. |
|
/
|
Targets/Pathways




























































































































































































































































































































































































































































































































































































































































































































































































































































































































